Official Title:  Topi[INVESTIGATOR_352825] 2 (TRuE-V2): A Phase 3, Double-Blind, 
Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream 
Study ID: [REMOVED]  
Document  Date : Clinical  Study Protocol Version 1: 23 June 2019Followed by [CONTACT_352925] 1 8424-3 07 
Topi[INVESTIGATOR_352825] 2 
(TRuE-V2) 
A Phase 3, Double- Blind, Randomized, Vehicle- Controlled, Efficacy 
and Safety Study of Ruxolitinib Cream Followed by [CONTACT_352926]:  Ruxolitinib Cream  
IND Number:  77,[ADDRESS_439336] Number:  2019-000847-28 
Phase of Study:  3 
Sponsor:  Incyte Corporation 
1801 Augustine Cut- Off 
Wilmington, DE [ZIP_CODE] 
Original Protocol:  [ADDRESS_439337] their origin in the Declaration of 
Helsinki and conducted in adherence to the study Protocol, applicable Good Clinical Practices, and applicable laws 
and country- specific regulations in which the study is being conducted.  
The information in this document is confidential.  No part of this information may be duplicated, referenced, or 
transmitted in any form or by [CONTACT_61076] (electronic, mechanical, photocopy, recording, or otherwise) without prior 
written consent.  
Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 1 of 79
23 JUN 2019
CONFIDENTIAL
INVESTIGATOR' S AGREEMENT  
I have read the INCB [ZIP_CODE]-307 Protocol (dated 23 JUN 2019) and agree to conduct the study as 
outlined.  I agree to maintain the confidentiality of all information receive d or developed in 
connec
tion with this Protocol. 
(Printed N
ame of Investigator) 
(Signatur
e of Investigator)  (Date)  
Incyte Corporation
Protocol INCB [ZIP_CODE]-[ADDRESS_439338] OF  ABBREVIATIONS  ..........................................................................................................8  
1. PROTOCOL SUMMARY ..........................................................................................10  
2. INTRODUCTION  ......................................................................................................18  
2.1. Epi[INVESTIGATOR_352826]  ............................................................................................18  
2.2. Current Treatment and Unmet Need in Vitiligo  .........................................................19  
2.3. Role of Janus Kinases in Vitiligo  ...............................................................................20  
2.4. Ruxolitinib Cream  ......................................................................................................21  
 21 
2.4.2.  Clinical Experience .....................................................................................................22  
 22 
[IP_ADDRESS].  Efficacy of Ruxolitinib Cream  ....................................................................................24  
 28 
 28 
 28 
 29 
3. OBJECTIVES AND ENDPO INTS  ............................................................................30  
4. STUDY DESIGN  .......................................................................................................33  
4.1. Overall Design  ............................................................................................................33  
4.2. Overall Study Duration  ...............................................................................................33  
4.3. Study Termination  ......................................................................................................34  
5. STUDY POPULATION  .............................................................................................34  
5.1. Inclusion Criteria  ........................................................................................................34  
5.2. Exclusion Criteria  .......................................................................................................35  
5.3. Lifestyle Considerations .............................................................................................37  
5.4. Screen Failures  ............................................................................................................37  
5.5. Replacement of Participants  .......................................................................................37  
6. STUDY TREATMENT  ..............................................................................................38  
6.1. Study Treatment Application  ......................................................................................38  
6.1.1.  Application During the Double- Blind Vehicle -Controlled Treatment Period ...........39  
6.1.2.  Application During the Treatment Extension Period  .................................................39  
6.2. Preparation, Handling, and Accountability ................................................................39  
Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 3 of 79 
23 JUN 2019
CONFIDENTIAL

6.3. Measures to Minimize Bias:  Randomization and Blinding  .......................................40  
6.4. Study Treatment Compliance  .....................................................................................40  
6.5. Dose Modifications .....................................................................................................41  
6.5.1.  Criteria and Procedures for Application Interruptions of Study Drug .......................41  
6.5.2.  Criteria for Permanent Discontinuation of Study Drug Due to an Adverse 
Event ...........................................................................................................................42  
6.6. Concomitant Medications and Procedures .................................................................42  
 43 
 43 
 44 
6.8. Treatment After the End of the Study .........................................................................44  
7. DISCONTINUATION OF STUDY TREATMENT AND PARTICIPANT DISCONTINUATION/WITHDRAWAL  ..................................................................[ADDRESS_439339] to Follow- Up.......................................................................................................46  
8. STUDY ASSESSMENTS AND PROCEDURES  ......................................................47  
8.1. Administrative and General Procedures .....................................................................47  
8.1.1.  Informed Consent Process ..........................................................................................47  
8.1.2.  Screening Procedures ..................................................................................................48  
8.1.3.  Interactive Response Technology Procedure ..............................................................48  
8.1.4.  Distribution of Study Reminder Cards and Diaries ....................................................48  
8.1.5.  Demography and Medical History ..............................................................................49  
[IP_ADDRESS].  Demographics and General Medical History  .............................................................49  
[IP_ADDRESS].  Disease Characteristics and Treatment History  ..........................................................49  
8.2. Efficacy Assessments  .................................................................................................49  
8.2.1.  Body Surface Area  ......................................................................................................49  
8.2.2.  Vitiligo Area Scoring Index  ........................................................................................49  
8.2.3.  Physician’s Global Vitiligo Assessment (Facial)  .......................................................50  
8.2.4.  Physician’s Global Vitiligo Assessment (Total Body)  ...............................................50  
8.2.5.  Photography ................................................................................................................51  
Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 4 of 79 
23 JUN 2019
CONFIDENTIAL

8.2.6.  Patient -Reported Outcomes  ........................................................................................51  
[IP_ADDRESS].  Vitiligo Noticeability Scale  ........................................................................................52  
[IP_ADDRESS].  Color- Matching Question ...........................................................................................52  
[IP_ADDRESS].  Patient Global Impression of Change- Vitiligo (Facial)  ..............................................52  
[IP_ADDRESS].  Patient Global Impression of Change- Vitiligo (Total Body)  .....................................52  
[IP_ADDRESS].  Dermatology Life Quality Index  ................................................................................53  
[IP_ADDRESS].  WHO-5 .......................................................................................................................53  
[IP_ADDRESS].  Treatment Satisfaction Questionnaire for Medication  ................................................54  
[IP_ADDRESS].  VitiQoL  .......................................................................................................................54  
[IP_ADDRESS].  Hospi[INVESTIGATOR_5620] .....................................................................54  
8.3. Safety Assessments  .....................................................................................................54  
8.3.1.  Adverse Events  ...........................................................................................................54  
8.3.2.  Physical Examinations  ................................................................................................55  
8.3.3.  Vital Signs  ..................................................................................................................55  
8.3.4.  Electrocardiograms  .....................................................................................................55  
8.3.5.  Laboratory Assessments  .............................................................................................56  
[IP_ADDRESS].  Pregnancy Testing  ......................................................................................................57  
[IP_ADDRESS].  Serology ......................................................................................................................58  
8.4. Pharmacokinetic Assessments  ....................................................................................58  
8.5. Pharmacodynamic and Translational Assessments  ....................................................58  
8.6. Unscheduled Visits .....................................................................................................58  
8.7. End of Treatment and/or Early Termination  ..............................................................58  
8.8. Safety Follow -Up ........................................................................................................59  
9. ADVERSE EVENTS:  DEF INITIONS AND PROCEDURES FOR 
RECORDING, EVALUATING, FOLLOW -UP, AND REPORTING  ......................59  
9.1. Definition of Adverse Event .......................................................................................59  
9.2. Definition of Serious Adverse Event ..........................................................................60  
9.3. Recording and Follow-Up of Adverse Events and/or Serious Adverse Events .........[ADDRESS_439340] Complaints ....................................................................................................65  
Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 5 of 79 
23 JUN 2019
CONFIDENTIAL
9.9. Treatment of Overdose  ...............................................................................................66  
10. STATISTICS  ..............................................................................................................66  
10.1.  Sample Size Determination  ........................................................................................66  
10.2.  Populations for Analysis .............................................................................................66  
10.3.  Statistical Analyses  .....................................................................................................67  
10.3.1.  Efficacy Analyses  .......................................................................................................68  
[IP_ADDRESS].  Primary Analysis  ........................................................................................................68  
[IP_ADDRESS].  Key Secondary Analysis .............................................................................................69  
[IP_ADDRESS].  Secondary Analysis  ....................................................................................................[ADDRESS_439341] OF TABLES  
Table 1:  Primary and Secondary Objectives and Endpoints .....................................................10  
Table 2:  Key Study Design Elements  .......................................................................................11  
Table 3:  Schedule of Activities:  Double -Blind, Vehicle-Controlled Treatment Period 
(Day  1-Week 24)  ........................................................................................................13  
Table 4:  Schedule of Activities:  Treatment Extension Period (Week 28-Week 52) ...............16  
 
23 
 
24 
 27 
Table 8:  Objectives and Endpoints ...........................................................................................30  
Table 9:  Study Treatment Information  .....................................................................................38  
Table 10:  Guidelines for Interruption and Restarting of Study Drug .........................................42  
Table 11:  Facial Physician's Global Vitiligo Assessment Scale  .................................................50  
Table 12:  Total Body Physician's Global Vitiligo Assessment Scale  ........................................51  
Table 13:  Required Laboratory Analytes  ....................................................................................57  
Table 14:  Powering for Primary and Key Secondary Endpoints ................................................66  
Table 15:  Populations for Analysis .............................................................................................[ADDRESS_439342] OF FIGURES  
Figure  1: Study Design Schema  .................................................................................................12  
 
23 
Figure  3: INCB [ZIP_CODE]-[ADDRESS_439343]  aspartate aminotransferase  
BID twice daily  
BSA  body surface area  
CDLQI  Children’s Dermatology Life Quality Index  
CFR  Code of Federal Regulations  
CTCAE  Common Terminology Criteria for Adverse Events  
CYP  cytochrome P450  
DLQI  Dermatology Life Quality Index  
ECG  electrocardiogram  
eCRF  electronic case report form  
EDC  electronic data capture  
EOS  end of study  
EOT  end of treatment  
F-BSA  facial body surface area  
F-PaGIC -V facial assessment of Patient Global Impression of Change -Vitiligo  
F-PaGVA  facial assessment of Patient's Global Vitiligo Assessment  
F-PhGVA  facial assessment of Physician Global Vitiligo Assessment  
FSH follicle -stimulating hormone  
F-VASI  Face Vitiligo Area Scoring Index  
F-VASI25/50/75/90  ≥ 25%/ 50%/ 75%/ 90%  improvement from base line in F ace Vitiligo Area 
Scoring Index score  
GCP  Good Clinical Practice  
HADS  Hospi[INVESTIGATOR_352827]'s Brochure  
ICF informed consent form  
ICH International Conference on Harmonisation  
ID identification  
Incyte Corporation
Protocol INCB [ZIP_CODE]-[ADDRESS_439344] operating procedure  
STAT  signal transducer and activator of transcription  
S[LOCATION_003]R  suspected unexpected adverse reaction  
T-BSA  total body surface area  
TCS topi[INVESTIGATOR_352828] -emergent adverse event  
T-PaGIC -V total body assessment of Patient Global Impression of Change -Vitiligo  
T-PaGVA  total body assessment of Patient's Global Vitiligo Assessment  
T-PhGVA  total body assessment of Physician Global Vitiligo Assessment  
TSH  thyroid -stimulating hormone  
TSQM  Treatment Satisfaction Questionnaire for Medication  
T-VASI  total body Vitiligo Area Scoring Index  
T-VASI25/50/75/90  ≥ 25%/ 50%/ 75%/ 90% improvement in t otal body Vitiligo Area Scoring Index  
TYK  tyrosine kinase  
ULN  upper limit of normal  
UV ultraviolet  
VASI  Vitiligo Area Scoring Index  
VitiQoL  Vitiligo-specific quality of life  
VNS  Vitiligo Noticeability Scale  
Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 9 of 79 
23 JUN 2019
CONFIDENTIAL
1. PROTOCOL SUMMARY
Protocol  Title:  A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety 
Study of Ruxolitinib Cream Followed by [CONTACT_352927]:  INCB [ZIP_CODE]-307
Obje
ctives an d Endpoints : 
Table 1 presents the primary, key secondary , and  selected secondary objective s and endpoints. 
Table 1: Pr
imary and Secondary Objectives and Endpoints  
Objectives Endpoints  
Primary  
To evaluate the efficacy of ruxolitinib cream in 
participants  with vitiligo . •Proportion of participants achieving F-VASI75 at
Week 24.
Key Secondary  
To further assess the efficacy of ruxolitinib 
cream . •Percentage change from baseline in F -BSA at
Week 24 .
•Proportion of participants achieving F-VASI50  at
Week 24.
•Proportion of participants achieving F-VASI75 atWeek 52.
•Proportion of participants achieving F -VASI 90 at
Week 24.
•Proportion of participants ac hieving F -VASI90 at
Week 52.
•Proportion of participants achieving T-VASI50 atWeek 24 .
•Proportion of participants achieving T-VASI50 atWeek 52 .
•Proportion of participants achieving T-VASI75 atWeek 52 .
•Proportion of par ticipants achieving a VNS of
“4 – A lot less noticeable” or “5 – No longer
noticeable” at Week 24.
Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 10 of 79
23 JUN 2019
CONFIDENTIAL
Table 1: Primary and Secondary Objectives and Endpoints  (Continued)  
Objectives Endpoints  
Selected Secondary  
To evaluate the safety and tolerability of 
ruxolitinib cream . • The frequency, duration, and severity of AEs; 
physical examinations; vital signs; and laboratory 
data for hematology, serum chemistry, and 
urinalysis.  
To further assess the efficacy of ruxolitinib cream.  • Proportion of participants achieving F-VASI25/50/75/90 during the treatment period (double-blind and treatment extension period s).  
• Proportion of participants achieving T-VASI25/50/75/90 during the treatment period 
(double-blind and treatment extension period s).  
• Proportion of participants in each category of VNS 
during the treatment period (double-blind and 
treatment extension  period s). 
Overall Design:  
Table 2 presents the key study design elements.  Further study details are presented after the 
table . 
Table 2: Key Study Design Elements  
Study Phase  Phase 3  
Clinical Indication  Vitiligo  
Population Males and females, aged ≥ [ADDRESS_439345] vitiligo with ≥ 0.5% BSA on the 
face, ≥ 0.5 F- VASI, ≥ 3% BSA on nonfacial areas, and ≥ 3 T -VASI .  Total 
body vitiligo area (facial and nonfacial) should not exceed 10% BSA. 
Number of 
Participants  Approximately 300 participants will be randomized 2:1 (ruxolitinib c ream  1.5% 
BID:vehicle).  
Study Design  Randomized, double- blind, vehicle -controlled, with a treatment  extension 
period. 
Estimated 
Duration of Study Participation  Screening:  Up to 32 days 
Double-blind period:  24 weeks Treatment  extension period:   28 weeks 
Safety follow-up:  [ADDRESS_439346] 
study visit  
Total:  Up to approximately 60  weeks 
The study design is shown in Figure  1.  The SoA is detailed in Table 3 ( for the double-blind 
period) and  Table 4 ( for the treatment  extension period).  Adherence to the study design 
requirements, including those specified in the SoA, is essential and required for study conduct. 
Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 11 of 79 
23 JUN 2019
CONFIDENTIAL
Figure  1: Study Design Schema  
This is a
 randomized, vehicle-controlled study in adolescent and adult participants ( age 
≥ 12 years) with non-segmental  vitiligo who have depi[INVESTIGATOR_352829] ≥ 0.5% BSA on 
the face, ≥ 0.5 F-VASI, ≥ 3% BSA on nonfacial areas, and ≥ 3 T- VASI .  Total b ody involved 
vitiligo  area (facial and nonfacial)  should not exceed 10% BSA.  Approximately 300 participants 
will be randomized 2:1 to receive initial study treatment (ruxolitinib cream 1.5% BID:vehicle; 
applied to depi[INVESTIGATOR_352830] d body up to 10% total BSA ) for 24  weeks  
(see Figure  1).  Participants will be stratified by [CONTACT_654] (≤ 40 or > 40 years) and skin type 
(Fitzpatrick scale T ype I and II vs Type III, IV, V, and VI).  Adolescents (≥ 12 to < 18 years ) 
will make up at least 10% of the study population, and no more than 50% of participants will be 
> 40 years old. 
After completion of the Week 24 assessments, participants will be offered the opportunity to 
receive an additional 28 weeks of treatment extension with ruxolitinib cream 1.5% BID.  To be 
eligible  for the treatment extension , participants must have completed the baseline and Week  [ADDRESS_439347] any safety issues.  The total 
treated area should not exceed 1 0% BSA  (facial and nonfacial) . 
See Section  4.[ADDRESS_439348] and maintenance regimens.  
Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 12 of 79
23 JUN 2019
CONFIDENTIAL

Table 3:  Schedule of A ctivitie s:  Double -Blind, Vehicle- Controlled Treatment Period  (Day  1-Week 24)  
Procedure  Screening  Double -Blind , Vehicle Controlled Treatment  Notes  
Days  
-32 to -1 Day 1 
 Wk 4  
± 3 d  Wk 8  
± 3 d  Wk 12  
± 3 d  Wk 18  
± 7 d Wk 24 * 
(EOT1) 
± 7 d *Week [ADDRESS_439349] IRT  X X X X X X X  
Inclusion and exclusion criteria  X X       
Demography  X        
General and disease medical 
history  X        
Prior/concomitant medications  X X X X X X X  
Apply s tudy drug  X X X X X X* At each study visit starting at Day 1, the participant  should 
apply the study drug under direct supervision of the site staff.   
*Not applicable to the EOT1 visit.  
Dispense  (D) and return (R)  
study drug and diary cards   D R/D R/D R/D R/D R/D*  All tubes of study drug will be weighed before being 
dispensed.  All returned tubes of study drug will be weighed, 
and those that are unused may be  re-dispensed. 
Re-dispens ion is not allowed at  Week 24 . 
*Dispension is not applicable to the EOT1 visit.  At the 
Week [ADDRESS_439350]/ 
review study drug diary cards    X X X X X  
Assess compliance    X X X X X  
Safety assessments   
AE assessment  X X X X X X X Ad hoc photography of skin -related AEs may  also occur as 
applicable.  
Targeted physical examinations   X X X X X   
Comprehensive physical 
examination  X      X  
Vital signs  X X X X X X X  
12-lead ECG  X       12-lead ECG performed within 2 months  before baseline is 
acceptable.  
Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 13 of 79 
23 JUN 2019
CONFIDENTIAL
Table 3:  Schedule of Activities :  Double -Blind, Vehicle -Controlled Treatment Period (Day  1-Week 24) (Continued)  
Procedure  Screening  Double -Blind , Vehicle Controlled Treatment  Notes  
Days  
-32 to -1 Day 1 
 Wk 4  
± 3 d  Wk 8  
± 3 d  Wk 12  
± 3 d  Wk 18  
± 7 d Wk 24*  
(EOT1) 
± 7 d *Week [ADDRESS_439351] visit of the treatment 
extension period. 
Efficacy assessments   
F-BSA  X X X X X X X  
T-BSA  X X X X X X X Includes facial and nonfacial areas.  
F-VASI  X X X X X X X  
T-VASI  X X X X X X X Includes facial and nonfacial areas.  
F-PhGVA   X   X  X  
T-PhGVA   X   X  X  
Photography of face  X X*   X  X 2D photography at  all sites; 3D photography a t selected sites . 
*If photo quality at screening is not adequate, the 
photography may be repeated at Day 1. The baseline photos 
are defined as the adequate ones either taken at screening or 
Day 1.  
Photography of nonfacial  target 
area X X*   X  X 2D photography at all sites. The genitalia  area should not be 
photographed.  
*If photo quality at screening is not adequate, the 
photography may be repeated at Day 1. The baseline photos are defined as the adequate ones either taken at screening or 
Day 1.  
Patient -reported outcomes  To be evaluated prior to any other study 
procedures/assessments.  
VNS      X  X The participant  will be provide d their baseline photo  and a 
mirror  to perform this assessment . 
Color -matching question      X  X The participant will be provided their baseline  photo  and a 
mirror  to perform this assessment.  
F-PaGIC -V     X  X  
T-PaGIC -V     X  X  
DLQI   X   X  X For participants who are age ≥ 12 years to < 16 years at 
baseline, the CDLQI will be completed instead.  
WHO -5  X   X  X  
TSQM      X  X  
VitiQoL   X   X  X  
HADS   X     X  
Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 14 of 79 
23 JUN 2019
CONFIDENTIAL
Table 3:  Schedule of Activities :  Double -Blind, Vehicle- Controlled Treatment Period (Day  1-Week 24) (Continued)  
Procedure  Screening  Double -Blind , Vehicle Controlled Treatment  Notes  
Days  
-32 to -1 Day 1 
 Wk 4  
± 3 d  Wk 8  
± 3 d  Wk 12  
± 3 d  Wk 18  
± 7 d Wk 24*  
(EOT1) 
± 7 d *Week [ADDRESS_439352] visit of the treatment 
extension period. 
Laboratory assessments   
Hematology and chemistry 
assessments  X X X X* X X* X *The bl ood draw at Week  8 and Week  18 is optional for 
participants who are age <  [ADDRESS_439353] 
12 months before screening.  
Pregnancy testing  X* X X X X X X *Female participants of childbearing potential will have a 
serum test at screening and safety follow -up visits.  A urine 
test will be conducted at all other visits.  A positive urine test 
must be confirmed by a serum test.  
PK and translational assessments   
Population -based PK plasma 
sampling (trough)    X    X Time of last study drug application to be recorded in eCRF.  
Blood samples must not be drawn from the area that has been 
treated with study drug.  
Samples will be drawn at predose.  
Serum sampling for biomarker 
analysis   X   X  X  
Note:  Unscheduled visits may occur at any time at the investigator's discretion, and appropriate clinical and laboratory tests may be performed, as clinically indicated.  
Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 15 of 79 
23 JUN 2019
CONFIDENTIAL
Table 4: Schedule of Activities:  Treatment Extension  Period (Week 28 -Week 52)  
Procedure  Treatment Extension  Safety Follow -Up Notes  
Wk 28  
± 7 d  Wk 34  
± 7 d  Wk 40  
± 7 d  Wk 46  
± 7 d  Wk 52 
(EOT2 *) 
± 7 d  30 days  
+ 7 d  After 
EOT1/EOT2 ** 
(EOS)  *EOT 2 assessments should be performed in the 
event a participant’s treatment is stopped before 
Week  52 at any relevant study visit before that time.  
**After last application  of study drug  or last visit . 
Administrative procedures   
Contact [CONTACT_12067]  X X X X X X  
Prior/concomitant medications  X X X X X X  
Apply study drug  X X X X   At ea ch study visit , the participant should apply the 
study drug under direct supervision of the site staff.  
Dispense (D) and return (R) study 
drug and diary cards  R/D R/D R/D R/D R  All tubes of study drug will be weighed before 
being dispensed.  All returned tubes of study drug will be weighed, and those that are unused may be  
re-dispensed.  
Collect study drug and collect/ 
review study drug diary cards  X X X X X   
Safety assessments   
AE assessment  X X X X X X  
Targeted physical examinations  X X X X  X  
Comprehensive physical 
examination      X   
Vital signs  X X X X X X  
Efficacy assessments   
F-BSA  X X X X X X  
T-BSA  X X X X X X Includes facial and nonfacial areas.  
F-VASI  X X X X X X  
T-VASI  X X X X X X Includes facial and nonfacial areas.  
F-PhGVA    X  X   
T-PhGVA    X  X   
Photography  of face    X  X  2D photograph at all sites; 3D photography a t 
selected sites.  
Photography of nonfacial target 
area   X  X  2D photography at all sites. The genitalia  area 
should not be photographed.  
Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 16 of 79 
23 JUN 2019
CONFIDENTIAL
Table 4: Schedule of Activities:  Treatment Extension  Period (Week 28 -Week 52)  (Continued)  
Procedure  Treatment Extension  Safety Follow -Up Notes  
Wk 28  
± 7 d Wk 34  
± 7 d  Wk 40  
± 7 d  Wk 46  
± 7 d  Wk 52 
(EOT2 *) 
± 7 d  30 days  
+ 7 d  After 
EOT1/EOT2 ** 
(EOS)  *EOT 2 assessments should be performed in the 
event a participant’s treatment is stopped before 
Week  52 at any relevant study visit before that time.  
**After last application  of study drug  or last visit . 
Patient -reported outcomes  To be evaluated prior to any other study 
procedures/assessments.  
VNS    X  X  The participant will be provided their baseline photo 
and a mirror to perform this assessment.  
Color -matching question    X  X  The participant will be provided their baseline photo 
and a mirror to perform this assessment.  
F-PaGIC -V   X  X   
T-PaGIC -V   X  X   
DLQI    X  X  For participants who are age ≥ 12 years to 
< 16 years at baseline, the CDLQI will be 
completed instead.  
WHO -5   X  X   
TSQM    X  X   
VitiQoL    X  X   
HADS      X   
Laboratory assessments   
Hematology and chemistry 
assessments  X X X X* X X *The blood draw at Week 46 is optional for 
participants who are age <  18 years  
Urinalysis         
Pregnancy testing  X X X X X X* *Female participants of childbearing potential will 
have a serum test at screening and safety follow -up 
visits.  A urine test will be conducted at all other 
visits.  A positive urine test must be confirmed by a 
serum test.  
PK and Translational assessments  
Population -based PK plasma 
sampling (trough)    X    Time of last study drug application to be recorded in 
eCRF.  Blood samples must not be drawn from the 
area that has been treated with study drug.  
Samples will be drawn at predose.  
Serum sampling for biomarker 
analysis    X  X   
Note:  Unscheduled visits may occur at any time at the investigator's discretion, and appropriate clinical and laboratory tests may be performed, as clinically indicated.  
Incyte Corporation
Protocol INCB [ZIP_CODE]-[ADDRESS_439354] 0.5% to 2% of the population worldwide  
(Krüger and Schallreuter 2012).  The prevalence is similar between men and women, and there is 
no known difference in presentation according to skin type or race.  Almost 50% of patients 
present before 2 0 years of age, and many of them present before 10 years of age ( Rodrigues et al  
2017).  Generalized (n on-segmental ) vitiligo is the most common type,  accounting for up to 
90% of cases ( Taieb  et al  2009).   Vitiligo is associated with autoimmune diseases such as Sutton 
nevus, thyroid disorders, juvenile diabetes mellitus, pernicious anemia, and Addison's disease.  
The natural course of the disease is generally unpredictable, but it is often progressive.  Some 
degree of spontaneous repi[INVESTIGATOR_352831] 10% to 20% of patients; however, it is typi[INVESTIGATOR_352832] ( Castanet and Ortonne 1997).  
Vitiligo is a serious disease owing to its substantial psychological impact on patients’ day -to-day 
functioning, and its progressive course if left untreated.  Studies have shown that the effect 
vitiligo has on quality of life, particularly psychological impairment, is similar to other skin 
diseases, such as psoriasis and AD ( Linthorst et al  2009).  Involvement of exposed skin, such as 
the face and hands, can have a major impact on self- esteem  and eventually link to the 
psychological burden and quality of life ( Silverberg and Silverberg 2013 ).  In some societies, 
there is poor acceptance and understanding of the disease, to the extent of discrimination against affected individuals ( Yazdani Aby[CONTACT_312341] 2014).  Approximately 75% of vitiligo sufferers feel 
their appearance is moderately to severely intolerable, and 41% of patients feel that there is little they can do to improve their condition, and fee lings of hopelessness increase with time ( Salzer 
and Schallreuter 1995).  Not surprisingly, 66% of patients report being distressed by [CONTACT_352928], and 92% have experienced stigmat ization ( Krüger  et al 2014).  Feelings of 
embarrassment and fear of rejection can cause vitiligo patients to withdraw and lead to social isolation in both personal and professional relationships.  A majority of patients with vitiligo 
have reported feelings of anxiety and embarrassment when meeting strangers or beginning a new 
sexual relationship ( Porter  et al  1990). Additionally, clinical depression or depressive symptoms 
are associated with vitiligo.  Based on var ious meta -analyses, patients with vitiligo were 
approximately 5 times more likely to suffer from depression than healthy controls ( Lai et al 
2017, Osinubi et al 2018).  A recent result s of the analysis indicated that the pooled prevalence 
of depression across 17 unique populations (n = 1711) was 29% ( Wang  et al 2017).  
Incyte Corporation
Protocol INCB [ZIP_CODE]-[ADDRESS_439355] self -consciousness of all pediatric age groups ( Silverberg  and Silverberg 
2013).  In a study comparing social development and the health- related quality of life of young 
adult patients with childhood vitiligo with healthy controls, vitiligo patients reporting negative 
childhood experiences reported significantly more problems in social development than those not 
reporting negative experiences.  Furthermore, negati ve childhood experiences were significantly 
associated with more health -related quality of life impairment in early adulthood ( Linthorst 
Homan et al 2008).  Thus, vitiligo is considered to be one of the most psychologically devastating diseases in dermatology.  
2.2. Current Treatment and Unmet Need in Vitiligo  
Currently , there is no approved drug  treatment for vitiligo.  The conclusions of the most recent 
updated Cochrane systematic review were hampered by [CONTACT_352929] ( Whitton et al 2016).  A systemic review on outcomes in a vitiligo study also 
showed that the 25 different outcomes had been measured in 54 randomized clinical studie s.  
Although repi[INVESTIGATOR_352833] 94% of studies, 48 different scales were used to measure it, making comparison among studies imposs ible ( Eleftheriadou  et al 2012).  Therefore, 
a definitive clinical recommendation for treatment of vitiligo could not be proposed , and the 
management of vitiligo is empi[INVESTIGATOR_352834] (American Academy of Dermatology , Gawkrodger et al 2008, Taieb  et al 2013, Vitiligo 
Research Foundation ).  In general, first -line treatments consist of topi[INVESTIGATOR_352835], which are most useful for treating disease that is localized.  Second- line treatments 
consist of phototherapy (NB- UVB and PUVA) and systemic steroid treatment.  Third -line 
treatments consist of surgical grafting techniques and depi[INVESTIGATOR_352836].    However, 
response to current treat ment varies, can be time -intensive, can be slow to respond to treatment, 
and often produces disappointing results if repi[INVESTIGATOR_312293]. 
There has been  a limited number of randomized controlled clinical studies conducted to 
adequately support the efficacy of drug treatments in vitiligo.   Factors that further limit the 
evidence for efficacy are variations in study design and outcome measures, small study size (the 
majority of which included fewer than 50 participants), and deficiencies in methodological 
quality based on a systematic review of randomized clinical studies evaluating interventions for 
vitiligo ( Whitton et al 2016).  Apart from inconclusive (or insufficient) evidence for the efficacy 
of current off- label drug treatments in vitiligo, their safety profiles may also carry specific 
restrictions for their topi[INVESTIGATOR_44785].  For example, TCS may be associated with local adverse effects, 
including irreversible ones such as skin atrophy and striae distensae, and an increased susceptibility to skin infec tions ( Coondoo et al 2014).  More potent TCS, through their 
percutaneous absorption and depot-like accumulation in the epi[INVESTIGATOR_49196], may also produce well-known systemic AE s typi[INVESTIGATOR_352837].  Additionally, there are restrictions on the 
use of such TCS on sensitive skin areas , particularly on the face,  and for the overall treatment 
duration (ie, not to exceed 4 weeks).  Therefore, judicious use of high potency preparations of TCS is critical.  Topi[INVESTIGATOR_352838], which makes their use on the face problematic.  
Incyte Corporation
Protocol INCB [ZIP_CODE]-[ADDRESS_439356] been implied in their possible contribution to cutaneous 
malignan cy when used long- term.  
Available phototherapy treatments include NB-UVB and PUVA.  Phototherapy regimens 
typi[INVESTIGATOR_1435] 2 to 3 treatments per week and long-term duration of treatment.  For both 
NB-UVB and PUVA, 12 to 24 months of continuous phototherap y may be necessary to acquire 
maximal repi[INVESTIGATOR_371] ( Taieb et al 2013 ).  A minimum of 6 months of continuous 
phototherapy is recommended before being considered nonresponsive ( Taieb et al 2013, Ba e 
et al 2017) .  Relapses are common; approximately  60% to  70% of patients resume 
depi[INVESTIGATOR_352839] 1 year with PUVA or NB -UVB 
therapy ( Boniface et al 2018 ).  There are also important safety limitations with phototherapy.  
PUVA carries a risk of phototoxic effects, nausea, and the potential risk for skin cancer.  
Moreover, PUVA phototherapy is not recommended for children or pregnant women due to risks associ ated with systemic exposure of psoralen.  NB-UVB phototherapy is considered to have 
safety advantages over PUVA but is also associated with AEs such as erythema, itching, and 
mild burning or pain ( Bae et al 2017 ).  Excimer laser or m onochromatic excimer lamp (both at 
308 nm) that  may reach deeper targets such as amelanotic melanocytes of the hair follicle, and 
also avoid irradiation of uninvolved skin, may improve clinical outcomes; however, they are limited to localized treatment ( Boniface et al 2018 ). 
Lastly, surgical treatments in vitiligo may be considered  after failure to respond to drug and light 
therapi[INVESTIGATOR_352840] s, 
no Koebner phenomenon, and no extension of the vitiligo area  in the previous [ADDRESS_439357] been reported with certain 
surgical procedures ( Gawkrodger  et al 2008, Taieb et al 2013 ).  Surgery is best indicated for 
stable and localized forms of vitiligo , and only a small number of patients with vitiligo are 
considered suitable candidates.  
Given the lack of approved therapi[INVESTIGATOR_352841]-label drug treatments, there is a need to identify a safe and effective new treatment  for 
vitiligo . 
2.3. Role of Janus Kinases in Vitiligo 
Vitiligo pathogenesis involves intrinsic defects within melanocyte s and autoimmunity that 
targets these cells.  Studies have shown that melanocytes from vitiligo patients are more 
vulnerable than those from healthy individuals ( Rodrigues et al 2017, Speeckaert and van Geel 
2017) .  Once melanocytes become stressed, they release inflammatory signals that activate  innate 
immunity, which may represent the initiation even t in vitiligo.  The oxidative stress, cell damage , 
and cytokines secreted from innate immune  cells then trigger CXCL10 release by [CONTACT_352930] , and 
that recruits CD8+ T cells to the site.  Activated CD8+ T cells produce IFN -γ and other 
inflammatory mediators to target and destroy melanocytes  (Frisoli and Harris 2017) .  Because 
IFN-γ signaling utilizes the JAK -STAT pathway, inhibition of JAK signaling may be an 
effective strategy for vitiligo treatment development.  
There are several case reports and case series suggesting that modulatio n of the immune response 
through JAK inhibition may be effective in treating vitiligo.  A patient with both AA and vitiligo 
was treated with oral ruxolitinib 20 mg BID for 20 weeks and subsequently had hair regrowth as 
well as significant repi[INVESTIGATOR_352842]  (Harris et al 2016).  In another 
Incyte Corporation
Protocol INCB [ZIP_CODE]-[ADDRESS_439358] a response to topi[INVESTIGATOR_28709], tacrolimus ointment, and NB-UVB phototherapy treated with oral tofacitinib at 5 mg 
QD and resulted in near complete repi[INVESTIGATOR_352843] 5 months of treatment ( Craiglow and 
King 2015).  
There was a 20 -week open -label study using topi[INVESTIGATOR_352844] (INCB 018424) in 
12 participants  with vitiligo who had a minimum of 1% BSA affected.  The results showed a 
76% improvement in F-VASI and 26% improvement in T-VASI within 7 of 9 participants  who 
completed the study ( Rothstein et al 2017).   The same group conducted an additional 32- week 
extension study with optional NB- UVB treatment  (Joshipura et al  2018).  Five participants 
completed the study, and 3 of them received NB- UVB.  At Week 5 2 (Week 20 + Week 32), 
results showed 92% improvement in F- VASI and 37% in T -VASI.  The results also indicated 
that [ADDRESS_439359] also been characterized f ollowing oral administration.  
 
 
 
 
 
Please refer to the ruxolitinib cream IB. 
  
 
Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 21 of 79 
23 JUN 2019
CONFIDENTIAL

 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
2.4.2. Cli
nical Experience 
Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 22 of 79 
23 JUN 2019
CONFIDENTIAL

Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 23 of 79 
23 JUN 2019
CONFIDENTIAL

[IP_ADDRESS]. Efficacy  of Ruxolitinib Cream  
[IP_ADDRESS].1. Psoriasis 
Ruxolitinib cream has been evaluated in over 200 adults with plaque psoriasis in 3 clinical 
studies with application of 4 to 12 weeks duration.  Overall, ruxolitinib cream (0.5 %, 1.0%, or 
1.5%) was effective in decreasing disease severity.  Observed AEs were mild to moderate in 
intensity and most were judged unrelated to study medication, with no treatment- related SAEs or 
withdrawals.  Ruxolitinib cream demonstrated to be safe and well-tolerated when applied QD for 
12 weeks to plaque psoriasis affecting 2% to 20% of the BSA. 
[IP_ADDRESS].2. Atopic Dermatitis  
There were 307 adult participants with mild to moderate AD affecting total 3% to 20% BSA 
enrolled in a Phase 2, randomized, vehicle- and active (triamcinolone 0.1% cream)-controlled 
dose- ranging study.  The mean percentage change from baseline at Week 4 in EASI score 
demonstrated a significant improvement (1.5% BID [-71.6%0 vs vehicle [ -15.5%]).  At the 
highest exposure (1.5% BID), ruxolitinib cream was noninferior to triamcinolone.  In addition, 
significant reductions in itch were noted as early as within a day from the initiation of therapy 
with ruxolitinib  cream .  The most frequently reported TEAE was nasopharyngitis, which 
occurred in 2.0% to 7.8% of participants across dose strengths in the double-blind period and in 
5.2% of participants in the open-label period.  No fatal or serious TEAEs occurred in participants 
who received ruxolitinib cream.  Phase 3 studies (INCB [ZIP_CODE]-303 and -304) in adults and adolescents  are ongoing.  
More details are included in the ruxolitinib cream IB. 
[IP_ADDRESS].3. Vitiligo  
INCB [ZIP_CODE]-211 (see Figure  3) is a Phase 2, randomized, double-blind, vehicle-controlled study 
in adults with vitiligo who have depi[INVESTIGATOR_352845] 0.5% BSA on the face and 
at least 3% BSA on nonfacial areas .  A total of 157 participants  were equally randomized to 
receive ruxolitinib cream 1.5% BID, 1.5% QD, 0.5% QD, 0.15% QD, or vehicle BID for 
Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 24 of 79 
23 JUN 2019
CONFIDENTIAL

24 weeks.  In the second part of the study, all participants  initially randomized to vehicle  BID 
and participants  initially randomized to 0.15% QD who did not achieve ≥ 25% improvement 
from baseline in F-VASI were rerandomized to 1 of the 3 higher dosing groups for an additional 
28 weeks.  All other participants maintained the same treatment until Week 52.  After Week 52, 
participants  could receive open -label 1.5% BID for an additional 52 weeks.  The primary 
endpoint was the proportion of participants who achieved a ≥ 50% improvement from baseline in F-VASI50  at Week 24 . 
Figure  3: INCB [ZIP_CODE]-211 Study Schema  
 
All ruxolitinib treatment arms demonstrated clinically meaningful efficacy and superiority over 
vehicle.  The proportion of participants who achieved an F- VASI50 at Week 24 was statistically 
significantly greater for ruxolitinib cream versus vehicle with response rates of 32.3%, 25.8%, 
50.0%, and 45.5% for ruxolitinib cream 0.15% QD, 0.5% QD, 1.5% QD, and 1.5% BID, respectively, and 3.1% for vehicle.  The proportion of participants who achieved an F- VASI75 at 
Week 24 was also statistically si gnificantly greater for ruxolitinib cream versus vehicle with 
response rates of 9.7%, 16.1%, 16.7%, and 30.3% for ruxolitinib cream 0.15% QD, 0.5% QD, 1.5% QD, and 1.5% BID, respectively,  and 0% for vehicle.  Participants who were initially 
randomized to ruxolitinib cream 0.5% QD, 1.5% QD, and 1.5% BID continued on these 
treatments until Week 52.  Continued improvement in F- VASI response in these treatment was 
observed with the proportion of participants who achieved an F-VASI75 at Week 52 demonstrating response rates of 29.0%, 30.0%, and 51.5% for ruxolitinib cream 0.5% QD, 1.5% QD, and 1.5% BID.  
Improvements in T-VASI were observed for both Week 24 and Week 52.  The proportion of participants who achieved a T -VASI50 at Week 24 was also statistically significantly greater for 
ruxolitinib cream 0.15% QD, 0.5% QD, 1.5% QD, and 1.5% BID compared with  vehicle with 
response rates of 16.1%, 6.5%%, 23.3%, and 12.1% , respectively,  compared with 0% in 
vehicle-t reated participants .  Continued improvement in participants treated with 0.5% QD, 
1.5% QD, and 1.5% BID through Week 52 was observed with response rates in T-VASI50 of 
25.8%, 30.0%, and 36.4%, respectively.  
Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 25 of 79 
23 JUN 2019
CONFIDENTIAL
Compared with F-VASI, improvement in T- VASI was slower.   This observation is not 
unexpected given  that repi[INVESTIGATOR_352846] a slower rate 
than facial repi[INVESTIGATOR_371].   Despi[INVESTIGATOR_129840], response rates for the F -VASI50, F -VASI75, and 
T-VASI50 favor ed the higher strength tr eatment regimens (both 1.5% QD and 1.5% BID) versus 
vehicle at Week  24 and 1. 5% BID regimen at Week 52  across the endpoints.  Given that many 
participants  may not achieve peak response by [CONTACT_10585] 24  and that there are constraints to the 
length of the vehicle period, the 1.5% BID regimen appears to have given a higher response over 
time.  Key secondary endpoints including percentage change in F-BSA, F-PhGVA, and PaGIC 
also follow ed a similar pattern , with separation from vehicle at Week 24 and continued 
improvement through Week 52.  
All ruxolitinib treatment ar ms were generally safe and well -tolerated with no significant TEAE s 
or application site events and no clinically relevant hematological changes.  TEAE ra te overall is 
low and similar between active treatment and vehicle treatment.  There were 4 SAEs through 
52 weeks and all of them were not treatment -related.  Discontinuations from treatment through 
52 weeks was low.  Safety and tolerability were similar b etween the Week 24 and Week 52 
period.   
Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 26 of 79 
23 JUN 2019
CONFIDENTIAL

Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 27 of 79 
23 JUN 2019
CONFIDENTIAL

Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 28 of 79 
23 JUN 2019
CONFIDENTIAL

Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 29 of 79 
23 JUN 2019
CONFIDENTIAL

3. OBJECTIVES AND ENDPO INTS  
Table 8 presents the objectives and endpoints. 
Table 8: Objectives and Endpoints  
Objectives Endpoints  
Primary  
To evaluate the efficacy of ruxolitinib cream in 
participants with vitiligo.  • Proportion of participants achieving F- VASI 75 
at Week 24.  
Key Secondary  
To further assess the efficacy of ruxolitinib cream.  • Percentage change from baseline in F -BSA at 
Week 24 . 
• Proportion of participants achieving F-VASI50 
at Week 24.  
• Proportion of participants achieving F-VASI75 at Week 52.  
• Proportion of participants achieving F- VASI 90 
at Week 24.  
• Proportion of participants achieving F-VASI90 at Week 52.  
• Proportion of participants achieving T-VASI50 at Week 24 . 
• Proportion of participants achieving T-VASI50 at Week 52 . 
• Proportion of participants achieving T-VASI75 at Week 52 . 
• Proportion of par ticipants achieving a VNS of 
“4 – A lot less noticeable” or “5 – No longer 
noticeable” at Week 24.  
Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 30 of 79 
23 JUN 2019
CONFIDENTIAL

Table 8: Obje
ctives and Endpoints  (Continued)  
Objectives Endpoints  
Secondary  
To evaluate the safety and tolerability of 
ruxolitinib cream. • The frequency, duration, and severity of AEs; 
physical examinations; vital signs; and 
laboratory data for hematology, serum 
chemistry, and urinalysis.  
To further assess the efficacy of ruxolitinib cream. • Proportion of participants achieving F-VASI25/50/75/90 during the treatment period (double-blind and treatment extension period s).  
• Percentage change from baseline in F -VASI 
during the treatment period (double-blind and 
treatment extension  period s). 
• Percentage change fr om baseline in F- BSA 
during the treatment period (double-blind and treatment extension  period s). 
• Percentage change from baseline in T -VASI 
during the treatment period (double-blind and 
treatment extension  period s). 
• Percentage change from baseline in T -BSA 
during the treatment period (double-blind and treatment extension  period s). 
• Proportion of participants achieving T-VASI25/50/75/90 during the treatment period (double-blind and treatment extension period s).  
• Proportion of participants in each category of VNS during the treatment period (double-blind 
and treatment extension periods) . 
To evaluate the ruxolitinib PK in plasma after 
treatment of ruxolitinib cream. • Population- based (trough) plasma 
concentration s of ruxolitinib at Weeks 4, 24 and 
40. 
Exploratory  
To determine the participants’ quality of life. • Proportion of participants achieving an F-PhGVA of clear (0) or almost clear (1) during  
the treatment period (double-blind and treatment extension  period s). 
• Proportion of participants achieving an T-PhGVA of clear (0) or almost clear (1) during  
the treatment period (double-blind and treatment extension  period s). 
• Proportion of participants in each F- PhGVA 
category during the treatment period (double-blind and treatment extension period s). 
Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 31 of 79 
23 JUN 2019
CONFIDENTIAL
Table 8: Obje
ctives and Endpoints  (Continued)  
Objectives Endpoints  
Exploratory (continued)  
To determine the participants’ quality of life. 
(continued) • Proportion of participants in each T- PhGVA 
category during the treatment period 
(double-blind and treatment extension periods). 
• Proportion of participants who report F-PaGIC -V of very much improved or much 
improved during the treatment period (double-blind and treatment extension period s). 
• Proportion of participa nts in each F -PaGIC -V 
category during the treatment period (double-blind and treatment extension period s). 
• Proportion of participants who report T-PaGIC -V of very much improved or much 
improved during the treatment period (double-blind and treatment extension periods). 
• Prop ortion of participants in each T- PaGIC -V 
category during the treatment period (double-blind and treatment extension period s). 
• Proportion of participant in each category for the color-matching question during the 
treatment period (double-blind and treatment 
extension  period s). 
• Change from baseline in DLQI (or CDLQI) during the treatment period (double-blind and treatment extension  period s). 
• Change from baseline in WHO-5 during the treatment period (double-blind and treatment 
extension  perio ds). 
• Change from baseline in  TSQM  during the 
treatment period (double-blind and treatment extension  period s). 
• Change from baseline in VitiQoL during the 
treatment period (double-blind and treatment extension  period s). 
• Change from baseline in HADS during th e 
treatment period (double-blind and treatment 
extension  period s). 
To evaluate translational biomarkers in the blood 
of participants treated with ruxolitinib cream. • Change from baseline in the expression of select 
biomarkers in peripheral blood at Weeks 12, 24, 
40, and 52. 
Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 32 of 79 
23 JUN 2019
CONFIDENTIAL
4. STUDY DESIGN 
4.1. Overall Design  
This is a randomized, vehicle-controlled study in adolescent and adult participants ( age 
≥ 12 years) with non-segmental  vitiligo who have depi[INVESTIGATOR_352829] ≥ 0.5% BSA on 
the face, ≥ 0.5 F- VASI , ≥ 3% BSA on nonfacial areas, ≥ 3 T- VASI,  and for whom total body 
involved vitiligo  area (facial and nonfacial)  does not exceed 10% BSA.  Approximately 
300 participants will be randomized 2:1 to receive initial study treatment (ruxolitinib cream 1.5% 
BID: vehicle) for 24  weeks  (see Figure  1).  Participants will be stratified by [CONTACT_654] (≤ 40 or 
> 40 years) and skin type (Fitzpatrick scale Type I and II vs Type III, IV, V, and VI).  
Adolescents (≥ 12 to < 18  years ) will make up at least 10% of the study population, and no more 
than 50% of participants will be > 40 years  old. 
During the double- blind, vehicle -control led period, participants will receive ruxolitinib cream 
1.5% BID  or vehicle for 24 weeks to be applied to depi[INVESTIGATOR_352847] 10% total BSA.  Participants should continue to treat depi[INVESTIGATOR_352848]. 
After completion of the Week 24 assessments, participants will be off ered the opportunity to 
continue in the treatment extension period.  P articipants initially randomized to vehicle will be 
crossed over to active drug, and participants treated with ruxolitinib cream will receive an 
additional 28 weeks of treatment with ruxolitinib cream 1.5% BID .  To be eligible  for the 
treatment extension , participants must have completed the baseline and Week [ADDRESS_439360] any safety issues.  During the treatment extension, participants should continue to treat depi[INVESTIGATOR_352849].  Total treated areas 
(facial and nonfacial areas)  should not exceed to 10% BSA.   
Safety endpoints, such as nature of AEs (type, frequency, and severity), vital signs, targeted 
physical examination, and routine laboratory investigations, will be monitored and recorded 
throughout the course of this study. 
Following the last application of ruxolitinib cream at Week 52, there will be a 30- day safety 
follow-up period to evaluate safety and duration of response.   
Participants  who successfully complete the [ADDRESS_439361] and maintenance 
regimens.   
See Section  6.5 for detailed  information of study drug modification and application guidance. 
4.2. Overall Study Duration  
Screening is up to 32 days ( ~4 weeks) ; the double-blind, vehicle-controlled treatment peri od is 
24 weeks ; the treatment extension period is 28 weeks ; and safety follow-up is 30 days.  Total 
duration is up to approximately 60 weeks  (see Figure 1). 
The study will begin when the first participant (or parent or guardian) signs the ICF.  The end of 
the study is defined as the date of the last visit of the last participant in the study or  the date that 
the last participant discontinued study drug and completed applicable safety follow-up 
Incyte Corporation
Protocol INCB [ZIP_CODE]-[ADDRESS_439362] completed the study if 
he/she has completed all study visits, including the safety follow-up visit. 
4.3. Study Termination  
The investigator retains the right to terminate study participation at any time, according to the 
terms specified in the study contract.  The investigator is to notify the IRB/IEC in writing of the 
study's completion or early termination, send a copy of the notification to the sponsor or 
sponsor's designee, and retain 1 copy for the site study regulatory file.  
The sponsor may terminate the study electively or if required by [CONTACT_352931].  In the event 
of significant safety findings, the study will be terminated.  If the study is terminated prematurely, the sponsor or designee will notify the investigators, the IRBs/IECs, and regulatory bodies of the decision and reason for termination of the study.   
5. STUDY POPULATIO N 
Deviations from eligibility criteria are prohibited because they can potentially jeopardize the 
scientific integrity of the study, regulatory acceptability, and/or participant safety.  Therefore, 
adherence to the criteria as specified in the Protocol is essential.  Prospective approval of 
Protocol deviations to recruitment and enrollment criteria, also known as Protocol waivers or exemptions, are not permitted. 
5.1. Inclusion Criteria 
Participants are eligible to be included in the study only if all of the fol lowing criteria apply:  
1. Adolescents and adults aged ≥ 12 years. 
2. Participants with a clinical diagnosis of non- segmental  vitiligo  with depi[INVESTIGATOR_352850] ≥ 0.5% BSA on the face, ≥ 0.5 F- VASI , ≥ 3% BSA on nonfacial areas, 
≥ 3 T- VASI,  and total body vi tiligo area (facial and nonfacial)  not exceed ing 10% BSA.  
3. Participants who agree to discontinue all agents used to treat vitiligo from screening through the final safety follow-up visit.  Over-the-counter preparations deemed 
acceptable by [CONTACT_352932].  
4. Male and female participants must be willing to take appropriate contraceptive measures to avoid pregnancy or fathering a child for the duration of study participation with the exception of the following: 
a. Females of non- childbearing potential (ie, or surgically sterile with a hysterectomy  
and/or bilateral oophorectomy OR ≥ 12 months of amenorrhea ). 
b. Prepubescent adolescents.  
Note:  Information about specific types of acceptable contraceptive measures and 
duration of contraceptive use are provided in Appendix A . 
Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 34 of 79 
23 JUN 2019
CONFIDENTIAL
5. Ability t
o comprehend and willingness to sign an ICF or written informed consent of the 
parent(s) or legal guardian and written assent from the participant when possible. 
Note:  Adolescents, who during the course of the study become legal adults, will be asked 
for their consent to continue the study, and in the event of lack thereof, will be 
discontinued from further participation. 
5.2. Exclusion Criteria  
Participants are excluded from the study if any of the following criteria apply:  
1. Participants who have no pi[INVESTIGATOR_352851]. 
2. Other forms of vitiligo (e g, segmental)  or other differential diagnosis of vitiligo  or other 
skin depi[INVESTIGATOR_262807] ( eg, pi[INVESTIGATOR_312303], pi[INVESTIGATOR_80166], leprosy, postinflammatory 
hypopi[INVESTIGATOR_371], progressive macule hypomelanosis, nevus anemicus, chemical leukoderma, and tinea versicolor). 
3. Participants who have used depig mentation treatments  (eg, monobenzone ) for past 
treatment of vitiligo or other pi[INVESTIGATOR_312294]. 
Note:  Prior use of hydroquinone is not prohibited ( as it is a bleaching a gent, not a 
depi[INVESTIGATOR_352852]) . 
4. Participants with concurrent conditions and history of other diseases: 
a. Any other skin disease that, in the opi[INVESTIGATOR_871], would interfere with 
the study medication application or study assessments.  
b. Activ e acute bacterial, fungal, or viral skin infection (eg, herpes simplex, herpes 
zoster, chicken pox) within 1 week before baseline. 
c. Conditions at baseline that would interfere with evaluation of vitiligo.  
d. Any serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opi[INVESTIGATOR_1649], would interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpret ation of study data.  
Examples include but are not limited to the following : 
− Clinically significant or uncontrolled cardiac disease, including unstable angina, 
acute myocardial infarction within 6 months from Day 1 of study drug 
administration, [LOCATION_001] He art Association Class III or IV congestive heart 
failure, and arrhythmia requiring therapy or uncontrolled hypertension (blood 
pressure > 150/90 mmHg) unless approved by [CONTACT_352933]/sponsor.  
− History of thrombosis, including deep venous thrombosis and pulmonary embolism.  
− Participants with concurrent malignant disease or a history of that in the 5 years preceding the baseline visit except for adequately treated nonmetastatic malignancies.  
− Current and/or history of liver disease, including known hepatitis B or C, with 
hepatic or biliary abnormalities.  
Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 35 of 79 
23 JUN 2019
CONFIDENTIAL
− History of 
alcoholism or drug addiction within 1 year before screening or current 
alcohol or drug use that, in the opi[INVESTIGATOR_871], will interfere with the 
participant' s ability to comply with the administration schedule and study 
assessments.  
− Participants who are committed to a n institution by [CONTACT_352934].  
5. Participants using any of the following treatments within the indicated washout period 
before baseline:  
a. 1 week:   Topi[INVESTIGATOR_352853], for example,  corticosteroids, 
calcineurin , and phosphodiesterase type 4 inhibitors or retinoids. 
b. 4 weeks:  
− Melanocyte- stimulating agents (eg, afamelanotide).  
− Immunomodulating systemic medications (eg, corticosteroids, methotrexate, 
cyclosporine). 
− Any other systemic therapi[INVESTIGATOR_352854] y to UV/ visible 
light or impact skin pi[INVESTIGATOR_371], for example,  tetracyclines,  metoxypsoralens . 
− Received live vaccine.  
Note:   Live vaccine is prohibit ed during the course of the study and  within 
4 weeks after the EOT  visit. 
c. 8 weeks:   Laser or any kind of phototherapy, including tanning bed or intentional UV 
exposure. 
d. 5 half- lives  or 12 weeks , whichever is longer:  Biologic agents, investigational or 
experimental therapy or procedures for vitiligo.  Investigational biologics should be 
discussed with the sponsor to determine whether  a longer period of discontinuation is 
required. 
6. Parti cipants who have previously received JAK inhibitors, systemic or topi[INVESTIGATOR_2855]. 
7. Participants with clinically significant abnormal laboratory values at screening:  
a. Hemoglobin (< 10 g/dL).  
b. Liver function tests:  
− AST or ALT ≥ 2 × ULN. 
− Alkaline phosphatase and/or bilirubin > 1.5 × ULN (isolated bilirubin 
> 1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%). 
c. Severe renal disease ( with creatinine clearance < 30 ml/min ) or renal disease 
requiring dialysis . 
d. Clinically significant abnormal TSH or free T4 at screening as determined by [CONTACT_1275].  
e. Positive serology test results at screening for HIV antibody . 
8. Body mass index < 17 or > 40 kg/m2. 
Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 36 of 79 
23 JUN 2019
CONFIDENTIAL
9. Pregnant
 or lactating participants, or those considering pregnancy during the period of 
their study participation . 
10. Participants who, in the opi[INVESTIGATOR_871], are unable or unlikely to comply with 
the administration schedule and study evaluations.  
11. Employees of the sponsor or investigator or are otherwise dependents of them.  
5.3. Lifestyle Considerations  
Participants should be cautioned to avoid excessive exposure to artificial sunlight (including tanning booths, sun lamps, etc). 
If sunscreen , makeup, or other cosmetics have been applied to the areas to be treated, participants 
should wash the treatment areas with mild soap and water and pat dry before application of study drug (see Section  6.6.1). 
It is recommended that swimming should not take place within 2 hours before and after the planned study drug application. 
5.4. Screen Failures  
Screen failures are defined as participants who con sent to participate in the clinical study but are 
not subsequently assigned to study treatment.  Tests with results that fail eligibility requirements 
may be repeated once during screening if the investigator believes  that the participant would be 
eligible  if retested.  Additionally, a participant who fails screening may repeat the screening 
process 1 time if the investigator believes that there has been  a change in eligibility status or any 
laboratory abnormality is inconsistent with the participant’s medical history.  Participants who 
rescreen must be assigned a new screening number.   
5.5. Replacement of Participants  
Participants will not be replaced during the study.  
Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 37 of 79 
23 JUN 2019
CONFIDENTIAL
6. STUDY TREATMENT  
6.1. Study Treatment A pplication  
Table 9 presents the study treatment information.  
Table 9: Study Treatment Information  
Study treatment name:  [CONTACT_352990]:  Cream  
Unit dose strength(s)/dosage 
level(s): 1.5% Not applicable  
Route of administration:  Topi[INVESTIGATOR_352855]:  Double-blind and treatment extension period s:  BID .  A thin 
film is  applied to depi[INVESTIGATOR_352856].  Double-blind period:   BID .  A 
thin film is applied to the 
depi[INVESTIGATOR_352857].  
Treatment  extension period:  Not 
applicable. 
Packaging and labeling: Ruxolitinib cream and vehicle cream will be provided in 60 g tube.  Each tube will be labeled as required per country requirement.  
Storage: Ambient (15°C -30°C/59°F-86°F) 
Status of treatment in 
participating countries: Investigational  Not applicable  
On visit days, s tudy drug will be applied in the clinic during the visit.  Participants should 
remove study drug from the tube in fingertip units until all of the areas to be treated are covered 
by a thin film; the tube will be weighed before and after  application to determine the 
participant’s dosage.  On the day of a visit, the participant should not apply the study drug at 
home and will apply study drug from the new kit in the clinic.  Participants will be instructed to document treated areas and advised to limit use to no more than one [ADDRESS_439363] the study site to discuss with the investigator whether additional 
evaluation at the clinic is required.  If any other skin products that are permitted under the study 
Protocol are used, participants should continue these unchanged during the study.  
Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 38 of 79 
23 JUN 2019
CONFIDENTIAL
6.1.1. Applicatio
n During  the Double -Blind Vehicle -Controlled Treatment Period  
During the double- blind vehicle -controlled period (up to Week 24 ), participants should follow 
the below s tudy drug application guidance:  
• Participants should apply study drug only to depi[INVESTIGATOR_352858] a 
T-BSA  (facial and nonfacial) of ≤ 10% BSA . 
• Participants should continue to treat all depi[INVESTIGATOR_352859]. 
6.1.2. Application During the Treatment Extension Period  
During treatment extension period (Week 24 to Week 52), participants should follow the below 
study drug application guidance: 
• Participants should apply study drug to depi[INVESTIGATOR_352860] a T-BSA  
(facial and nonfacial) of  ≤ 10% BSA. 
• Participants should continue to treat all depi[INVESTIGATOR_352861]. 
• Participants who have an expansion of existing areas of vitiligo during the course of 
the treatment  extension period may treat these areas after a visit to document the 
VASI score and other measures of vitiligo (may be unscheduled vi sit), as  long as the 
new treated T-BSA  (facial and nonfacial) does not exceed 10% BSA . 
6.2. Preparation, Handling, and Accountability  
The investigator or designee must confirm appropriate temperature conditions (both ruxolitinib cream and vehicle cream are to b e stored between 15°C and 30°C [59°F-86°F]) have been 
maintained during transit for all study treatments received and any discrepancies are reported and resolved before use of the study treatment.  
Only participants enrolled in the study may receive study treatment, and only authorized site 
staff may supply study treatment.  Immediately after application of ruxolitinib cream, 
participants are to wash their hands thoroughly with soap and warm water.  Refer to the Study 
Pharmacy Manual for participant instructions for handling of study drug. 
All study treatment must be stored in a secure, environmentally controlled, and monitored 
(manual or automated) area in accordance with the labeled storage conditions with access limited to the investigator and authorized s ite staff.  Participants should store study treatment at ambient 
temperature conditions. 
The investigator (or designee) is responsible for study treatment accountability, reconciliation, 
and record maintenance (ie, receipt, reconciliation, and final disposition records).  Inventory and 
accountability records must be maintained and readily available for inspection by [CONTACT_147117].  The investigator or designee must maintain records that document: 
• Delivery of study drug(s) to the study site. 
• Inventory of study drug(s) at the site. 
Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 39 of 79 
23 JUN 2019
CONFIDENTIAL
• Partici
pant use of the study drug(s) including tube counts from each supply 
dispensed. 
• Return of study drug(s) to the investigator or designee by [CONTACT_352935].  
The investigational product must be used only in accordance with the Protocol.  The investigator 
will also maintain records adequately documenting that the participants were provided the 
specified study drug.  These records should include dates, quantities, and any available batch or serial numbers or unique code numbers assigned to the investigational product and study participants.  
Completed accountability records will be archived by [CONTACT_779].  The investigator or designee will be expected to collect and retain all used, unused, and partially used containers of study drug 
until verified by [CONTACT_11200] (unless otherwise agreed to by [CONTACT_456]).  At the conclusion of the study, the investigator or designee will oversee shipment of any remaining study drug back to the sponsor or its designee for destruction according to institutional SOP s.  If 
local procedures mandate on -site destruction of investigational supply, the site should (where 
local procedures allow) maintain the investigational s upply until the study monitor inspects the 
accountability records in order to evaluate compliance and accuracy of accountability by [CONTACT_198373].  At sites where the study drug is destroyed before monitor inspection, the 
monitors rely on documentation of destruction per the site SOP. 
Further guidance and information for the final disposition of unused study treatments are 
provided in the study materials provided to sites. 
6.3. Measures to Minimize Bias:   Randomization and Blinding  
All participants will be centrally assigned to study treatment using an IRT system.  The system 
will assign in a 2:1 ratio ( ruxolitinib cream 1.5% BID:vehicle), stratified by [CONTACT_654] ( ≤ 40 or 
> 40 years old ) and skin type (Fitzpatrick scale Type I and II vs Type III, IV, V, and VI).  
Adolescents will make up at least 10% or participants, and no more than 50% of participants will 
be aged greater than 40 years.   The IRT will assign  participant ID numbers, track participant 
visits, randomize participants according to the defined param eters, maintain the blinding, and 
manage study drug inventory.  Full details will be provided in the IRT Manual.  Study treatment will be dispensed at the study visits summarized in the Schedule of Activities (see Table 3 and 
Table 4).  
After the database lock for the primary analysis, the sponsor will be unblinded, but investigators 
and participants will still be blinded to individual treatment assignment s.  This is implemented to 
minimize bias for the Week [ADDRESS_439364] be emphasized to the participant by [CONTACT_89184], and appropriate steps should be taken to optimize compliance during the study.  
Compliance with ruxolitinib cream will be evaluated by [CONTACT_4317]' adherence to the application 
regimen and drug accountability documented by [CONTACT_352936] t he 
sponsor/designee (tube count s).  
Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 40 of 79 
23 JUN 2019
CONFIDENTIAL
In general, t
he application compliance will be determined by [CONTACT_352937], which should be within 70% to 130% of the prescribed 
number of applications.  Participants will be instructed to bring all study drugs with them to the study visits in order for site personnel to conduct tube counts to assess study drug accountability.  
The drug accountability documentation will be used by [CONTACT_352938]. 
6.5. Dose Modifications  
6.5.1. Criteria and Procedures for Application Interruptions of Study Drug  
Safety concerns should be discussed with the sponsor immediately upon occurrence or awareness to determine whether the participant should continue or discontinue study treatment.  
In some circumstances, it may be necessary to temporarily interrupt treatment with ruxolitinib cream.  Except in cases of emergency, it is recommended that any findings of concern (eg, AE) 
be confirmed and that the investigator consult with the sponsor medical monitor (or other 
representative of the sponsor) before interrupting study drug.  Additionally, the investigator must obtain approval from the sponsor before restarting study drug.  Participants who experience a 
recurrence of the init ial AEs upon restarting the study drug may need the study drug to be 
permanently discontinued.  
Instructions for application interruptions for ruxolitinib cream are outlined in Table 10.  
Individual decisions regarding interruptions should be made using clinical judgment in 
consultation with the medical monitor (whenever possible), taking into account relatedness of the AE to the study treatment and the participant's underlying condition. 
Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 41 of 79 
23 JUN 2019
CONFIDENTIAL
Table 10: Guide
lines for Interruption and Restarting of Study Drug  
Adverse Event  Action Taken 
Chemistry  
ALT (> 3 × ULN) or AST (> 3 × ULN)  • Laboratory abnormalities should be confirmed with 
repeat testing within 48 hours whenever possible 
and immediate delivery of the laboratory results 
requested . 
• Study drug applications must be interrupted.  At the discretion of the investigator, after consultation with 
the sponsor, study drug application may be restored 
once these have resolved.  
Other laboratory abnormalities  
Any other Grade 3 or higher laboratory 
abnormality, with the exception of 
asymptomatic elevations in triglyc eride, 
cholesterol, or amylase • Laboratory abnormalities should be confirmed with 
repeat testing within 48 hours whenever possible and immediate delivery of the laboratory results 
requested . 
• Study drug applications must be interrupted.  At the 
discretion of the investigator, after consultation with the sponsor, study drug application may be restored once these have resolved.  
Any Grade [ADDRESS_439365] or ALT (> 5 × ULN)  • Laboratory abnormalities should be confirmed with repeat testing within 48 hours whenever possible 
and immediate delivery of the laborato ry results 
requested.  
• Discontinue study drug if lab abnormalities are 
confirmed.  
6.5.2. Criteria for Permanent Discontinuation of Study Drug Due to an Adverse Event 
The occurrence of unacceptable severity of an AE not caused by [CONTACT_352939].  Unacceptable severity is defined as follows: 
• Occurrence of an AE that is related to treatment with the study drug that, in the judgment of the investigator or the sponsor's medical monitor, compromises the participant's ability to continue study -specific procedures or continuing treatment is 
considered to not be in the participant's best interest. 
• Worsening of vitiligo that requires treatment with a prohibited concomitant 
medication.  
See Section  7 for discontinuation procedures. 
6.6. Concomitant Medications and Procedures  
All concomitant medications and treatments (including over -the-counter or prescription 
medicines, vitamins, vaccines, and/or herbal supplements) must be recorded in the eCRF.  Any 
prior medication received up to [ADDRESS_439366] dose of study treatment will be recorded in the eCRF.  Any addition, deletion, or 
change in the dose of these medications will also be recorded.  Concomitant 
treatments/procedures that are required to manage a participan t's medical condition during the 
study will also be recorded in the eCRF.  The medical monitor should be contact[CONTACT_31182]. 
Incyte Corporation
Protocol INCB [ZIP_CODE]-[ADDRESS_439367] and maintenance 
regimens.   
Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 44 of 79 
23 JUN 2019
CONFIDENTIAL

7. DISCONTINUATION OF STUDY TREATMENT AND 
PARTICIPANT DISCONTI NUATION/WITHDRAWAL  
7.1. Discontinuation of Study Treatment  
7.1.1. Reasons for Discontinuation 
Participants must  be discontinued from study treatment for the following reasons: 
• The participant becomes pregnant. 
• Consent is withdrawn. 
Note:  Consent withdrawn means that the participant ha s explicitly indicated that they 
do not want to be followed any longer; in this case no further data, except data in 
public domain, may be solicited from or collected on the participant.  Participants 
may choose to discontinue study treatment and remain in t he study for safety 
monitoring. 
• Further participation would be injurious to the participant's health or well-being, in the investigator's medical judgment.  
• Any AE of unacceptable severity as noted in Section  6.5.2. 
• The study is terminated by [CONTACT_456]. 
• The study is terminated by [CONTACT_19407], IRB, or IEC. 
A participant may be discontinued from study treatment as follows: 
• If, at 2 consecutive study visits, a participant's drug usage exceeds one 60 g tube per week .   
• If, during the course of the study, a participant is found not to have met eligibility 
criteria, the medical monitor, in collaboration with the investigator, will determine 
whether the participant should be withdrawn from study treatment. 
• If a participant is noncompliant with study procedures or study drug administration in the investigator's opi[INVESTIGATOR_1649], the medical monitor should be consulted for instruction on handling the participant.  
7.1.2. Discontinuation Procedures  
In the event that the decision is made to permanently discontinue the study treatment, the EOT visit should be conducted ( EOT 1 or EOT2 depending on the period during with the participant 
discontinues treatment) .  Reasonable efforts should be made to have the participant return for a 
safety follow-up visit.  The last date of the last dose of study drug(s)/treatment and the reason for 
discontinuation of study treatment will be recorded in the eCRF. 
Incyte Corporation
Protocol INCB [ZIP_CODE]-307
Version 1
Page 45 of 79 
23 JUN 2019
CONFIDENTIAL
If a partici
pant i s discontinued from study treatment:  
• The study monitor or sponsor must be notified. 
• The reason(s) for withdrawal must be documented in the participant's medical record 
and the primary reason for withdrawal must be included in the eCRF. 
• The EOT visit should be performed. 
• The date of the EOT visit should be recorded in the eCRF. 
• Participants must be followed for safety until the time of the safety follow-up visit or 
until study drug/treatment–related AEs resolve, return to baseline, or are deemed irreversible, whichever is longest. 
If the participant discontinues study treatment and actively withdraws consent for collection of follow-up data (safety follow-up or disease assessment), then no additional data collection should occur; however, participants will have the option of withdrawing consent for study 
treatment but continuing in the safety follow-up period of the study for safety/efficacy 
assessments.  
7.2. Participant Withdrawal From the Study  
A participant may withdraw from the study at any time at his/her own request, or may be 
withdrawn at any time at the discretion of the investigator for safety, behavioral, compliance, or 
administrative reasons.  
If the participant withdraws consent for disclosure of future information, the sponsor may retain and continue to use any data collected before such a withdrawal of consent.  
If a participant withdraws from the study, he/she may request destruction of any samples taken and not tested, and the investigator must document this in the site study records. 
See Table [ADDRESS_439368] be taken if a participant fails to return to the clinic for a required 
study visit: 
• The site must attempt to contact [CONTACT_185610].  The participant will be counseled regarding the importance of 
maintaining the assigned visit schedule and ascertain whether or not the participant 
wishes to and/or should continue in the study. 
• Before a participant is deemed lost to follow-up, the investigator or designee must make every effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if necessary, a certified letter to the participant's last known mailing address 
Incyte Corporation 
Protocol INCB [ZIP_CODE]-307
 
Version 1
Page 46 of 79 
23 JUN 2019
CONFIDENTIAL
or local equiva
lent methods).  These contact [CONTACT_21457]'s medical record.  
• Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study with a primary reason of lost to follow-up. 
8. STUDY ASSESSMENTS AND PROCE DURES  
8.1. Administrative and General Procedures  
8.1.1. Informed Consent Process  
• The investigator or his/her representative will explain the nature of the study to the 
participant or his/her legally authorized representative and answer all questions regarding the stu dy. 
− Informed consent /assent  must be obtained before any study- related procedures are 
conducted, unl ess otherwise specified by [CONTACT_941] p rotocol. 
Note: Adolescent participants who become legal adults during the study will be asked for their signed consent to continue the study, and in the event of lack thereof, will be discontinued from further participation. 
− Informed consent /assent  must be obtained using the IRB/IEC-approved version in 
a language that is native and understandable to the participant.  A template will be 
provided by [CONTACT_3552].  The sponsor or its designee must review and acknowledge the site -specific changes to the ICF/assent  template.  The 
ICF/assent  must include a statement that the sponsor or its designee and 
regulatory authori ties have direct access to participant records.  
− The ICF /assent  must contain all required elements and describe the nature, scope, 
and possible consequences of the study in a form understandable to the study participant.  
• Participants must be informed that their participation is voluntary.  Participants or their legally authorized representative will be required to sign a statement of informed 
consent that meets the applicable requirements and regulations for the country in 
which the study is being conducted as well as the IRB/IEC or study center.  
• The participant must be informed that his/her personal study- related data will be used 
by [CONTACT_89192].  The level of disclosure must also be explained to the participant. 
• The participant must be informed that his/her medical records may be examined by [CONTACT_340764], by [CONTACT_6667]/IEC members, and by [CONTACT_6668].  
Incyte Corporation 
Protocol INCB [ZIP_CODE]-307
 
Version 1
Page 47 of 79 
23 JUN 2019
CONFIDENTIAL
• The medical 
record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study and the date the written 
consent was obtained.  The authorized person obtaining the informed consent must also sign the ICF. 
• Participants must provide consent to the most current version of the ICF(s) during their participation in the study.  
• A copy of the ICF(s) must be provided to the participant or the participant's legally authorized representative. 
• Participants who are rescreened are required to sign a new ICF.  
8.1.2. Screening Procedures  
Screening is the interval between signing the ICF and the day that the participant is assigned to 
the study drug (Day 1).  Screening assessments for determination of eligibility may be performed 
over a period lasting up to 32 days.  
Procedures conducted as part of the participant's routine clinical management (eg, clinical 
laboratory tests) and collected before informed consent is obtained may be used for screening or 
baseline purposes, provided the procedure meets the Protocol- defined criteria and has been 
performed within [ADDRESS_439369] the IRT system 
to obtain the participant ID number during screening.  Upon determining that the participant is eligible for study entry, the IRT system will be contact[CONTACT_352940].  Additionally, the IRT system will be contact[CONTACT_352941].  Additional details are provided in the IRT Manual. 
8.1.4. Distribution of Study Reminder Cards and Diaries  
Starting at the Day  1 visit and each visit thereafter, a study drug–specific diary will be given to 
each participant in order to record use of the study drug.  The completed diary will be collected 
during each of the participant's visits. 
Qualified clinical site staff will r eview the participants' entries for compliance.  Participants who 
are noncompliant with their study drug schedule (defined as < 70% or > 130% of the expected 
number of applications between study visits) will have their administration instructions 
Incyte Corporation 
Protocol INCB [ZIP_CODE]-[ADDRESS_439370] 70% but no more than 130% of the expected 
applications during participation in the treatment period of the study.  
Participants will be provided with a reminder card starting on Day 1 and at all visits ( through 
Week 52).  The reminder card will indicate the date/time of the next visit and will also remind 
the particip ant that they should have their application at the clinic during the visit under site 
supervision after their blood draws for PK and safety evaluations have been completed. 
8.1.5. Demography and Medical History 
[IP_ADDRESS]. Demographics and General Medical History  
Demographic data and general medical history will be collected at screening by [CONTACT_312356]/age, race, ethnicity, medical and surgical history, and current illnesses.  Medical history will include relevant medical or surgical treatment within the last 2 years that are considered to be clinically significant by [CONTACT_093].  
[IP_ADDRESS]. Disease Characteristics and Treatment History  
A vitiligo medical and treatment history, including date of diagnosis, relevant disease 
characteristics, and prior treatments, including systemic treatments, phototherapy, and surgical 
procedures, will be recorded.  A medical history of other conditions related to vitiligo will also 
be collected at screening.  
8.2. Efficacy Assessments  
8.2.1. Body Surface Area  
Total %  BSA (includes facial and non facial areas)  depi[INVESTIGATOR_352862].  Body surface area assessment will be performed by [CONTACT_352942].  BSA should 
be estimated to the nearest 0.1%.  T he approximate size of the participant’s entire palmar surface 
(ie, the palm plus 5 digits) should be considered as 1% BSA , and the approximate size of the 
participant’s thumb should be considered as 0.1% BSA . 
8.2.2. Vitiligo Area Scoring Index  
Areas affected by [CONTACT_61911][INVESTIGATOR_352863].  It is based on a composite estimate of the overall area of vitiligo patches at baseline and the degree of macular repi[INVESTIGATOR_312316].  
Facial VASI  is measured by [CONTACT_352943] ( % of BSA) and the degree of 
depi[INVESTIGATOR_371].  The percentage of BSA (hand unit) vitiligo involvement is estimated by [CONTACT_352944] (see Section  8.2.1).  Hand unit is based on participant ’s 
hand size.  Investigator uses his/her hand to mimic the participant’s hand size to evaluate 
percenta ge of BSA vitiligo involvement.  The degree of depi[INVESTIGATOR_352864]:  0, 
10%, 25%, 50%, 75%, 90%, or 100%.  At 100% depi[INVESTIGATOR_371], no pi[INVESTIGATOR_352865]; at 90%, specks of pi[INVESTIGATOR_352866]; at 75%, the depi[INVESTIGATOR_352867]; at 
50%, the depi[INVESTIGATOR_352868]; at 25%, the pi[INVESTIGATOR_352869] [ZIP_CODE]-307
 
Version 1
Page 49 of 79 
23 JUN 2019
CONFIDENTIAL
depi[INVESTIGATOR_352870]; at 10%, only specks of depi[INVESTIGATOR_352871].  The F -VASI is then 
derived by [CONTACT_352945] e ach site on the face and summing the values of all sites together  (possible 
range 0 -3). 
 
 
Total body VASI  is calculated using a formula that includes contributions from all body regions 
(poss ible range,  0-100). 
𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉  = Σ [ℎ𝑎𝑎𝑎𝑎𝑎𝑎 𝑢𝑢𝑎𝑎𝑢𝑢𝑢𝑢𝑢𝑢] 𝑥𝑥 [𝑅𝑅𝑅𝑅𝑢𝑢𝑢𝑢𝑎𝑎𝑢𝑢𝑎𝑎𝑅𝑅 𝐷𝐷𝑅𝑅𝐷𝐷𝑢𝑢𝐷𝐷𝐷𝐷𝑅𝑅𝑎𝑎𝑢𝑢𝑎𝑎𝑢𝑢𝑢𝑢𝐷𝐷𝑎𝑎] 𝑎𝑎𝑅𝑅𝑅𝑅 𝑏𝑏𝐷𝐷𝑎𝑎𝑏𝑏 𝑢𝑢𝑢𝑢𝑢𝑢𝑅𝑅𝑢𝑢  
The body is divided int
o the following 6 separate and mutually exclusive sites:   (1) head/neck, 
(2) hands, (3) upper extremities (excluding hands), (4) trunk, (5) lower extremities (excluding 
feet), and (6) feet.  The percentage of vitiligo involvement is estimated in hand units (% of BSA) 
by [CONTACT_312357].  Hand unit is based on 
participant ’s hand size.  The i nvestigator uses his/her hand to mimic the participant’s hand size to 
evaluate % BSA vitiligo involvement.  The degree of depi[INVESTIGATOR_352872] i s 
determined and estimated to the nearest of the followin g percentages:  0, 10%, 25%, 50%, 75%, 
90%, or 100%.  The T-VASI is then derived by [CONTACT_352946] (Hamzavi et al 2004).  Full details will b e provided in the Study Manual. 
8.2.3. Physician’s Global Vitiligo Assessment  (Facial) 
The severity of vitiligo will be assessed by [CONTACT_352947], which has a 5-point scale ( Table 11).  Response will be reported for face (F -PhGVA).  
Table 11: Facial Physician's Global Vitiligo Assessment  Scale  
Score  Severity  Description  
0 Clear  No signs of vitiligo  or complete/near complete  repi[INVESTIGATOR_371] 
[ADDRESS_439371] Clear  Mostly pi[INVESTIGATOR_352873] ( eg, philtrum, nares, corners of eyes, perioral skin)  
[ADDRESS_439372] areas of depi[INVESTIGATOR_371] (not more than half of facial skin) with approximately 50% pi[INVESTIGATOR_352874] s or significant 
perifollicular pattern present  
3 Moderate Disease Large areas of depi[INVESTIGATOR_352875] s (more than  half of facial skin); 
significan t depi[INVESTIGATOR_352874] s 
4 Severe Disease Extensive areas of vitiligo to complete depi[INVESTIGATOR_352876] 
8.2.4. Physician’s Global Vitiligo Assessment (Total Body) 
The severity of total body vitiligo will be assessed by [CONTACT_352947], which has 
a 5-point scale ( Table 12 ).  Response will be reported for total body (T- PhGVA).  
Incyte Corporation 
Protocol INCB [ZIP_CODE]-307
 
Version 1
Page 50 of 79 
23 JUN 2019
CONFIDENTIAL

Table 12: Tot
al Body Physician's Global Vitiligo Assessment Scale  
Score  Severity  Description  
0 Clear  No signs of vitiligo or complete/near complete repi[INVESTIGATOR_371] 
[ADDRESS_439373] Clear  Mostly pi[INVESTIGATOR_352877] (eg , hands, feet, philtrum, nares, corners of eyes, perioral skin ) 
[ADDRESS_439374] areas of depi[INVESTIGATOR_352878] 50% pi[INVESTIGATOR_352879]  
3 Moderate Disease  Large areas of depi[INVESTIGATOR_352857]; significant depi[INVESTIGATOR_352880] s 
4 Severe Disease  Extensive areas of vitiligo with complete depi[INVESTIGATOR_371]  
8.2.5. Photography 
Photography of the face and/or body areas affected with vitiligo will be obtained at visits listed 
in Table 3 and Table 4. 
All sites will use 2D photography, and selected sites will also use 3D photography, to 
photograph areas of the participant’s face affected with vitiligo .  2D photography will be used at 
all sites for the target nonfacial depi[INVESTIGATOR_312320].  
Target nonfacial vitiligo depi[INVESTIGATOR_352881] :  At the baseline visit, depi[INVESTIGATOR_352882] s that are representative of the participant's overall disease and that are to be 
treated with  study drug will be selected as targeted  nonfacial vitiligo depi[INVESTIGATOR_312294].  Th ese 
areas will be assessed, measured, and documented in the participant's medical record at each 
subsequent visit during the study (see Table 3 and Table 4).  A note should be made in their 
medical record, and the baseline photographs can be marked with the location of the target 
depi[INVESTIGATOR_312320].   The genitalia area should not be photographed. 
Ad hoc photography of skin -related AEs is recommended.  
Photographic procedures will be standardized, and a full description of the methodology will be 
provided in a photography manual to be provided to the sites. 
8.2.6. Patient -Reported Outcomes  
Quality of life will be assessed (see Table 3 and Table 4) using the following tools: 
• VNS  (Section  [IP_ADDRESS]) 
• Color- matching question (Section  [IP_ADDRESS]) 
• F-PaGIC -V (Section  [IP_ADDRESS]) 
• T-PaGIC -V (Section  [IP_ADDRESS]) 
• DLQI  or CDLQI  (Section  [IP_ADDRESS]) 
• WHO- 5 (Section  [IP_ADDRESS]) 
• TSQM (Section  [IP_ADDRESS]) 
Incyte Corporation 
Protocol INCB [ZIP_CODE]-307
 
Version 1
Page 51 of 79 
23 JUN 2019
CONFIDENTIAL
• VitiQoL (S
ection  [IP_ADDRESS]) 
• HADS (Section  [IP_ADDRESS]) 
In order to avoid bias in the participants' responses to the questionnaires, all these assessments 
should be completed before any other evaluations or study procedures on the day of the study visit and prior to discussions with the investigator or study si te staff.  
At the baseline visit, all patient-reported outcomes must be completed before the participant' s 
first study drug application.  
[IP_ADDRESS]. Vitiligo Noticeability Scale  
The VNS is a patient ‐reported measure of vitiligo treatment success, which has a 5 -point scale 
(Batchelor et al 2016 ).  The baseline facial photograph will be shown to the participants for 
reference and a mirror will be provided for the participants to assess the vitiligo on their face. The participant will be asked to respond to the following query: 
Compared with before treatment, how noticeable is the vitiligo now?  Responses:  (1) More 
noticeable, (2) As noticeable, (3) Slightly less noticeable, (4) A lot less noticeable, and 
(5) No longer noticeable.  
VNS scores of 4 or 5 can be interpreted as representing treatment success.  
[IP_ADDRESS]. Color- Matching Question  
The baseline photo graph  and current participants’ facial image (participants will be provided a 
mirror) will be shown to the participant for reference, and t he participant will be asked to 
respond to the following query: 
At this point of your treatment, how well does your skin color match between your face treated vitiligo skin and face normal skin?  Responses:  (1) Excellent, (2) V ery good, 
(3) Good, (4) Poor, and (5) Very poor. 
[IP_ADDRESS]. Patient Global Impression of Change- Vitiligo  (Facial) 
The F-PaGIC -V is an assessme nt of improvement by [CONTACT_2299].  It is a 7 -point scale 
comparing the vitiligo areas at baseline with the participant's treated areas of facial vitiligo at the 
study visit.  Response will be reported for face (F- PaGIC -V).  The participant will be asked to 
respond to the following query: 
Since the start of the treatment you've received in this study, your vitiligo on your face  
treated with the study drug is:  (1) Very much improved, (2) Much improved, (3) M inimally 
improved, (4) No change, (5) M inimally worse, (6) Much worse, and (7) V ery much worse.  
F-PaGIC -V scores of 1 or 2 can be interpreted as representing treatment success.  
[IP_ADDRESS]. Patient Global Impression of Change-Vitiligo (Total Body) 
The T -PaGIC -V is an assessment of improvemen t by [CONTACT_2299].  It is a 7 -point scale 
comparing the vitiligo areas at baseline with the participant's treated areas of total body vitiligo 
Incyte Corporation 
Protocol INCB [ZIP_CODE]-307
 
Version 1
Page 52 of 79 
23 JUN 2019
CONFIDENTIAL
at the study
 visit.  Response will be reported for total body (T- PaGIC -V).  The participant will be 
asked to respond to the following query: 
Since the start of the treatment you've received in this study, your vitiligo on your total body 
treated with the study drug is:  (1) Very much improved, (2) Much improved, (3) M inimally 
improved, (4) No change, (5) M inimally  worse, (6) Much worse, and (7) V ery much worse.  
T-PaGIC -V scores of 1 or 2  can be interpreted as representing treatment success.  
[IP_ADDRESS]. Dermatology Life Quality Index 
The DLQI is a simple, 10-question validated questionnaire to measure how much the skin 
problem has affected the participant over the previous 7 days ( Finlay and Khan 1994).  
Participant s age  ≥ 16 years will answer the questionnaire with (1) very much, (2) a lot, (3) a 
little, or (4) not at all.  
The questionnaire is analyzed under 6 headings as follows: 
• Symptoms and feelings (Questions 1 and 2)  
• Daily activities (Questions 3 and 4)  
• Leisure (Questions 5 and 6)  
• Work and school (Question 7)  
• Personal relations (Questions 8 and 9)  
• Treatment (Question 10)  
CDLQI i s the youth/children’s version of the DLQI.  For participants who are age ≥ 12 years to 
< 16 years at baseline, the CDLQI will be completed instead  of the CDLQI throughout their 
participation in the study .  This  questionnaire is self -explanatory and can be simply given to the 
participant who is asked to fill it in and who may ask the help of the parent or guardian.  The 
questionnaire is analyzed under 6 headings as follows:  
• Symptoms and feelings (Questions 1 and 2)  
• Leisure (Questions 4, 5, and 6)  
• School or holidays (Question 7)  
• Personal relationships (Questions 3 and 8)  
• Sleep (Question 9)  
• Treatment (Question 10)  
Full details will be provided in the Study Manual. 
[IP_ADDRESS]. WHO-[ADDRESS_439375] 2 weeks, which can be used as an outcome measure for the wanted and 
unwanted effects of treatments  (WHO Collaborating Center for Mental Health , Topp et al 2015).  
The questionnaire consists of 5 statements, which respondents rate according to the following 
Incyte Corporation 
Protocol INCB [ZIP_CODE]-307
 
Version 1
Page 53 of 79 
23 JUN 2019
CONFIDENTIAL
scale:  0  = At n
o time; 1  = Some of the time; 2  = Less than half of the time; 3  = More than half of 
the time; 4  = Most of the time; 5  = All of the time . 
The raw score is calculated by [CONTACT_352948] [ADDRESS_439376] possible quality of life.  A score 
below 13 indicates poor well- being . 
Full details will be pro vided in the Study Manual. 
[IP_ADDRESS]. Treatment Satisfaction Questionnaire for Medication  
TSQM is a  validated  9-item questionnaire that  measures a participant’s  satisfaction with 
medication  taken in a clinical study using a recall period of the past [ADDRESS_439377] used.  The questionnaire uses a 7 -point scale for each question  (Bharmal 
et al 2009).   Full details will be provided in the Study Manual.  
[IP_ADDRESS]. VitiQoL  
VitiQoL is a [ADDRESS_439378] month using a 7- point scale ( “Not at all” to “ All of the time”) 
(Lilly et al 2013 ).  Full details will be provided in the Study Manual. 
[IP_ADDRESS]. Hospi[INVESTIGATOR_352883] 14-item questionnaire that assesses the levels of anxiety  and depression that a person is 
currently experiencing  (Zigmond and Snaith  1983).  There are 7 questions each for measuring 
anxiety and for measuring depression, with 4 possible responses to each question (responses are 
scored as 0, 1, 2, or 3).  Separate scores are calculated for anxiety and depression.  Full details 
will be provided in the Study Manual. 
8.3. Safety Assessments  
Planned timepoints for all safety assessments are provided in the Table [ADDRESS_439379] dose of study treatment.  Adverse events that begin or worsen after 
informed consent should be recorded on the Adverse Event Form in the eCRF regardless of the assumption of a causal relationship with the study drug.  Conditions that were already present at 
the time of informed consent should be recorded on the Medical History Form in the eCRF.  
Adverse events (including laboratory abnormalities that constitute AEs) should be described using a diagnosis whenever possible rather than by [CONTACT_147108]. 
Adverse events will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, 
surrogate, or the participant's legally authorized representative).  The investigator and any qualified designees are responsible for detecting, documenting, and recording events that meet 
the definition of an AE or SAE and remain responsible for following-up on AEs that are serious, 
considered related to the study treatment, or that caused the participant to discontinue the study 
Incyte Corporation 
Protocol INCB [ZIP_CODE]-307
 
Version 1
Page 54 of 79 
23 JUN 2019
CONFIDENTIAL
treatment
.  Care will be taken not to introduce bias when detecting AEs and/or SAEs.  
Open -ended and nonleading verbal questioning of the participant, such as "How are you 
feeling?" is the preferred method to inquire about AE occurrences.  Adver se events may also be 
detected when they are volunteered by [CONTACT_352949], or through physical examinations, laboratory tests, or other assessments.  The definition, 
reporting, and recording requirements for AEs are described in Section  9. 
All SAEs will be recorded and reported to the sponsor or designee within 24 hours.  The 
investigator will submit any upda ted SAE data to the sponsor within 24 hours of it being 
available.  
After the initial AE/SAE report, the investigator is required to proactively follow each participant at subsequent visits/contacts.  All SAEs will be followed until resolution, stabilizatio n, the event 
is otherwise explained, or the participant is lost to follow -up (as defined in Section 7.3).  
8.3.2. Physical Examinations 
Physical examinations will be conducted at the time points listed in Table 3 and Table 4. 
A comprehensive physical examination will include height and body weight and assessment of 
the following organ or body systems:  skin; head, eyes, ears, nose, and throat; thyroid; lungs; cardiovascular system; abdomen (liver, spleen); extremities; and lymph nodes.  A brief neurological examination will also be performed. 
A targeted physical examination should be conducted as indicated by [CONTACT_312361], AEs, or other findings.  Abnormalities that are considered clinically significant in the judgment of the investigator are to be reported as AEs. 
Physical examinations must be performed by a medically qualified  individual such as a licensed 
physician, physician's assistant, or an advanced registered nurse practitioner, as local law 
permits.  
8.3.3. Vital Signs 
Vital sign measurements include blood pressure, pulse, respi[INVESTIGATOR_697], and body temperature.  Blood pressure and pulse will be taken with the participant in the recumbent, semi-recumbent, or 
sitting position after [ADDRESS_439380].  Electrocardiograms should be performed as indicated in Table 3.  
Additional 12- lead ECGs may be performed at other visits as deemed clinically necessary.  
Twelve-lead ECG performed within 2 months before baseline is acceptable for using as a screening value.  
Electrocardiograms will be interpreted by [CONTACT_312362], and the results will be used for immediate management of the participant's care.  There is no central reader of 
ECGs for this study. The decision to include or exclude a pa rticipant or withdraw a participant 
from the study based on an ECG flagged as "Abnormal, Clinically Significant" is the 
Incyte Corporation 
Protocol INCB [ZIP_CODE]-307
 
Version 1
Page 55 of 79 
23 JUN 2019
CONFIDENTIAL
responsibili
ty of the investigator, in consultation with the sponsor's medical monitor, as 
appropriate.  Any abnormalities that are cons idered clinically significant in the judgment of the 
investigator are to be reported as AEs.  
8.3.5. Laboratory Assessments 
Required laboratory tests are listed in  Table 13, which include hematology, chemistry, urinalysis, 
serology, free T4, TSH, FSH, and pregnancy test (see Table 3 and  Table 4).  Clinical laboratory 
tests will be performed at a central laboratory (refer to the Laboratory Manual for sample 
handling and shippi[INVESTIGATOR_3931]). 
Clinically significant abnormal laboratory findings are those that are not associated with the 
underlying disease, unless judged by [CONTACT_19448]'s condition.  All laboratory tests with values considered clinically signific antly 
abnormal during participation in the study, or within [ADDRESS_439381] dose of study treatment, should be repeated until the values return to normal or baseline or are no longer considered clinically significant by [CONTACT_10982]. 
See Section  9.1 for information regarding laboratory abnormalities that should be recorded as an 
AE in the eCRF.  
Incyte Corporation 
Protocol INCB [ZIP_CODE]-307
 
Version 1
Page 56 of 79 
23 JUN 2019
CONFIDENTIAL
Table 13: Re
quired Laboratory Analytes 
Serum Chemistriesa Hematology  Urinalysis With 
Microscopic 
Examination  Serology  Other  
Albumin  
Alkaline phosphatase  
ALT  
AST  
Bicarbonate or CO [ADDRESS_439382] bilirubin (if total bilirubin is elevated above ULN)  
Total protein  Complete blood 
count, including:  
• Hemoglobin 
• Hematocrit  
• Mean 
corpuscular 
volume (MCV)  
• Platelet count  
• Mean platelet volume  
• Red blood cell count  
• Reticulocyte count  
• White blood cell count  
 
Differential count, 
including:  
• Basophils  
• Eosinophils  
• Lymphocytes  
• Monocytes  
• Neutrophils  Color and 
appearance 
pH and specific gravity  
Bilirubin  
Glucose  
Ketones  
Leukocytes  
Nitrite  
Occult blood  
Protein  HIV antibody  FSH 
Free T4  
TSH  
Pregnancy Testing  
Female participants of childbearing potential have a serum test 
at screening and safety follow -up visits.  A urine test will be 
conducted at all other visits.  A positive urine test will be 
confirmed by a serum test. 
a All serum chemistries will be performed on samples collected without respect to food intake (ie, non -fasting).  
Note:  Additional tests may be required, as agreed by [CONTACT_147100], based on emerging safety data.  
[IP_ADDRESS]. Pregnancy Testing  
A serum pregnancy test will be required for all women of childbearing potential during screening 
and at the safety follow-up visit (30 [+ 7] days after EOT ; EOT1 or EOT2 as applicable).  Urine 
pregnancy tests will be conducted as outlined in Table [ADDRESS_439383] was positive, the investigator will assess the potential benefit/risk to the participant and de termine whether it is in the participant's best 
interest to resume study drug and continue participation in the study. 
If a pregnancy is confirmed by a serum pregnancy test, see Section  9.6 for reporting 
requirements.  
Incyte Corporation 
Protocol INCB [ZIP_CODE]-307
 
Version 1
Page 57 of 79 
23 JUN 2019
CONFIDENTIAL
[IP_ADDRESS]. Serology 
An HIV a
ntibody assessment will be performed at the screening visit to rule out infection (see  
Table 3).  Serology tests should be performed early in the screening process due to the length of 
time needed to obtain the results.  Additional tests may be performed if clinically indicated.  
8.4. Pharmacokinetic  Assessments 
Venous blood samples will be collected to assess the PK of ruxolitinib cream in this study population at each study visit indicated in Table 3. 
The exact date and time of the PK blood draws and the date and time of the last application of 
study drug preceding the blood draw (if applicable) will be recorded in the eCRF.  
Instructions for sample preparation and shippi[INVESTIGATOR_352884].  
Participants will receive reminder cards in advance of the study visit providing instruction to hold the application of study drug on the day of the visit and a pl ace to record the time of the 
prior dose of study drug.  
Pharmacokinetic blood samples can be collected at any time during study visits noted in the 
Table 3.  Blood samples must not be drawn from the area that has been treated with study drug.  
If it is not possible to access an area that is not treated with study drug, the site must adequately 
document this in the eCRF and not take the PK blood sample for that visit.  After the PK sample 
is drawn, participants will apply ruxolitinib cream 1.5% or vehicle cream at the site.  
All analyses will be conducted by [CONTACT_109912] (Wilmington, DE) or Incyte's designee.
 
8.5. Pharmacodynamic and Translational Assessm ents 
Serum will be collected from all participants at all sites for proteomic analysis at timepoints 
outlined in Table 3 and  Table 4.  The purpose of this analys is will be to retrospectively evaluate 
correlat ive and pharmacodynamic biomarkers of response. 
All analyses will be conducted by [CONTACT_109912] (Wilmington, DE) or Incyte's designee.  Refer to the Study Man ual for detailed instructions.  
8.6. Unscheduled Visits 
Unscheduled visits may occur at any time at  the investigator's discretion, and appropriate clinical 
and laboratory tests may be performed, as clinically indicated.  
8.7. End of Treatment and/or Early Termination  
If a decision is made that the participant will permanently discontinue study drug, then the EOT  
visit should be conducted (EOT1 or EOT2 depending on the study period when the participant 
discontinues).  If the EOT visit coincides with a regular study visit, then the EOT evaluations 
will supersede those of that scheduled visit, and the data should be entered in the EOT page in 
the eCRF.  If this decision does not coincide with a regular visit, reasonable efforts should be made to have the participant return to the site to have the EOT procedures completed. 
Incyte Corporation 
Protocol INCB [ZIP_CODE]-307
 
Version 1
Page 58 of 79 
23 JUN 2019
CONFIDENTIAL
8.8. Safety Follow -Up 
For participants who do not participate in a separate extension study , the safety follow -up period 
is the interval between the EOT  visit ( EOT 1 or EOT2 depending on the study period when the 
participant discontinues ) and the scheduled safety follow-up visit, which should occur 
30 (+ 7) days after the EOT visit (or after the last dose of study drug/treatment if an EOT visit 
was not performed).  
Adverse events and SAEs must be reported up until at least [ADDRESS_439384] dose of study 
drug/treatment, the date of the safety follow-up visit, or until toxicities resolve, return to 
baseline, or are deemed irreversible, whichever is longer.  Reasonable efforts should be made to have the participant return for the safety follow-up visit and report any AEs that may occur 
during this period. 
9. ADVERSE EVENTS:  DEFINITIONS AND PROCEDURES FOR 
RECORDING, EVALUATING, FOLLOW-UP, AND RE PORTING  
9.1. Definition of Adverse Event  
Adverse Event Definition  
• An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or 
not considered drug- related.  
• An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment.  
Events Meeting  the Adverse Even t Definition  
• Any safety assessments (eg, ECG, vital signs measurements), including those that worsen from baseline, considered clinically significant in the medical and scientific judgment of the investigator 
(ie, not related to progression of underlying disease).  
• Abnormal laboratory test results constitute an AE if they are considered clinically meaningful, 
induce clinical signs or symptoms, require concomitant therapy, or require changes in study drug.  Whenever possible, a diagnosis (eg, anemia, thrombocytopenia) should be recorded in the eCRF 
rather than the abnormal lab result (eg, low hemoglobin, platelet count decreased). 
• Exacerbation of a chronic or intermittent pre -existing condition including either an increase in 
frequency and/or intensity of the  condition. 
• New conditions detected or diagnosed after study treatment administration even though it may have 
been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction. 
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study treatment or a concomitant medication.  Overdose per se will not be reported as an AE/SAE unless it is an intentional overdose taken with possible suicidal/self-harming intent.  Such overdoses should be 
reported regardless of sequelae.  
• "Lack of efficacy" or "failure of expected pharmacological action" per se will not be reported as an 
AE or SAE.  Such instances will be captured in the efficacy assessments.  However, the signs, 
Incyte Corporation 
Protocol INCB [ZIP_CODE]-307
 
Version 1
Page 59 of 79 
23 JUN 2019
CONFIDENTIAL
symptoms, and/or clin ical sequelae resulting from lack of efficacy will be reported as AE or SAE if 
they fulfill the definition of an AE or SAE.   
Events NOT  Meeting the Adverse Event Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety assessments that are 
associated with the underlying disease, unless judged by [CONTACT_19448]'s condition. 
• The disease/disorder being studied or expected progression, signs, or symptoms of the disease/d isorder being studied, unless more severe than expected for the participant's condition or 
considered to be treatment- related by [CONTACT_093].  
• Medical or surgical procedure (eg, endoscopy, appendectomy):  the condition that leads to the procedure is the AE if it occurred after signing the ICF.  If present before entering the study, the condition should be captured as medical history. 
• Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospi[INVESTIGATOR_307]).  
• Anticipated day -to-day fluctuations of pre- existing disease(s) or condition(s) present or detected at 
the start of the study that do not worsen. 
9.2. Definition of Serious Adverse Event  
If an event is not an AE per the definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study, death due to progression of disease). 
A Serious Adverse Event is defined as any untoward medical occurrence that, at any dose:  
a. Results in death  
b. Is life-threatening  
The term "life -threatening" in the definition of "serious" refers to an adverse drug experience that 
places the participant, in the opi[INVESTIGATOR_89155], at immediate risk of death from the adverse 
experience as it occurred.  This does not include an adverse drug experience that, had it occurred in a 
more severe form, might have caused death.  
c. Requires inpatient hospi[INVESTIGATOR_12993], hospi[INVESTIGATOR_19949] (usually involving at least an 
overnight stay) at the hospi[INVESTIGATOR_9235]/or treatment that would not have 
been appropriate in the physician's office or outpatient setting.  Complications that occur during 
hospi[INVESTIGATOR_1084].  If a complication prolongs hospi[INVESTIGATOR_9236], the event is serious.  When in doubt as to whether "hospi[INVESTIGATOR_059]" occurred or was necessary, the AE 
should be considered serious. 
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen from baseline is 
not considered an AE. 
d. Results in persistent or significant disability/incapacity  
• The term disability means a substantial disruption of a person's ability to conduct norma l life 
functions. 
• This definition is not intended to include experiences of relatively minor medical significance, such 
as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma 
Incyte Corporation 
Protocol INCB [ZIP_CODE]-307
 
Version 1
Page 60 of 79 
23 JUN 2019
CONFIDENTIAL
(eg, sprained ankle), that may interfere with or  prevent everyday life functions but do not constitute a 
substantial disruption. 
e. Is a congenital anomaly/birth defect  
f. Other situations (Important Medical Event)  
An event that may not result in death, be immediately life -threatening, or require hospi[INVESTIGATOR_059], but 
may be considered serious when, based on appropriate medical judgment, the event may jeopardize the 
participant and may require medical or surgical intervention to prevent one of the outcomes listed in 
the above definition.   Examples o f such events include invasive or malignant cancers (excluding the 
disease[s] under study in oncology protocols), intensive treatment in an emergency department or at 
home for allergic bronchospasm, blood dyscrasias, or convulsions that do not result in hospi[INVESTIGATOR_059], 
or development of drug dependency or drug abuse. 
9.3. Recording an d Follow -Up of  Adverse Event s and/or Serious Adverse 
Event s 
Adverse Event and Serious Adverse Event Recording  
• An AE/SAE that begins or worsens after informed consent is signed should be recorded on the 
Adverse Event Form in the eCRF.  Conditions that were present at the time informed consent was 
given should be recorded on the Medical History Form in the eCRF. 
• When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation (eg, hospi[INVESTIGATOR_1088], laboratory reports, and diagnostics reports) related to the event. 
• The investigator (or delegate) will then record all relevant AE/SAE information in the eCRF.  
• It is not acceptable for the investigat or to send photocopi[INVESTIGATOR_10914]'s medical records to 
sponsor or designee in lieu of completing the AE eCRF page. 
• There may be instances when copi[INVESTIGATOR_63475].  In this case, all participant identifiers, with the exception of the participant number, will be redacted on the copi[INVESTIGATOR_89159].  
• The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or 
other clinical information.  Whenever possible, the diagnosis (not the individual signs/symptoms) will be documented as the AE/SAE.  When a clear diagnosis cannot be identified, each sign or 
symptom should be reported as a separate AE/SAE. 
To the extent possible, each AE/SAE should be evaluate d to determine: 
• The severity grade (CTCAE Grade 1 to 5).  See below for further instructions on the assessment of 
intensity.  
• Whether there is at least a reasonable possibility that the AE is related to the study drug:  suspected (yes) or not suspected (no).  See below for further instructions on the assessment of causality.  
• The start and end dates, unless unresolved at final safety follow-up. 
• The action taken with regard to study drug as a result of the AE/SAE(s). 
• The event outcome (eg, not recovered/not resolved, recovered/resolved, recovering/resolving, recovered/resolved with sequelae, fatal, unknown). 
• The seriousness, as per the SAE definition provided in Section 9.2 . 
• The action taken with regard to the event.  Note:  If an AE is treated with a concomitant medication 
or nondrug therapy, this action should be recorded on the Adverse Event Form, and the treatment 
Incyte Corporation 
Protocol INCB [ZIP_CODE]-307
 
Version 1
Page 61 of 79 
23 JUN 2019
CONFIDENTIAL
should be specified on the appropriate eCRF (eg, Prior/Concomitant Medications, Procedures and 
Non-Drug Therapy). 
Assessment of Intensity  
The severity of AEs will be assessed using CTCAE v5.0 Grades 1 through 5.  If an event is not 
classified by [CONTACT_3989], the severity of the AE will be graded according to the scale below to estimate 
the grade of severity.  
The investigator will make an assessment of intensity for each AE and SAE reported during the study and assign it to 1 of the following categories:  
• Grade 1:   Mild; asymptomatic or m ild symptoms; clinical or diagnostic observations only; 
intervention not indicated.  
• Grade 2:   Moderate; minimal, local, or noninvasive intervention indicated; limiting age appropriate 
activities of daily living.  
• Grade 3:   Severe or medical ly significant but not immediately life -threatening; hospi[INVESTIGATOR_8942]; disabling; limiting self -care activities of daily living.  
• Grade 4:   Life -threatening consequences; urgent intervention indicated.  
• Grade 5:   Fatal. 
Assessment of Causality  
• The investigator is obligated to assess the relationship between study treatment and each occurrence 
of each AE/SAE.  
• A "reasonable possibility" of a relationship conveys that there are facts, evidence, and/or arguments to suggest a causal relationship, rather than that a relationship cannot be ruled out. 
• The investigator will use clinical judgment to determine the relationship.  
• The investigator will also consult the RSI in the IB and/or Product Information, for marketed 
products, in his/her assessment. 
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well as the temporal relationship of the event to study treatment administration, will be considered and 
investigated.  
• For each AE/SAE, the investigator must  document in the medical notes that he/she has reviewed the 
AE/SAE and has provided an assessment of causality.  
• With regard to assessing causality of SAEs:  
− There may be situations in which an SAE has occurred and the investigator has minimal information to include in the initial report to the sponsor or designee.  However, it is very 
important that the investigator always make an assessment of causality for every event 
before the initial transmission of the SAE data to the sponsor or designee.  
− The investigator may change his/her opi[INVESTIGATOR_9242] -up information and 
send a SAE follow- up report with the updated causality assessment.  
Follow -Up of Adverse Events and Serious Adverse Events  
• The investigator is obligated to perform or arrange for the conduct of supplemental measurements 
and/or evaluations as medically indicated or as requested by [CONTACT_352950]/or causality of the AE/SAE as fully as possible.  This may include additional laboratory 
tests or investigations, histopathological examinations, or consultation with other healthcare professionals. 
Incyte Corporation 
Protocol INCB [ZIP_CODE]-307
 
Version 1
Page 62 of 79 
23 JUN 2019
CONFIDENTIAL
• If a participant dies during participation in the stu dy or during a recognized safety follow -up period, 
the investigator will provide the sponsor or designee with a copy of any postmortem findings, 
including histopathology. 
• New or updated information will be recorded in the originally completed eCRF. 
• Any updated SAE data will be submitted to the sponsor or designee within 24 hours of receipt of the 
information. 
• Once an AE is detected, it should be followed until it has resolved or until it is judged to be permanent; assessment should be made at each visit (or  more frequently if necessary) of any changes 
in severity, the suspected relationship to the study drug, the interventions required to treat the event, and the outcome. 
• When the severity of an AE changes over time for a reporting period (eg, between visits ), each 
change in severity will be reported as a separate AE until the event resolves.  
9.4. Reporting of Serious Adverse Events  
Regar dless of suspected causality (eg , relationship to study drug or study procedure[s]), all SAEs 
occurring after the participant has signed the ICF through the last study visit (or [ADDRESS_439385] dose of study treatment, whichever occurs later) must be reported to the sponsor (or 
designee) within 24 hours of learning of its occurrence, unless otherwise specified by [CONTACT_352951].  The investigator will submit any updated SAE data to the sponsor (or designee) within 
24 hours of it being available. 
Investigators are not obligated to actively seek AE or SAE information after conclusion of the 
study participation.  However, if the investigator learns of any SAE, including a death, at any 
time after a participant has been discharged from the study, and he/she considers the event to be 
reasonably related to the study treatment or study participation, the investigator must notify the sponsor (or designee) within 24 hours of becoming aware of the event. 
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts.  All SAEs will be followed until resolution, stabiliza tion, the event 
is otherwise explained, or the participant is lost to follow -up (as defined in Section  7.3).  
Prompt notification by [CONTACT_352952] a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of a study treatment under clinical investigation are met.  
If the SAE is not documented in the IB for the study drug (new occurrence) and is thought to be 
related to the sponsor's study drug, the sponsor or its designee may urgently require further information from the investigator for reporting to health authorities.  The sponsor or its designee 
may need to issue an Investigator Notification to inform all investigators involved in any study 
with the same drug that this SAE has been reported.  Suspected Unexpected Serious Adverse Reactions will be collected and reported to the competent authorities and relevant ethics 
committees in accordance with Directive 2001/20/EC, or as per national regulatory requirements 
in participating countries.  
The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study treatment under clinical investigation.  The 
sponsor will comply with country- specific regulatory requirements relating to safety reporting to 
the regulatory authority, IRB/IEC, and investigators. 
Incyte Corporation 
Protocol INCB [ZIP_CODE]-[ADDRESS_439386] be prepared for S[LOCATION_003]Rs according to local regulatory 
requirements and sponsor policy and forwarded to investigators as necessary. 
An investigator who receives an investigator safety report describing a SAE or other specific 
safety information ( eg, summary or listing of SAEs) from the sponsor will review and then file it 
along with the IB and will notify the IRB/IEC, if appropriate according to local requirements. 
Serious Adverse Event Reporting  
• Information about all SAEs is collect ed and recorded on the Adverse Event Form in the eCRF.  
• The investigator must also complete the Incyte Serious Adverse Event Report Form, in English.  
Refer to the Incyte Reference Guide for Completing the Serious Adverse Event Report Form.  
• Facsimile or email transmission of the Serious Adverse Event Report Form is the preferred method to transmit this information to the PhV/designee.  The contact [CONTACT_89208]'s study- specific representatives is listed in the Study Manual provided to each site.   The original copy 
of the Serious Adverse Event Report Form and the confirmation sheet must be kept at the study site.  
• Follow-up information is recorded on an amended or new Serious Adverse Event Report Form, with an indication that it is follow -up to the previously reported SAE and the date of the original report.  
The follow-up report should include information that was not provided on the previous Serious 
Adverse Event Report Form, such as the outcome of the event (eg, resolved or ongoing), treatment 
provided, action taken with study drug because of the SAE (eg, dose reduced, interrupted, or 
discontinued), or participant disposition (eg, continued or withdrew from study participation).  Each 
recurrence, complication, or progression of the original event should be reported as follow-up to that 
event, regardless of when it occurs.  
• In rare circumstances and in the absence of facsimile or computer equipment, notification by [CONTACT_9337] a copy of the Incyte Serious Adverse Event Report Form sent by [CONTACT_22855].  Initial notification via telephone does not replace the need for the investigator to complete and sign the Serious Adverse Event Report Form within the designated 
reporting time frames.  
• Contacts for SAE reporting c an be found in the Study Manual. 
9.5. Emergency Unblinding of Treatment Assignment  
In a medi cal emergency during the double-blind, vehicle-control led period, if the investigator 
deems it necessary to determine optimal medical management of the participant, emergency 
unblinding will be performed exclusively by [CONTACT_079] [INVESTIGATOR_352885].   The IRT system has an option to select for "Emergency 
Code Break" action for a given participant.  After entering the 6 -digit study drug tube number 
and verification of the unmasking information, the investigator/subinvestigator will proceed to 
either final confir mation or cancellation of the code break procedure. 
If a participant's treatment assignment is unblinded, the sponsor or its designee must be notified immediately by [CONTACT_352953] -up with an email.  
If an investigator, site personnel performing assessments, or participant is unblinded, the participant must be withdrawn from the study treatment, unless there are ethical reasons to have the participant remain on the study treatment.  In these cases, the investigator must obtain 
specific approval from the sponsor's (or its designee's) medical monitor for the participant to continue in the study
 
Incyte Corporation 
Protocol INCB [ZIP_CODE]-[ADDRESS_439387] interfered with the effectiveness of a contracept ive medication or method.  When a 
pregnancy has been confirmed in a participant during maternal or paternal exposure to study 
drug, the following procedures should be followed in order to ensure safety: 
• The study drug must be discontinued immediately. 
• The investigator must complete and submit the Incyte Clinical Trial Pregnancy Form 
to the sponsor or its designee within 24 hours of learning of the pregnancy. 
Data on fetal outcome are collected for regulatory reporting and  drug safety evaluation.  
Follow-up should be conducted for each pregnancy to determine outcome, including spontaneous or voluntary termination, details of the birth, and the presence or absence of any birth defects, 
congenital abnormalities, or maternal and/or newborn complications, by [CONTACT_352954]-baby [CONTACT_765].  Pregnancy should be recorded on a Clinical Trial Pregnancy Form and reported 
by [CONTACT_89211].  Pregnancy follow-up information should be recorded on the same form and should include an assessment of the possible causal relationship 
to the sponsor's study drug to any pregnancy outcome, as well as follow- up to the first well- baby 
[CONTACT_89212], whichever is later.  Refer to the Incyte Reference Gu ide for Completing the Clinical Trial Pregnancy Form.  
Any SAE occurring during pregnancy of a study participant must be recorded on the Serious Adverse Event Report Form and submitted to the sponsor or designee.  
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital anomalies, or ectopic pregnancy) are considered SAEs (if occurring in the study participant) and must be reported as described in Section  9.4.  If an abnormal pregnancy outcome is reported in a 
study participant's partner, the event should be reported to the sponsor on the Clinical Trial Pregnancy Form.  
9.7. Warnings and Precautions  
Special warnings or precaut ions for the study drug, derived from safety information collected by 
[CONTACT_3552], are presented in the IB.  Additional safety information collected 
between IB updates will be communicated in the form of Investigator Notifications.  Any important new safety information should be discussed with the participant during the study, as necessary.  If new significant risks are identified, they will be added to the ICF. 
9.8. Product Complaints  
The sponsor collects product complaints on study drugs and drug delivery systems used in clinical studies in order to ensure the safety of study participants, monitor quality, and facilitate process and product improvements. 
All product complaints associated with material packaged, labeled, and released by [CONTACT_319862].  All product complaints associated with other 
study material will be reported directly to the respective manufacturer.  
Incyte Corporation 
Protocol INCB [ZIP_CODE]-307
 
Version 1
Page 65 of 79 
23 JUN 2019
CONFIDENTIAL
The investiga
tor or his/her designee is responsible for reporting a complete description of the 
product complaint via email or other written communication to the sponsor contact [CONTACT_147111].  Any AE associated with a product complaint should be recorded as described in Section  9.3. 
If the investigator is asked to return the product for investigation, he/she will return a copy of the product complaint communication with the product. 
9.9. Treatment of Overdose  
There has been no clinical experience with overdose of ruxolitinib cream .  Treatment of 
overdose should consist of general supportive measures. 
10. STATISTICS  
10.1. Sample Size Determination  
Approximately 300 participants will be randomized 2:1 to ruxolitinib cream 1.5% BID  or vehicle 
and stratified by [CONTACT_352955] (Fitzpatrick scale Type I and II vs Type III, IV, V , and VI) 
and age ( ≤ 40 vs > 40 years ).  The sample size is calculated to provide s ufficient power (>  85%) 
to detect a difference between the 1.5% BID with the vehicle in primary and key secondary 
endpoints.  The powers for different endpoints are  provided in Table 14.  The Fisher’s exact test 
with a 2 -sided alpha of 0.05 is used to provide a conservative evaluation of statistical power, and 
it is accurate when there is a small expected number of responders in the vehicle group. 
Table 14: Powering for Primary and Key Secondary Endpoints 
Endpoints  Response Rates in  
Ruxolitinib 1.5% BIDa Response Rates  
in Vehiclea Powerb 
F-VASI75 at Week 24  20% 5% 95% 
F-VASI50 at Week 24  30% 10%   95% 
F-VASI75 at Week 52  30% 10% 95% 
F-VASI90 at Week 24  10% 1% 88% 
F-VASI90 at Week 52  20% 5% 95% 
T-VASI50 at Week 24  10% 1% 88% 
T-VASI50 at Week 52  20% 5% 95% 
T-VASI75 at Week 52  10% 1% 88% 
Vitiligo - VNS 
Response at Week 24  10% 1% 88% 
a Based on the results from a Phase 2, randomized, dose- ranging study (INCB18424 -211).  
b Based on the Fisher’s exact test with a 2 -sided alpha of 0.05.  
10.2. Populations for Analysis  
The populations for analysis are presented in Table 15. 
Incyte Corporation 
Protocol INCB [ZIP_CODE]-307
 
Version 1
Page 66 of 79 
23 JUN 2019
CONFIDENTIAL
Table 15: Pop
ulations for Analysis 
Population Description  
ITT The ITT population includes all randomized participants.  Treatment groups for 
this population will be defined according to the treatment assignment at randomization. 
PP The PP population includes randomized participants who are considered to be sufficiently compliant with the Protocol.  
Safety  The safety population includes all participants who applied at least 1 dose of 
study drug.  Treatment groups for this population will be determined according to the actual treatment the participant received on Day 1.  
PK/ 
pharmacodynamic evaluable  The PK/pharmacodynamic evaluable population includes participants who applied at least [ADDRESS_439388] will review data listings of 
participant administration and sample records to identify participants to be 
excluded from the analysis.  
10.3. Statistical Analyses  
The Statistical Analysis Plan will be developed and finalized before database lock and will 
describe the details of the statistical analyses and procedures for accounting for missing data.  
This section is a summary of the planned statistical analyses of the primary and secondary endpoints. 
The gatekeepi[INVESTIGATOR_352886] I error rate, 2- sided α = 0.05.  These endpoints will be 
tested in a fixed  sequence at 2 -sided α = 0.05 level in the following order:  
• Proportion of participants achieving F-VASI75 at Week 24 
• Percentage change from baseline in F- BSA at Week 24  
• Proportion of participants achieving F-VASI50 at Week 24 
• Proportion of participants achieving F-VASI75 at Week 52 
• Proportion of participants achieving F-VASI90 at Week 24 
• Proportion of participants achieving F-VASI90 at Week 52 
• Proportion of participants achieving T-VASI50 at Week 24 
• Proportion of participants achieving T-VASI50 at Week 52 
• Proportion of participants achieving T-VASI75 at Week 52 
• Vitiligo - VNS Response at Week 24 
Incyte Corporation 
Protocol INCB [ZIP_CODE]-307
 
Version 1
Page 67 of 79 
23 JUN 2019
CONFIDENTIAL
10.3.1. Efficacy A
nalyses 
[IP_ADDRESS]. Primary Analysis 
The primary analysis will be based on the intent- to-treat population.  The primary alternative 
hypothesis (superiority of ruxolitinib cream 1.5% BID  compared with vehicle) will be tested 
using logistic regression.  This model will include the treatment group (1.5% BID and vehicle) 
and stratification factors.  The p -value for between -treatment group testing will be calculated 
based on the Wald test, which will be compared with 0.05.  Exact logistic regression ( Mehta and 
Patel 1995) will be used for all of the comparisons if 1.5% BID  or vehicle group has an expected 
cell count less than 5. 
The d ifference in F -VASI 75 rates (ruxolitinib cream 1.5% BID vs vehicle) at Week 24 will also 
be computed.  The 95% confidence interval for the difference will be computed based on a 
large-sample normal approximation with continuity correction.  All nonresponders in the 
double- blind treatment period, as well as all participants who discontinue study treatment at any 
time before the timepoint  of interest, or discontinue from the study for any reason, will be 
defined as nonresponders for the nonresponder imputation analysis.  
Analysis will also be performed in the PP population for the primary endpoint.  The following 
deviations are considered major:  
• Lack of informed consent; 
• Missing primary endpoints on F- VASI;  
• Compliance less than 60% based on the application num bers.  
Participants  with 1 or more such deviations will be excluded from the PP population.  In 
addition, Protocol deviations related to inclusion/exclusion criteria, discontinuation criteria, and use of excluded concomitant medications will be evaluated an d decided whether  they should be 
excluded.  
In addition, s ensitivity analyses, including MI and LOCF , may be performed.  For MI, a fully 
conditional specification method ( van Buuren et al 2007) that assumes the existe nce of a joint 
distribution for all variables will be used to impute F -VASI scores. After the missing values are  
imputed, the binary variables will be derived based on the definition. The imputation will be repeated  a number of times to generate corresponding complete data sets, in order to reflect the 
uncertainty around the true value. Logistic regression will be applied to each imputed dataset, 
and then the results will be combined for the inference.  For LOCF, f or the subjects who 
discontinue study treatment at any time before the timepoint of interest or discontinue from the study for an y reason, the last observed nonmissing value will be used to fill in missing values at 
the timepoint of interest.   A tippi[INVESTIGATOR_352887].  The missing binary response on F-VASI75 at Week [ADDRESS_439389]. 
Subgroup analysis by [CONTACT_352956], for example, skin type, age, and region, will be 
performed.  Details will be provided in the Statistical Analysis Plan.  
Incyte Corporation 
Protocol INCB [ZIP_CODE]-307
 
Version 1
Page 68 of 79 
23 JUN 2019
CONFIDENTIAL
[IP_ADDRESS]. Key Secon
dary Analysis 
If the primary objective is achieved, the statistical hypotheses for key secondary endpoints will 
be tested in th e frequency specified in Section  10.3. 
Key secondary efficacy analyses at Week 24 will be conducted in the ITT population.  The statistical compariso ns for binary outcomes (VASI50/90 and VNS response) will be analyzed 
using the similar method as specified in the primary analysis.   For F-BSA, an MMRM will be 
fitted for the comparisons between INCB018424 1.5% BID and vehicle cream based on percentage change in F -BSA from baseline to Week 24.  The MMRM will include the fixed 
effect of treatment, the randomization stratification factors, the visit, and treatment by [CONTACT_23259].  The variance -covariance matrix of the within -subject errors in MMRM will be 
modeled as unstructured.  A test for superiority between INCB018424 1.5% BID and vehicle 
cream will be performed using the least squares mean estimate of the percentage change from 
baseline in F -BSA at Week 24 from the MMRM specified above.  Superiority will be established 
if the p -value of the difference (INCB018424 1.5% BID minus vehicle) is less than 0.05. 
ANCOVA (LCOF) models will be fit as sensitivity analysis.  
Key secondary endpoints analyses at Week 52 (F -VASI75/90 and T-VASI50/75) will be 
perform ed in the ITT population with the following method: 
• Patients who discontinue the study drug before Week 24, due to any reason, will be 
defined as nonresponders for subsequent visits until Week 52. 
• For patients who completed Week 24 in Vehicle and 1.5% BID group, missing values of VASI in treatment extension period (including Week 52) will be imputed using linear extrapolation method.  The binary outcomes on responses, VASI50/75/90, will be derived based on the imputed values.  The statistical comparisons for these 
endpoints will be analyzed using the similar method as specified in the primary 
analysis.  
• LOCF will also be applied to impute missing data as a sensitivity analysis.  
[IP_ADDRESS]. Secondary Analysis 
All other secondary and exploratory efficacy variables will be summarized using descriptive 
statistics.  For categorical measurements, summary statistics will include sample size, frequency, 
and percentages.  Similar logistic regression models as specified  in the primary and key 
secondary analysis will be used if applicable.  For continuous measurements, summary statistics 
will include sample size, mean, median, SD, standard error of the mean, minimum, and 
maximum.  Continuous efficacy endpoints, including the actual measurement, change from 
baseline, and percentage change from baseline may also be analyzed by [CONTACT_352957].  
10.3.2. Safety Analyses 
A TEAE is any AE either reported for the first time or worsening of a pre- existing e vent after 
first dose of study drug.  Analysis of AEs will be limited to TEAEs, but data listings will include 
all AEs regardless of their timing to study drug administration.  Adverse events will be tabulated 
by [CONTACT_169108].  Severity of AEs will be based on the National Cancer Institute CTCAE v5 .[ADDRESS_439390] igator does not specify the relationship of 
the AE to study drug, then the AE will be considered treatment- related.  The incidence of AEs 
and treatment -related AEs will be tabulated.  
The clinical laboratory data will be analyzed using summary statistics; n o formal treatment group 
comparisons are planned.  Laboratory test values outside the normal range will be assessed for 
severity based on the normal ranges for the clinical reference laboratory.  The incidence of abnormal laboratory values and shift tables relative to baseline will be tabulated.  
Descriptive statistics and mean change from baseline will be determined for vital signs (blood pressure, pulse, respi[INVESTIGATOR_697], and body temperature) at each assessment time.  
10.4. Analysis  Plan  
No formal interim analysis is planned in this study.  The primary analysis will occur after the primary database lock, when all participants have completed the vehicle -controlled, double-blind 
treatment period.  Sponsors will all be unblinded, while investigators and participants  will still be 
blinded, to the study treatment after the primary database lock.  After Week 52, investigators and 
participants will be unblinded.   
11. SUPPORTING DOCUMENTATION AND OPERATIONAL  
CONSIDERATIONS  
11.1. Investigator Responsibilities  
• The Protocol, Protocol amendments, ICF, IB, and other relevant documents 
(eg, advertisements) must be submitted to an IRB/IEC by [CONTACT_31846]/IEC before the study is initiated. 
• The investigator is responsible for ensuring that the safety reports provided by [CONTACT_89222], the policies and procedures established by [CONTACT_1201]/IEC, and institutional requirements. 
• Any amendments to the Protocol will require IRB/IEC approval bef ore 
implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study participants.  
• The investigator will be responsible for the following: 
− Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures established by [CONTACT_1201]/IEC.  
− Notifying the IRB/IEC of SAEs or other significant safety findings as required by [CONTACT_1744]/IEC procedures. 
− Providing oversight of the conduct of the study at the site and adherence to GCP, 
IRB/IEC requirements, institutional requirements, and applicable laws and 
country- specific regulations.  
Incyte Corporation 
Protocol INCB [ZIP_CODE]-307
 
Version 1
Page 70 of 79 
23 JUN 2019
CONFIDENTIAL
• Adhering t
o the Protocol as described in this document and agreeing that changes to 
the Protocol procedures, with the exception of medical emergencies, must be 
discussed and approved, first, by [CONTACT_89223], second, by [CONTACT_5040]/IEC.  Each investigator is responsible for enrolling participants who have met 
the specified eligibility criteria.  
• Retaining records in accordance with all local, national, and regulatory laws, but for a minimum period of at least [ADDRESS_439391] article for 
investigation to ensure the availability of study documentation should it become necessary for the sponsor or a regulatory authority to review. 
− The investigator must not destroy any records associated with the study without 
receiving approval from the sponsor.  The investigator must notify the sponsor or its designee in the event of accidental loss or destruction of any study records.  If the investigator leaves the institution where the study was conducted, the sponsor 
or its designee must be contact[CONTACT_89224]. 
− All eCRF data entered by [CONTACT_779] (including audit trail), as well as computer hardware and software (for acc essing the data), will be maintained or made 
available at the site in compliance with applicable record retention regulations.  The sponsor will retain the original eCRF data and audit trail.  
11.2. Data Management  
Data management will be performed in a validated  EDC system.  The investigator will be 
provided with access to an EDC system so that an eCRF can be completed for each participant.  
The site will be provided with eCRF completion guidelines for instructions on data entry in the 
eCRF.  The study monitor will reference the Monitoring Plan in order to ensure that each issue identified is appropriately documented, reported, and resolved in a timely manner in accordance 
with the plan's requirements.  Other data outside the EDC system required in the study conduc t 
of the protocol such as documents or results transmitted to the sponsor via a central laboratory or 
specialized technical vendors, and as designated by [CONTACT_456], will have their own data flow management plans, or study charters, or biomarker plans, as applicable.  
The sponsor (or designee) will be responsible for: 
• Managing the integrity of the data and the quality of the conduct of the study, such as ensuring that study monitors perform ongoing source data verification to confirm that data entered into the eCRF by [CONTACT_1191], complete, and 
verifiable from source documents; that the safety and rights of participants are being 
protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements. 
• Managing and reconciling the data generated, and/or collected including documents 
and results such as laboratory or imaging data analyzed centrally by a designated vendor of the sponsor. 
Incyte Corporation 
Protocol INCB [ZIP_CODE]-307
 
Version 1
Page 71 of 79 
23 JUN 2019
CONFIDENTIAL
The investiga
tor will be responsible for: 
• Recording, or ensuring the recording of, all relevant data relating to the study in the 
eCRF.  
• Delivering, or ensuring the delivery of, all other results, documents, data, know-how, 
or formulas relating to the study to the sponsor or designee electronically and/or 
centrally (eg, laboratory data, imaging data, biomarker data, photographs, diary data), 
or as otherwise specified in the Protocol.   
• Verifying that data entries are accurate and correct  by [CONTACT_108125].  
• Maintaining accurate documentation (source data) that supports the information 
entered in the eCRF , or sent to a central vendor designated by [CONTACT_456], or as 
described in other study and data flow manua ls.. 
− Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected.  Source documents are filed at the investigator's site.  
− Data entered in the eCRF that are transcribed from source documents must be 
consistent with the source documents or the discrepancies must be explained.  The 
investigator may need to request previous medical records or transfer records, depending on the study.  Also, current applicable medical records must be 
available.  
• May have responsibility for sending participants’ data, either as unique samples, or 
copi[INVESTIGATOR_014], or photographs, to be evaluated centrally or analyzed centrally, or both, by a qualified vendor designated by [CONTACT_456]. 
• Permitting study -related monitoring, sponsor audits, IRB/IEC review, and regulatory 
inspections by [CONTACT_190083]. 
− Monitoring:  Qualified representatives of the sponsor or its designee, study 
monitors, will monitor the study according to a predetermined plan.  The investigator must allow the study monitors to review any study materials and participant records at each monitoring visit.  
− Auditing:  Qualified representatives of the sponsor or its designee may audit the 
clinical study site and study data to evaluate compliance with the Protocol, 
applicable local clinical study regulations, and overall study conduct.  The investigator must allow the auditors to review original source records and study documentation for all participants. 
− Regulatory inspection:  Regulatory authorities may conduct an inspection of the 
study and the site at any time during the development of an investigational product.  The investigator and staff are expected to cooperate with the inspectors and allow access to all source documents supporting the eCRFs and other 
study-related documents.  The investigator must immediately notify the sponsor 
Incyte Corporation 
Protocol INCB [ZIP_CODE]-[ADDRESS_439392] adhere to applicable data privacy laws and 
regulations.  The investigator and the sponsor or its designee are responsible for ensuring that 
sensitive information is handled in accordance with local requirements (eg, HIPAA).  
Appropriate consent and authorizations for use and disclosure and/or transfer (if applicable) of protected information must be obtained. 
Participant names will not be supplied to the sponsor or its designee.  Only the participant 
number and the participant's initials (participant's initials will only be recorded if allowable by [CONTACT_427]) will be recorded in the eCRF, where permitted; if the participant's name 
[CONTACT_75502] (eg, laboratory report), it must be obliterated on the copy of the 
document to be supplied to the sponsor or its designee.  Study findings stored on a computer will be stored in accordance with local data protection laws.  
11.4. Financial Disclosure  
Before study initiation, all clinical investigators participating in clinical studies subject to 
21 CFR Part 54 – Financial Disclosure by [CONTACT_6230] (ie, "covered studies") are 
required to submit a completed Clinical Investigator Financial Disclosure Form that sufficiently detail s any financial interests and arrangements that apply.  For the purpose of this regulation, 
"clinical investigator" is defined as any investigator or subinvestigator who is directly involved in the treatment or evaluation of research participants, including the spouse and each dependent child of the clinical investigator or subinvestigator.  These requirements apply to both US and foreign clinical investigators conducting covered clinical studies. 
Any new clinical investigators added to the covered clinical  study during its conduct must also 
submit a completed Investigator Financial Disclosure Form.  During a covered clinical study, 
any changes to the financial information previously reported by a clinical investigator must be 
reported to the sponsor or its designee.  At the conclusion of the covered clinical study, the clinical investigators will be reminded of their obligations.  In the event that the clinical 
investigator is not reminded, they nevertheless will remain obligated to report to the sponsor or 
its designee any changes to the financial information previously reported, as well as any changes in their financial information for a period of 1 year after completion of the covered clinical study. 
11.5. Publication Policy  
By [CONTACT_89228], the investigator and his or her institution agree that the results of 
the study may be used by [CONTACT_456], Incyte Corporation (Incyte), for the purposes of national and international registration, publication, and information for medical and pharmaceutical 
professionals.  Study results will be published in accordance with applicable local and national 
regulations.  If necessary, the authorities will be notified of the investigator's name, address, qualifications, and extent of involvement.  The terms regarding the publication of study results 
are contained in the agreement signed with the sponsor or its designee.  A signed agreement will 
be retained by [CONTACT_3552]. 
Incyte Corporation 
Protocol INCB [ZIP_CODE]-[ADDRESS_439393] been collected and a study -site closur e visit has been performed. 
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination. 
Reasons for the early closure of a study site by [CONTACT_11004]:  
• Failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines. 
• Inadequate recruitment of participants b y the investigator.  
• Discontinuation of further study treatment development. 
Incyte Corporation 
Protocol INCB [ZIP_CODE]-307
 
Version 1
Page 74 of 79 
23 JUN 2019
CONFIDENTIAL
12. REFERENCES  
American Academy of Dermatology. Vitiligo: Treatment. https://www.aad.org/public/diseases/ 
color- problems/vitiligo#treatment. Accessed February 12, 2019. 
Bae JM, Jung HM, Hong BY, Lee JH, Choi WJ, Lee JH, Kim GM. Phototherapy for vitiligo : a 
systematic review and meta-analysis. JAMA Dermatol 2017;153:666-674. 
Bharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E. Validation of an 
abbreviated Treatment Satis faction Questionnaire for Medication (TSQM-9) among patients on 
antihypertensive medications. Health Qual Life Outcomes 2009;7:36. 
Batchelor JM, Tan W, Tour S, Yong A, Montgomery AA, Thomas KS. Validation of the Vitiligo 
Noticeability Scale: a patient -reported outcome measure of vitiligo  treatment success. Br J 
Dermatol 2016;174:386-394. 
Boniface K, Seneschal J, Pi[INVESTIGATOR_94593] M , Taïeb A. Vitiligo: focus on c linical aspects, 
immunopathogenesis, and therapy. Clin Rev Allergy Immunol 2018;54:52-67. 
Castanet J, Orton ne JP. Pathophysiology of vitiligo. Clin Dermatol 1997:15:845-851. 
Clinical Trial Facilitation Group. Recommendations related to contraception and pregnancy 
testing in clinical trials. September 15, 2014. http://www.hma.eu/ctfg.html. Accessed November 23, 2106. 
Coondoo A, Phiske M, Verma S, Lahiri K. Side-effects of topi[INVESTIGATOR_8826]: a long overdue 
revisit. Indian Dermatol Online J 2014;5:416-425. 
Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis -directed 
Therapy. JAMA Dermatol 2015;151:1110-1112. 
Eleftheriadou V, Thomas KS, Whitton ME, Batchelor JM, Ravenscroft JC. Which outcomes 
should we measure in vitiligo? Results of a systematic review and a survey among patients and clinicians on outcomes in vitiligo trials. Br J Dermatol 2012;167:804-814. 
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) --a simple practical measure for 
routine clinical use. Clin Exp Dermatol 1994;19:210-216. 
Frisoli ML, Harris JE. Vitiligo: mechanistic insights lead to novel treatments. J Allergy Clin 
Immunol 2017;140:654-662. 
Gawkrodger DJ, Ormerod AD, Shaw L, et al. Guideline for the diagnosis and management of 
vitiligo. Br J Dermatol 2008;159:1051-1076. 
González  U, Whitton M, Eleftheriadou V, Pi[INVESTIGATOR_352888] M, Batchelor J, Leonardi-Bee J. Guidelines for 
designing and reporting clinical trials in vitiligo. ArchDermatol 2011;147:1428-1436. Hamzavi I, Jain H, McLean D, Shapi[INVESTIGATOR_2152] J, Zeng H, Lui H. Parametric modeling of narrowband 
UV-B phototherapy for vitiligo using a novel quantitative tool: the  Vitiligo Area Scoring Index. 
Arch Dermatol 2004;140:677-683. 
Harris JE, Rashighi M, Nguyen N, et al. Rapid skin repi[INVESTIGATOR_352889] a 
patient with coexistent v itiligo and alopecia areata (AA). J Am Acad Dermatol 2016;74:370-371. 
Incyte Corporation 
Protocol INCB [ZIP_CODE]-307
 
Version 1
Page 75 of 79 
23 JUN 2019
CONFIDENTIAL
Joshipura D, Al
omran A, Zancanaro P, Rosmarin D. Treatment of vitiligo with the topi[INVESTIGATOR_352890]: a 32- week open -label extension study with optional narrow-band 
ultraviolet B. J Am Acad Dermatol 2018;78:1205-1207. 
Krüger C, Panske A, Schallreuter KU. Disease- related behavioral patterns and experiences affect 
quality of life in children and adolescents with vitiligo. Int J Dermatol 2014;53:43-50. 
Krüger C, Schallr euter KU. A review of the worldwide prevalence of vitiligo in 
children/adolescents and adults. Int J Dermatol 2012;51:1206-1212. 
Lai YC, Yew YW, Kennedy C, Schwartz RA. Vitiligo and depression: a systematic review and 
meta -analysis of observational studies. Br J Dermatol 2017;177:708-718. 
Lilly E, Lu PD, Borovicka JH, et al. Development and validation of a vitiligo -specific 
quality-of- life instrument (VitiQoL). J Am Acad Dermatol 2013;69:e11 -18. 
Linthorst Homan MW, de Korte J, Grootenhuis MA, Bos JD, Sprangers MA, van der Veen JP. 
Impact of childhood vitiligo on adult life. Br J Dermatol 2008;159:915-920. 
Linthorst Homan MW, Spuls PI, de Korte J, Bos JD, Sprangers MA, van der Veen JP. The 
burden of vitiligo: patient characteristics associated with quality of  life. J Am Acad Dermatol 
2009;61:411-420. 
Mehta CR, Patel NR. Exact logistic regression: theory and examples. Stat Med 
1995;14:2143-2160. 
Osinubi O, Grainge MJ, Hong L, et al. The prevalence of psychological comorbidity in people 
with vitiligo: a systematic review and meta -analysis. Br J Dermatol 2018;178:863-878. 
Porter J R, Beuf A H, Lerner A B, Nordlund JJ, et al. The effect of vitiligo on sexual relationship s. 
J Am Acad Dermatol 1990 ;22:221-222. 
Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE, Vitiligo Working Group. New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol 2017;77:1-13. 
Rothstein B, Joshipura D, Saraiya A, et al. Treatment of vitiligo with the topi[INVESTIGATOR_352891]. J Am Acad Dermatol 2017;76:1054-1060. 
Ruxolitinib Cream Investigator's Brochure. Wilmington, DE: Incyte Corporation. 
Salzer BA, Schallreuter KU. Investigation of the personality structure in patients with vitiligo 
and a possible association with impaired catecholamine metabolism. Dermatology 
1995;190:109-115. 
Silverberg JI, Silverberg NB. Association between vitiligo extent and distribution and 
quality-of- life impairment. JAMA Dermatol 2013;149:159-164. 
Speeckaert R, van Geel N. Vitiligo: an update on pathophysiology and treatment options. Am J Clin Dermatol 2017;18:733-744. 
Taieb A, Alomar A, Böhm M, et al. Guidelines for the management of vitiligo: the European 
Dermatology Forum consensus. Br J Dermatol 2013;168:5-19. 
Taieb A, Pi[INVESTIGATOR_94593] M. Clinical practice. Vitiligo. N E ngl J Med 2009;360:160-169. 
Topp CW, Østergaard SD, Søndergaard S, Bech P. The WHO -5 Well -Being Index: a systematic 
review of the literature.  Psychother Psychosom 2015;84:167-176. 
Incyte Corporation 
Protocol INCB [ZIP_CODE]-307
 
Version 1
Page 76 of 79 
23 JUN 2019
CONFIDENTIAL
van Buuren S. Mult
iple imputation of discrete and continuous data by [CONTACT_352958]. Stat Methods Med Res 2007;16:219-242. 
Vitiligo Research Foundation. Treatment Guidelines. 
https://vrfoundation.org/treatment_guidelines. Accessed February 12, 2019. 
Wang G, Qiu D, Yang H, Liu W. The prevalence and odds of depressi on in patients with vitiligo: 
a meta-analysis [published online ahead of print December 9, 2017]. J Eur Acad Dermatol 
Venereol. doi: 10.1111/jdv.[ZIP_CODE]. 
Whitton M, Pi[INVESTIGATOR_352888] M, Batchelor JM, et al. Evidence- based management of vitiligo: summary of a 
Cochrane s ystematic review. Br J Dermatol 2016;174:962-969. 
WHO Collaborating Center for Mental Health, Psychiatric Research Unit. WHO -5. 
https://www.psykiatri-regionh.dk/who-5/Pages/default.aspx. Accessed June 6, 2019. 
Yazdani Aby[CONTACT_352959], Griffith R, Falto -Aizpurua L, Nouri K. The dark history of white spots. 
JAMA Dermatol 2014;150:936. Zigmond AS, Snaith RP. The hospi[INVESTIGATOR_56105]. Acta Psychiatr Scand  
1983;67:361-370. 
Incyte Corporation 
Protocol INCB [ZIP_CODE]-307
 
Version 1
Page 77 of 79 
23 JUN 2019
CONFIDENTIAL
APPENDIX A. INFORMATION REGARDING EFFECTIVENESS OF 
CONTRACE PTIVE METHODS  
For male participants in the study:  
Male participants should use a condom during treatment through [ADDRESS_439394] had a vasectomy qualify as having met the requirement 
for a highly effective birth control method.  
For female participants  in the study:  
The following methods that can achieve a failure rate of less than 1% per year when used consistently 
and correctly are considered as highly effective birth control methods: 
• Combined (estrogen and progestogen containing) hormonal contracept ion associated with 
inhibition of ovulationa 
− oral 
− intravaginal  
− transdermal  
• Progestogen -only hormonal contraception associated with inhibition of ovulationa 
− oral 
− injectable  
− implantableb 
• Intrauterine deviceb 
• Intrauterine hormone- releasing systemb 
• Bilateral tubal occlusionb 
• Vasectomized partnerbc 
• Sexual abstinenced 
Acceptable birth control methods that result in a failure rate of more than 1% per year include:  
• Progestogen -only oral hormonal contraception, where inhibition of ovulation is not the primary 
mode of action 
• Male or female condom with or without spermicidee 
• Cap, diaphragm, or sponge with spermicidee 
• Tubal ligation  
a Hormonal cont raception may be susceptible to interaction with the investigational medicinal product, which may 
reduce the efficacy of the contraception method.  
b Contraception methods that in the context of t his guidance are considered to have low user dependency.  
c Vasectomized partner is a highly effective method of avoiding pregnancy provided that partner is the sole sexual 
partner of the woman of  childbearing potential study participant and that the vasectomized partner has received 
medical assessment of the surgical success.  
d In the context of this guidance, sexual abstinence is consid ered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated with the study treatments.  The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the 
preferred and usual lifestyle of the participant.  
e A combination of male condom with either cap, diaphragm, or sponge with spermicide (double barrier methods) 
are also co nsidered acceptable, but not highly effective, birth control methods.  
Source:  Clinical Trial Facilitation Group 2014 . 
Incyte Corporation 
Protocol INCB [ZIP_CODE]-307
 
Version 1
Page 78 of 79 
23 JUN 2019
CONFIDENTIAL
APPENDIX B.  PROTOCOL AMENDMENT SUMMARY OF CHANGES  
Not applicable.  
Incyte Corporation 
Protocol INCB [ZIP_CODE]-307
 
Version 1
Page 79 of 79 
23 JUN 2019
CONFIDENTIAL
Official Title:  Topi[INVESTIGATOR_352825] 2 (TRuE-V2): A Phase 3, Double-Blind, 
Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream 
Study ID: [REMOVED]  
Document  Date :  Clinical Study Protocol Version 4: 13 March 2020Followed by [CONTACT_352960] 1 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL   
Clinical Study Protocol  
 
INCB  [ZIP_CODE] -307 
Topi[INVESTIGATOR_352825] 2 
(TRuE-V2)  
A Phase 3, Double -Blind, Randomized, Vehicle- Controlled, Efficacy 
and Safety Study of Ruxolitinib Cream Followed by [CONTACT_352961]: Ruxolitinib Cream  
IND Number:  77,[ADDRESS_439395] Number:  2019- 000847 -28 
Phase of Study:  3 
Sponsor:  Incyte Corporation  
1801 Augustine Cut -Off 
Wilmington, DE [ZIP_CODE]  
Original Protocol:  23 JUN 2019  
Amendment  1: [ADDRESS_439396]  2019 
Amendment 2:   12 DEC 2019  
Amendment 3:  21 FEB 2020  
Amendment 3 -US-CA:  [ADDRESS_439397] their origin in the Declaration of 
Helsinki and conducted in adherence to the study Protocol, applicable Good Clinical Practices, and applicable laws 
and country- specific regulations in which the study is being conducted.  
The information in this document is confidential.  No part of this information may be duplicated, referenced, or 
transmitted in any form or by [CONTACT_61076] (electronic, mechanical, photocopy, recording, or otherwise) without prior 
written consent.  
 
Incyte Corporation  Page 2 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  INVESTIGATOR 'S AGREEMENT  
I have read the INCB [ZIP_CODE]-307 Protocol Amendment 3- US-CA (dated 13 MAR 2020) and 
agree to  conduct the study as outlined.  I agree to maintain the confidentiality of all information 
received or developed in connection with this Protocol. 
 
 
   
(Printed Name [CONTACT_7919])    
   
   
(Signature [CONTACT_7919])   (Date)  
 
Incyte Corporation  Page [ADDRESS_439398] OF ABBREVIATIONS ..........................................................................................................8  
1. PROTOCOL SUMMARY  ..........................................................................................11  
2. INTRODUCTION  ......................................................................................................20  
2.1. Epi[INVESTIGATOR_352826]  ............................................................................................20  
2.2. Current Treatment and Unmet Need in Vitiligo  .........................................................21  
2.3. Role of Janus Kinases in Viti ligo ...............................................................................22  
2.4. Ruxolitinib Cream  ......................................................................................................23  
 23 
2.4.2.  Clinical Experience  .....................................................................................................24  
 24 
[IP_ADDRESS].  Efficacy of Ruxolitinib Cream  ....................................................................................26  
 30 
 30 
 31 
 31 
3. OBJECTIVES AND ENDPOINTS  ............................................................................33  
4. STUDY DESIGN  .......................................................................................................36  
4.1. Overall Design  ............................................................................................................36  
4.2. Overall Study Duration  ...............................................................................................36  
4.3. Study Termination ......................................................................................................37  
5. STUDY POPULATION  .............................................................................................37  
5.1. Inclusion Criteria  ........................................................................................................37  
5.2. Exclusion Criteria  .......................................................................................................38  
5.3. Lifestyle Considerations  .............................................................................................40  
5.4. Screen Failures  ............................................................................................................40  
5.5. Replacement of Participants  .......................................................................................40  
6. STUDY TREATMENT  ..............................................................................................41  
6.1. Study Treatment Application ......................................................................................41  
6.1.1.  Application During the Double -Blind Vehicle -Controlled Treatment Period ...........42  
6.1.2.  Application During the Treatment Extension Period .................................................42  
6.2. Preparation, Handling, and Accountability ................................................................42  

Incyte Corporation  Page 4 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  6.3. Measures to Minimize Bias:  Randomization and Blinding  .......................................43  
6.4. Study Treatment Compliance .....................................................................................44  
6.5. Dose Modifications  .....................................................................................................44  
6.5.1.  Criteria and Procedures for Application Interruptions of Study Drug .......................44  
6.5.2.  Criteria for Permanent Discontinuation of Study Drug Due to an Adverse 
Event ...........................................................................................................................45  
6.6. Concomitant Medications and Procedures  .................................................................45  
 46 
 46 
 47 
6.8. Treatment After the End of the Study .........................................................................47  
7. DISCONTINUATION OF STUDY TREATMENT AND PARTICIPANT DISCONTINUATION/WITHDRAWAL  ..................................................................[ADDRESS_439399] to Follow- Up .......................................................................................................49  
8. STUDY ASSESSMENTS AN D PROCEDURES  ......................................................50  
8.1. Administrative and General Procedures .....................................................................50  
8.1.1.  Informed Consent Process ..........................................................................................50  
8.1.2.  Screening Procedures ..................................................................................................51  
8.1.3.  Interactive Response Technology Procedure ..............................................................51  
8.1.4.  Distribution of Study Reminder Cards and Diaries ....................................................51  
8.1.5.  Demography and Medical History ..............................................................................52  
[IP_ADDRESS].  Demographics and General Medical History  .............................................................52  
[IP_ADDRESS].  Disease Characteristics and Treatment History  ..........................................................52  
 52 
8.2. Efficacy Assessments .................................................................................................53  
8.2.1.  Body Surface Area ......................................................................................................53  
8.2.2.  Vitiligo Area Scoring Index  ........................................................................................53  
8.2.3.  Physician’s Global Vitilig o Assessment (Facial)  .......................................................54  
8.2.4.  Physician’s Global Vitiligo Assessment (Total Body)  ...............................................54  

Incyte Corporation  Page 5 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  8.2.5.  Photography ................................................................................................................55  
8.2.6.  Patient -Reported Outcomes  ........................................................................................55  
[IP_ADDRESS].  Vitiligo Noticeability Scale  ........................................................................................56  
[IP_ADDRESS].  Color-Matching Question ...........................................................................................56  
[IP_ADDRESS].  Patient Global Impression of Change -Vitiligo (Facial)  ..............................................56  
[IP_ADDRESS].  Patient Global Impression of Change -Vitiligo (Total Body)  .....................................57  
[IP_ADDRESS].  Dermatology Life Quality Index ................................................................................57  
[IP_ADDRESS].  WHO -5 .......................................................................................................................58  
[IP_ADDRESS].  Treatment Satisfaction Questionnaire for Medication  ................................................58  
[IP_ADDRESS].  VitiQoL  .......................................................................................................................58  
[IP_ADDRESS].  Hospi[INVESTIGATOR_5620]  .....................................................................58  
8.3. Safety Assessments .....................................................................................................58  
8.3.1.  Adverse Events ...........................................................................................................58  
8.3.2.  Physical Examinations ................................................................................................59  
8.3.3.  Vital Signs  ..................................................................................................................59  
8.3.4.  Electrocardiograms  .....................................................................................................59  
8.3.5.  Laboratory Assessments .............................................................................................60  
[IP_ADDRESS].  Pregnancy Testing ......................................................................................................61  
[IP_ADDRESS].  Serology ......................................................................................................................62  
8.4. Pharmacokinetic Assessments  ....................................................................................62  
8.5. Pharmacodynamic and Translational Assessments ....................................................62  
8.6. Unscheduled Visits  .....................................................................................................62  
8.7. End of Treatment and/or Early Termination  ..............................................................62  
8.8. Safety Follow -Up ........................................................................................................63  
9. ADVERSE EVENTS:  DEFINITIONS AND PROCEDU RES FOR 
RECORDING, EVALUATING, FOLLOW -UP, AND RE PORTING  ......................63  
9.1. Definition of Adverse Event .......................................................................................63  
9.2. Definition of Serious Adverse Event ..........................................................................64  
9.3. Recording and Follow-Up of Adverse Events and/or Serious Adverse Events .........[ADDRESS_439400] Complaints ....................................................................................................69  
9.9. Treatmen t of Overdose ...............................................................................................70  
10. STATISTICS ..............................................................................................................70  
10.1.  Sample Size Determination  ........................................................................................70  
10.2.  Populations for Analysis  .............................................................................................71  
10.3.  Statistical Analyses  .....................................................................................................71  
10.3.1.  Efficacy Analyses  .......................................................................................................71  
[IP_ADDRESS].  Primary Analysis  ........................................................................................................71  
[IP_ADDRESS].  Key Secondary Analysis .............................................................................................72  
[IP_ADDRESS].  Secondary Analysis  ....................................................................................................[ADDRESS_439401] OF TABLES  
Table  1: Primary and Secondary Objectives and Endpoints .....................................................11  
Table  2: Key Study Design Elements .......................................................................................12  
Table  3: Schedule of Activities:  Double- Blind, Vehicle -Controlled Treatment Period 
(Day  1-Week 24) ........................................................................................................14  
Table  4: Schedule of Activities:  Treatment Extension Period (Week 28-Week 52) ...............17  
 
25 
  
26 
 29 
Table  8: Objectives and Endpoints ...........................................................................................33  
Table  9: Study Treatment Information .....................................................................................41  
Table  10: Guidelines for Interruption and Restarting of Study Drug .........................................45  
Table  11: Facial Physician's Global Vitiligo Assessment Scale  .................................................54  
Table  12: Total Body Physician's Global Vitiligo Assessment Scale  ........................................55  
Table  13: Required Laboratory Analytes ....................................................................................61  
Table 14:  Powering for Primary and Key Secondary Endpoints ................................................70  
Table  15: Populations for Analysis  .............................................................................................[ADDRESS_439402] OF FIGURES  
Figure 1:  Study Design Schema .................................................................................................13  
  
25 
Figure 3:  INCB [ADDRESS_439403]  aspartate aminotransferase  
BID twice daily  
BSA body surface area  
CDLQI  Children’s Dermatology Life Quality Index  
CFR  Code of Federal Regulations  
CTCAE  Common Terminology Criteria for Adverse Events  
CYP  cytochrome P450  
DLQI  Dermat ology Life Quality Index  
DSMB  Data Safety Monitoring Board  
ECG electrocardiogram  
eCRF electronic case report form  
EDC  electronic data capture  
EOS  end of study  
EOT  end of treatment  
F-BSA facial body surface area  
F-PaGIC -V facial assessment of Patien t Global Impression of Change -Vitiligo  
F-PaGVA  facial assessment of Patient's Global Vitiligo Assessment  
F-PhGVA  facial assessment of Physician Global Vitiligo Assessment  
FSH follicle -stimulating hormone  
F-VASI  Face Vitiligo Area Scoring Index  
F-VASI2 5/50/75/90  ≥ 25%/ 50% / 75%/ 90%  improvement from base line in Face Vitiligo Area 
Scoring Index score 
GCP  Good Clinical Practice  
HADS  Hospi[INVESTIGATOR_352892] [ADDRESS_439404] 
HIV human immunodeficiency virus  
IB Investigator's Brochure  
ICF informed consent form  
ICH International Conference on Harmonisation  
ID identification  
IEC independent ethics committee  
INFO  International Initiative for Outcomes 
IRB institutional review board  
IRT interactive response technology  
ITT intent to treat  
JAK Janus kinase  
LOCF  last observation carry forward  
MI multiple imputation  
MMRM mixed -effect model repeat measurement  
NB-UVB narrow-band ultraviolet B  
Pa-GIC -V Patient Glob al Impression of Change -Vitiligo  
PhGVA  Physician Global Vitiligo Assessment  
PK pharmacokinetic  
PP per protocol  
PUVA  psoralen and ultraviolet A  
QD once daily  
SAE  serious adverse event  
SD standard deviation 
SoA schedule of assessments  
SOP standard o perating procedure  
STAT  signal transducer and activator of transcription  
S[LOCATION_003]R  suspected unexpected adverse reaction  
T-BSA total body surface area  
TCS topi[INVESTIGATOR_352893]-emergent adverse event 
T-PaGIC -V total body assessment of Patient Global Impression of Change -Vitiligo  
T-PaGVA  total body assessment of Patient's Global Vitiligo Assessment  
T-PhGVA  total body assessment of Physician Global Vitiligo Assessment  
TSH  thyroid -stimulating hormone  
TSQM  Treatment Satisfaction Questionnaire for Medication  
Incyte Corporation  Page 10 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  Abbreviations and 
Special Terms  Definition 
T-VASI  total body Vitiligo Area Scoring Index  
T-VASI25/50/75/90  ≥ 25%/ 50%/ 75%/ 90% improvement in total body Vitiligo Area Scoring Index  
TYK  tyrosine kinase  
ULN  upper limit of normal  
UV ultraviolet  
VASI  Vitiligo Area Scoring Index  
VitiQoL  Vitiligo-specific quality of life  
VNS  Vitiligo Noticeability Scale  
WHO-5 World Health Organization -Five Well-Being Index  
Incyte Corporation  Page 11 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  1. PROTOCOL  SUMMARY  
Protocol Title:  A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety 
Study of Ruxolitinib Cream Followed by [CONTACT_352962]:   INCB [ZIP_CODE]-307 
Objectives and Endpoints : 
Table  1 presents the primary, key secondary, and selected  secondary objectives and endpoints.  
Table  1: Primary and Secondary Objectives and Endpoints  
Objectives  Endpoints  
Primary  
To evaluate the efficacy of ruxolitinib cream  in 
participants  with vitiligo. • Proportion of participants achieving F- VASI75 at 
Week 24.  
Key Secondary  
To further assess the efficacy of ruxolitinib 
cream . • Proportion of participants  achieving F-VASI50  at 
Week  24. 
• Proportion of participants  achieving F -VASI 90 at 
Week  24. 
• Proportion of participants achieving T -VASI50 at 
Week  24. 
• Proportion of par ticipants achieving a VNS of  
“4 – A lot less noticeable” or “5 – No longer 
noticeable” at Week 24.  
• Percentage change from baseline in F -BSA at 
Week  24. 
Selected Secondary  
To evaluate the safety and tolerability of ruxolitinib cream . • The frequency, duration, and severity of AEs; 
physical examinations; vital sign s; and laboratory 
data for hematology and serum chemistry.  
To further assess the efficacy of ruxolitinib cream.  • Proportion of participants achieving F-VASI25/50/75/90 during  the treatment period 
(double -blind and treatment extension  periods) .  
• Proportion of participants achieving 
T-VASI25/50/75/90 during  the treatment period 
(double -blind and treatment extension  periods) .  
• Proportion of participants in each category of VNS 
during  the treatment period (double -blind and 
treatment extension  period s). 
Incyte Corporation  Page 12 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  Overall Design:  
Table  2 presents the key study design elements.  Further study details are presented after the 
table . 
Table  2: Key Study Design Elements  
Study Phase  Phase 3  
Clinical Indication Vitiligo  
Population  Males and females, aged ≥ [ADDRESS_439405] vitiligo with ≥ 0.5%  BSA on the 
face, ≥ 0.5 F -VASI, ≥ 3% BSA on nonfacial areas, and ≥  3 T-VASI .  Total body 
vitiligo area  (facial and nonfacial)  should not exceed 10% BSA. 
Partic ipants must have a clinical diagnosis of non-segmental vitiligo.  Other forms 
of vitiligo (eg, segmental) or other differential diagnosis of vitiligo or other skin 
depi[INVESTIGATOR_352894].  
See Section  5 for all inclusion and exclusion criteria.  
Number of Participants  Approximately 300 participants will be randomized 2:1 ( ruxolitinib cream  1.5% 
BID:vehicle).  
Study Design Randomized, d ouble -blind, vehicle -controlled, with a treatment extension pe riod. 
Exit interviews will be conducted  with participants at selected sites to better 
understand their perception of repi[INVESTIGATOR_352895] (see Section  8.1.6 ). 
Estimated Duration of Study  
Participation Screening:  Up to 32 days  
Double -blind period:  24 weeks  
Treatment  extension period:   28 weeks 
Safety follow -up:  [ADDRESS_439406] study 
visit 
Total:  Up to approximately 60 weeks 
DSMB  The study is not evaluating an endpoint with serious morbidity/mortality.  Thus , a 
DSMB is not required.  
The study design is shown in Figure 1.  The SoA  is detailed in Table  3 (for the double-blind 
period) and Table  4 (for the treatment  extension period).  Adherence to the study design 
requirements, including those specified in the SoA, is essential and required for study conduct. 
Incyte Corporation  Page 13 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  Figure  1: Study Design Schema  
 
This is a randomized, vehicle -controlled study in adolescent and adult participants ( age 
≥ 12 years) with non- segmental  vitiligo who have depi[INVESTIGATOR_352829] ≥ 0.5% BSA on 
the face, ≥  0.5 F- VASI , ≥ 3% BSA on nonfacial areas , and ≥  3 T- VASI .  Total body involved 
vitiligo  area  (facial and nonfacial)  should not exceed 10% BSA.  Approximately 300 participants 
will be randomized 2:1 to receive initial study treatment (ruxolitinib cream 1.5% BID:vehicle; 
applied to depi[INVESTIGATOR_352896] 10% total BSA) for 24 weeks 
(see Figure  1).  Participants will be stratified by [CONTACT_11338] ( North America or Europe ) and skin type 
(Fitzpatrick scale T ype I and II vs Type III, IV, V, and VI).  Adolescents (≥ 12 to < 18 years) 
will make up at least 10% of the study population, and no more than 50% of participants will be 
> 40 years old . 
After completion of the Week 24 assessments, participants will be offered the opportunity to 
receive an additional 28 weeks of treatment extension with ruxolitinib cream 1.5% BID.  To be 
eligible  for the treatment extension , participants must have completed the baseline and Week  [ADDRESS_439407] any safety issues.  The total 
treated area should not exceed 10% BSA (facial and nonfacial) . 
See Section  4.[ADDRESS_439408] and maintenance 
regimens.  
Incyte Corporation  Page 14 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  Table  3: Schedule of A ctivitie s:  Double -Blind, Vehicle- Controlled Treatment Period  (Day  1-Week 24)  
Procedure  Scre ening  Double -Blind , Vehicle Controlled Treatment  Notes  
Days 
-32 to -1 Day 1  
 Wk 4  
± 3 d  Wk 8  
± 3 d  Wk 12 
± 3 d  Wk 18 
± 7 d Wk 24 * 
(EOT1) 
± 7 d *Week [ADDRESS_439409] visit of the treatment 
extension period . 
Administrative procedures   
Informed  consent  X        
Informed consent for optional 
qualitative exit interviews  X*       A subgroup of participants at sponsor -selected sites will be 
included in a substudy involving exit interviews.  
*If consent to provide exit interviews was not obtained at 
screening, it can be obtained at the participant’s  next study 
visit.  
Contact [CONTACT_12067]  X* X X X X X X *Entry of a ge and skin type information  into the IRT  will be 
required  at screening . 
Inclusion and exclusion criteria  X X       
Demography  X        
General a nd disease medical 
history  X        
Prior/concomitant medications  X X X X X X X  
Apply s tudy drug  X X X X X X* At each study visit starting at Day 1, the participant  should 
apply the study drug under direct supervision of the site staff.   
*Not applicab le to the EOT1 visit.  
Dispense  (D) and return (R)  
study drug and diary cards   D R/D R/D R/D R/D R/D*  All tubes of study drug will be weighed before being 
dispensed.  All returned tubes of study drug will be weighed. 
*Dispension is not applicable to the EOT1 visit.  At the Week 
[ADDRESS_439410]/ 
review study drug diary cards    X X X X X  
Assess compliance    X X X X X  
Qualit ative e xit interview        X* *The qualitative exit interview is conducted only for the 
subgroup of participants who consented to participate . 
Incyte Corporation  Page 15 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  Table  3: Schedule of Activities :  Double -Blind, Vehicle -Controlled Treatment Period (Da y 1-Week 24) (Continued) 
Procedure  Screening  Double -Blind , Vehicle Controlled Treatment  Notes  
Days 
-32 to -1 Day 1  
 Wk 4  
± 3 d  Wk 8  
± 3 d  Wk 12 
± 3 d  Wk 18 
± 7 d Wk 24*  
(EOT1) 
± 7 d *Week [ADDRESS_439411] visit of the treatment 
extension period . 
Safety assessments   
AE assessment  X X X X X X X Ad hoc photography of skin -related AEs may also occur as 
applicable.  
Targeted physical examinations   X X X X X  A targeted physical examination should be conducted as 
indicated by [CONTACT_352963], AEs, or 
other findings.  Abnormalities that are considered clinically 
significant in the judgment of the investigator are to be 
reported as AEs.  See Section  8.3.2 . 
Comprehensive physical 
examin ation  X      X  
Vital signs  X X X X X X X  
12-lead ECG  X       12-lead ECG performed within 2 months before baseline is 
acceptable.  
Efficacy assessments   
F-BSA  X X X X X X X  
T-BSA  X X X X X X X Includes facial and nonfacial areas.  
F-VASI  X X X X X X X  
T-VASI  X X X X X X X Includes facial and nonfacial areas.  
F-PhGVA   X   X  X  
T-PhGVA   X   X  X  
Photography of face  X X*   X  X 2D photography at  all sites; 3D photography a t selected sites . 
*If photo quality at screening is not adequate, the photography 
may be repeated at Day 1. The baseline photos are defined as 
the adequate ones either taken at screening or Day 1.  
Photography of  nonfacial  target 
area X X*   X  X 2D photography at all sites. The genitalia  area should not be 
photographed. 
*If photo quality at screening is not adequate, the photography may be repeated at Day 1. The baseline photos are defined as 
the adequate ones either taken at screening or Day 1.  
Incyte Corporation  Page 16 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  Table  3: Schedule of Activities :  Double -Blind, Vehicle -Controlled Treatment Period (Day  1-Week 24) (Continued) 
Procedure  Screening  Double -Blind , Vehicle Controlled Treatment  Notes  
Days 
-32 to -1 Day 1  
 Wk 4  
± 3 d  Wk 8  
± 3 d  Wk 12 
± 3 d  Wk 18 
± 7 d Wk 24*  
(EOT1) 
± 7 d *Week [ADDRESS_439412] visit of t he treatment extension 
period. 
Patient -reported outcomes  To be evaluated prior to any other study procedures/assessments.  
VNS      X  X The participant  will be provide d their baseline photo  and a mirror  
to perform this assessment . 
Color -matching question      X  X The participant will be provided their baseline  photo  and a mirror  
to perform this assessment.  
F-PaGIC -V     X  X  
T-PaGIC -V     X  X  
DLQI   X   X  X For participants who are age ≥ 12 years to < 16 years at baseline, 
the CDLQI will be completed instead.  
WHO -5  X   X  X  
TSQM      X  X  
VitiQoL   X   X  X  
HADS   X     X  
Laboratory assessments   
Hematology and chemistry 
assessments  X X X X* X X* X *The bl ood draw at Week  8 and W eek 18 is optional for 
participants who are age <  [ADDRESS_439413] 
12 months without an alternative medical cause before screening.  
Pregnancy testing  X* X X X X X X *Female participants of childbearing potential will have a serum 
test at screening and safety follow -up visits.  A urine test will be 
conducted at all other visits.  A positive urine test must be 
confirmed by a serum test.  
PK and translational assessments   
Population -based PK plasma 
sampling (trough)   X    X Time of last study drug application to be recorded in eCRF.  
Blood samples must not be drawn from the area that has been 
treated with study drug.  
Samples will be drawn at predose.  
Serum sampling for biomarker 
analysis   X   X  X  
Note:  Unscheduled visits may occur at any time at the investigator's discretion, and appropriate clinical and laboratory tests may be performed, as clinically indicated. 
Incyte Corporation  Page 17 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  Table  4: Schedule of Activities:  Treatment Extension  Period (Week 28- Week 52)  
Procedure  Treatment Extension  Safety Follow -Up Notes  
Wk 28 
± 7 d  Wk 34 
± 7 d  Wk 40 
± 7 d  Wk 46 
± 7 d  Wk 52 
(EOT2*) 
± 7 d  30 days  
+ 7 d After 
EOT1/EOT2** 
(EOS)  *EOT 2 assessments should be performed in the 
event a participant’s treatment is stopped before 
Week  52 at any relevant study visit before that time.  
**After last application of study drug or last visit. 
Administrative procedures   
Contact [CONTACT_12067]  X X X X X X  
Prior/concomitant medications  X X X X X X  
Apply study drug  X X X X   At ea ch study visit , the participant should apply the 
study drug under direct supervision of the site staff.  
Dispense (D) and return (R) study 
drug and diary cards  R/D R/D R/D R/D R  All tubes of study drug will be weighed before being 
dispensed.  All returned tubes of study drug will be 
weighed . 
Collect study drug and collect/ 
review study  drug diary cards  X X X X X   
Assess compliance  X X X X X   
Qualitative e xit interview      X*  *The qualitative exit interview is conducted only for 
the subgroup of participants who consented to participate. 
Safety assessments   
AE assessment  X X X X X X A targeted physical examination should be 
conducted as indicated by [CONTACT_312361], AEs, or other findings.  Abnormalities 
that are considered clinically significant in the 
judgment of the investigator are to be reported as 
AEs.   See Section  8.3.2 . 
Targeted physical examinations  X X X X  X  
Comprehensive physical 
examination      X   
Vital signs  X X X X X X  
Efficacy assessments   
F-BSA  X X X X X X  
T-BSA  X X X X X X Includes facial and  nonfacial areas.  
F-VASI  X X X X X X  
T-VASI  X X X X X X Includes facial and nonfacial areas.  
F-PhGVA    X  X   
Incyte Corporation  Page 18 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  Table  4: Schedule of Activities:  Treatment Extension  Period (Week 28- Week 52)  (Continued)  
Procedure  Treatment Exten sion Safety Follow -Up Notes  
Wk 28 
± 7 d  Wk 34 
± 7 d  Wk 40 
± 7 d  Wk 46 
± 7 d  Wk 52 
(EOT2*) 
± 7 d  30 days  
+ 7 d After 
EOT1/EOT2** 
(EOS)  *EOT 2 assessments should be performed in the 
event a participant’s treatment is stopped before 
Week  52 at any relevant s tudy visit before that time.  
**After last application of study drug or last visit. 
T-PhGVA    X  X   
Photography  of face    X  X  2D photograph at all sites; 3D photography a t 
selected sites.  
Photography of nonfacial target 
area   X  X  2D photography at all sites. The genitalia  area should 
not be photographed.  
Patient -reported outcomes  To be evaluated prior to any other study 
procedures/assessments.  
VNS    X  X  The participant will be provided their baseline photo 
and a mirror to perform this assessment . 
Color -matching question    X  X  The participant will be provided their baseline photo 
and a mirror to perform this assessment.  
F-PaGIC -V   X  X   
T-PaGIC -V   X  X   
DLQI    X  X  For participants who are age ≥ 12 years to <  16 years 
at baseline, the CDLQI will be completed instead.  
WHO -5   X  X   
TSQM    X  X   
VitiQoL    X  X   
HADS      X   
Laboratory assessments   
Hematology and chemistry 
assessments  X X X X* X X *The blood dr aw at Week 46 is optional for 
participants who are age <  18 years  
Pregnancy testing  X X X X X X* *Female participants of childbearing potential will 
have a serum test at screening and safety follow -up 
visits.  A urine test will be conducted at all other 
visits.  A positive urine test must be confirmed by a 
serum test.  
Incyte Corporation  Page 19 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  Table  4: Schedule of Activities:  Treatment Extension  Period (Week 28- Week 52)  (Continued)  
Procedure  Treatment Extension  Safety Follow -Up Notes  
Wk 28 
± 7 d  Wk 34 
± 7 d Wk 40 
± 7 d  Wk 46 
± 7 d  Wk 52 
(EOT2*) 
± 7 d  30 days  
+ 7 d After 
EOT1/EOT2** 
(EOS)  *EOT 2 assessments should be performed in the 
event a participant’s treatment is stopped before 
Week  52 at any relevant study visit before that time.  
**After last applica tion of study drug or last visit. 
PK and Translational assessments  
Population -based PK plasma 
sampling (trough)   X    Time of last study drug application to be recorded in 
eCRF.  Blood samples must not be drawn from the 
area that has been treated with s tudy drug.  
Samples will be drawn at predose.  
Serum sampling for biomarker 
analysis    X  X   
Note:  Unscheduled visits may occur at any time at the investigator's discretion, and appropriate clinical and laboratory tes ts may be performed, as clinically in dicated. 
Incyte Corporation  Page [ADDRESS_439414] 0.5% to 2% of the population worldwide 
(Krüger and Schallreuter 2012).  The prevalence is similar between men and women, and there is 
no known difference in presentation according to skin type or race.  Almost 50% of patients 
present before 20 years of age, and many of them present before 10 years of age ( Rodrigues et al  
2017).  Generalized (n on-segmental ) vitiligo is the most common type, accounting for up to 
90% of cases ( Taieb  et al 2009).   Vitiligo is associated with autoimmune diseases such as Sutton 
nevus, thyroid disorders, juvenile diabetes mellitus, pernicious anemia, and Addison's disease.  
The natural course of the disease is generally unpredictable, but it is often progressive.  Some 
degree of spontaneous repi[INVESTIGATOR_352831] 10% to 20% of patients; however, it is 
typi[INVESTIGATOR_352832] ( Castanet and Ortonne 1997).  
Vitiligo is a serious disease owing to its substantial psychological impact on patients’ day -to-day 
functioning, and its progressive course if left untreated.  Studies have shown that the effect vitiligo has on quality of life, particularly psychological impairment, is similar to other skin 
diseases, such as psoriasis and AD ( Linthorst et al  2009).  Involvement of exposed skin, such as 
the face and hands, c an have a major impact on self -esteem  and eventually link to the 
psychological burden and quality of life ( Silverberg and Silverberg 2013 ).  In some societies, 
there is poor acceptance and understanding of the disease, to the extent of discrimination against 
affected individuals ( Yazdani Aby[CONTACT_312341] 2014 ).  Approximately 75% of vitiligo sufferers feel 
their appearance is moderately to severely intolerable, and 41% of patients feel that there is little 
they can do to improve their condition, and feelings of hopelessness increase with time ( Salzer 
and Schallreuter 1995).  Not surprisingly, 66% of patients report being distressed by [CONTACT_5025], and 92% have experienced stigmatization ( Krüger et al 2014).  Feelings of 
embarrassment and fear of rejection can cause vitiligo patients to withdraw and lead to social isolation in both personal and professional relationships.  A majority of patients with vitiligo have reported feelings of anxiety and embarrassment when meeting strangers or beginning a new 
sexual relationship ( Porter  et al  1990 ). Additionally , clinical depression or depressive symptoms 
are associated with vitiligo.  Based on various meta- analyses, patients with vitiligo were 
approximately 5 times more likely to suffer from depression than healthy controls ( Lai et al 
2017, Osinubi et al 2018 ).  A recent results of the analysis indicated that the pooled prevalence 
of depression across 17 unique populations (n = 1711) was 29% ( Wang  et al 2017 ). 
Incyte Corporation  Page [ADDRESS_439415] self -consciousness of all pediatric age groups ( Silverberg  and Silverberg 
2013).  In a study comparing social development and the health-related quality of life of young adult patients with childhood vitiligo with healthy controls, vitiligo patients reporting negative childhood experiences reported significantly more problems in social development than those not 
reporting negative experiences.  Furthermore, negative childhood experiences were significantly 
associated with more health -related quality of life impairment in early adulthood ( Linth orst 
Homan et al 2008).  Thus, vitiligo is considered to be one of the most psychologically 
devastating diseases in dermatology. 
2.2. Current Treatment and Unmet Need in Vitiligo  
Currently , there is no approved drug treatment for vitiligo.  The conclusions of the most recent 
updated Cochrane systematic review were hampered by [CONTACT_352964] ( Whitton et al 2016 ).  A systemic review on outcomes in a vitiligo study  also 
showed that the 25 different outcomes had been measured in 54 randomized clinical studie s.  
Although repi[INVESTIGATOR_352833] 94% of studies , 48 different scales were used to 
measure it, making comparison among studies impossible ( Eleftheriadou  et al 2012 ).  Therefore, 
a definitive clinical recommendation for treatment of vitiligo could not be proposed , and the 
management of vitiligo is empi[INVESTIGATOR_352834] (American Academy of Dermatology , Gawkrodger et al 2008, Taieb  et al 2013, Vitiligo 
Research Foundation ).  In general, first- line treatments consist of topi[INVESTIGATOR_352835], which are most useful for treating disease that is localized.  Second- line treatments 
consist of phototherapy (NB- UVB and PUVA) and systemic steroid treatment.  Thir d-line 
treatments consist of surgical grafting techniques and depi[INVESTIGATOR_352836].   However, 
response to current treat ment varies, can be time -intensive, can be slow to respond to treatment, 
and often produces disappointing results if repi[INVESTIGATOR_371] i s cosmetically unacceptable.  
There has been  a limited number of randomized controlled clinical studies conducted to 
adequately support the efficacy of drug treatments in vitiligo.  Factors that further limit the 
evidence for efficacy are variations in study design and outcome measures, small study size (the majority of which included fewer than 50 participants), and deficiencies in methodological 
quality based on a systematic review of randomized clinical studies evaluating interventions for 
vitiligo (Whitton et al 2016 ).  Apart from inconclusive (or insufficient) evidence for the efficacy 
of current off- label drug treatments in vitiligo, their safety profiles may also carry specific 
restrictions for their topi[INVESTIGATOR_44785].  For example, TCS may be associated with local adverse effects, 
including irreversible ones such as skin atrophy and striae distensae, and an increased susceptibility to skin infections ( Coondoo et al 2014).  More pot ent TCS, through their 
percutaneous absorption and depot-like accumulation in the epi[INVESTIGATOR_49196], may also produce well-known systemic AEs typi[INVESTIGATOR_352837].  Additionally, there are restrictions on the 
use of such TCS on sensitive skin areas, particu larly on the face,  and for the overall treatment 
duration (ie, not to exceed 4 weeks).  Therefore, judicious use of high potency preparations of TCS is critical.  Topi[INVESTIGATOR_73199] s are known for the induction of skin burning 
sensation immediately after their application, which makes their use on the face problematic.  
Incyte Corporation  Page [ADDRESS_439416] been implied in their possible contribution to cutaneous 
malignancy when used long- term.  
Available phototherapy treatments include NB- UVB and P UVA.  Phototherapy regimens 
typi[INVESTIGATOR_1435] 2 to 3 treatments per week and long-term duration of treatment.  For both NB-UVB and PUVA, 12 to  24 months of continuous phototherapy may be necessary to acquire 
maximal repi[INVESTIGATOR_371] ( Taieb et al 2013).  A minimum of 6 months of continuous 
phototherapy is recommended before being considered nonresponsive ( Taieb et al 2013, Ba e 
et al 2017 ).  Relapses are common; ap proximately 60% to  70% of patients resume 
depi[INVESTIGATOR_352839] 1 year with PUVA or NB -UVB 
therapy ( Boniface et al 2018).  There are also important safety limitations with phototherapy.  
PUVA c arries a risk of phototoxic effects, nausea, and the potential risk for skin cancer.  
Moreover, PUVA phototherapy is not recommended for children or pregnant women due to risks associated with systemic exposure of psoralen.  NB -UVB phototherapy is considered to have 
safety advantages over PUVA but is also associated with AE s such as erythema, itching, and 
mild burning or pain ( Bae et al 2017 ).  Excimer laser or monochromatic excimer lamp (both at 
308 nm) that may reach deeper targets such as amelanotic melanocytes of the hair follicle, and 
also avoid irradiation of uninvolved skin, may improve clinical outcomes; however, they are 
limited to localized treatment ( Boniface et al 2018). 
Lastly, surgical treatm ents in vitiligo may be considered after failure to respond to drug and light 
therapi[INVESTIGATOR_352840] s, 
no Koebner phenomenon, and no extension of the vitiligo area  in the previous [ADDRESS_439417] been reported with certain 
surgical procedures ( Gawkrodger et al 2008, Taieb et al 2013).  Surgery is be st indicated for 
stable and localized forms of vitiligo , and only a small number of patients with vitiligo are 
considered suitable candidates.  
Given the lack of approved therapi[INVESTIGATOR_352897]-label drug treatments, there is a need to identify a safe and effective new treatment  for 
vitiligo . 
2.3. Role of Janus Kinases in Vitiligo  
Vitiligo pathogenesis involves intrinsic defects within melanocytes and autoimmunity that 
targets these cells.  Studies have show n that melanocytes from vitiligo patients are more 
vulnerable than those from healthy individuals ( Rodrigues et al  2017, Speeckaert and van Geel 
2017) .  Once melanocytes becom e stressed, they release inflammatory signals that activate  innate 
immunity, which may represent the initiation event in vitiligo.  The oxidative stress, cell damage, and cytokines secreted from innate immune  cells then trigger CXCL10 release by [CONTACT_352930], and 
that recruits CD8+  T cells to the site.  Activated CD8+ T cells produce IFN -γ and other 
inflammatory mediators to target and destroy melanocytes ( Frisoli and Harris 2017 ).  Because 
IFN-γ signaling utilizes the JAK -STAT pathway, inhibition of JAK signaling may be an 
effective strategy for vitiligo treatment development. 
There are several case reports and case series suggesting that modulation of the immune response 
through JAK inhibition may be effective in treating vitiligo.  A patient with both AA and vitiligo 
was treated with oral ruxolitinib 20 mg BID for 20 weeks and subsequently had hair regrowth as 
well as significant repi[INVESTIGATOR_352898]  (Harris et al 2016).  In another 
Incyte Corporation  Page [ADDRESS_439418] a response to topi[INVESTIGATOR_28709], tacrolimus ointment, and NB- UVB phototherapy treated with oral tofacitinib at 5 mg 
QD and resulted in near complete repi[INVESTIGATOR_352843] 5 m onths of treatment ( Craiglow and 
King 2015).  
There was a 20 -week open-label study using topi[INVESTIGATOR_352844] (INCB018424) in 
12 participants  with vitiligo who had a minimum of 1% BSA affected.  The results showed a 
76% improvement in F-VASI and 26% improvement in T-VASI within 7 of 9 participants  who 
completed the study ( Rothstein et al 2017).   The same group conducted an additional 32- week 
extension study with optional NB- UVB treatment  (Joshipura et al  2018).  Five participants 
completed the study, and 3 of them received NB- UVB.  At Week 52  (Week 20 + Week 32), 
results showed 92% improvement in F-VASI and 37% in T -VASI.  The resu lts also indicated 
that [ADDRESS_439419] also been characterized following oral administration.  
 
 
 
 
 
Please refer to the ruxolitinib cream IB. 
  
 

Incyte Corporation  Page 24 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 20 20 
CONFIDENTIAL   
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
2.4.2. C
linical Experience  

Incyte Corporation  Page 25 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 20 20 
CONFIDENTIAL  

Incyte Corporation  Page 26 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 20 20 
CONFIDENTIAL  [IP_ADDRESS]. Efficacy  of Ruxolitinib Cream 
[IP_ADDRESS].1. Psoriasis  
Ruxolitinib cream has been evaluated in over 200 adults with plaque psoriasis in 3 clinical 
studies with application of 4 to 12 weeks duration.  Overall, ruxolitinib cream (0 .5%, 1.0%, or 
1.5%) was effective in decreasing disease severity.  Observed AEs were mild to moderate in 
intensity and most were judged unrelated to study medication, with no treatment- related SAEs or 
withdrawals.  Ruxolitinib cream demonstrated to be safe and well -tolerated when applied QD for 
12 weeks to plaque psoriasis affecting 2% to 20% of the BSA. 
[IP_ADDRESS].2. Atopic D ermatitis  
There were 307 adult participants with mild to moderate AD affecting total 3% to 20% BSA 
enrolled in a Phase 2, randomized, vehicle- and ac tive (triamcinolone 0.1% cream)-controlled 
dose-ranging study.  The mean percentage change from baseline at W eek 4 in EASI score 
demonstrated a significant im provement (1.5% BID [-71.6%0 vs vehicle [-15.5%]).  At the 
highest exposure (1.5% BID), ruxoliti nib cream was noninferior to triamcinolone.  In addition, 
significant reductions in itch were noted as early as within a day from the initiation of therapy 
with ruxolitinib cream .  The most frequently reported TEAE was nasopharyngitis, which 
occurred in 2.0% to 7.8% of participants across dose strengths in the double-blind period and in 
5.2% of participants in the open- label period.  No fatal or serious TEAEs occurred in participants 
who received ruxolitinib cream.   Phase 3 studies (INCB [ZIP_CODE]-303 and -304) in adults and 
adolescents are ongoing. 
More details are included in the ruxolitinib cream IB . 
[IP_ADDRESS].3. Vitiligo  
INCB [ZIP_CODE] -211 (see Figure 3) is a Phase 2, randomized, double-blind, vehicle-controlled study 
in adults with vitiligo who have depi[INVESTIGATOR_352845] 0.5% BSA on the face and 
at least 3% BSA on nonfacial areas .  A total of 157 participants  were equally randomized to 
receive ruxolitinib cream 1.5% BID, 1.5% QD, 0.5% QD, 0.15% QD, or vehicle BID for 

Incyte Corporation  Page 27 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 20 20 
CONFIDENTIAL  24 weeks.  In the second part of the study, all participants initially randomized to vehicle  BID 
and participants  initially randomized to 0.15% QD who did not achieve ≥  25% improvement 
from baseline in F -VASI were rerandomized to 1 of the 3 higher dosing groups for an additional 
28 weeks.  All other participants maintained the same treatment until Week 52.  After Week 52, 
participants  could receive open-label 1.5% BID for an additional 52 weeks.  The primary 
endpoint was the proportion of participants who achieved a ≥ 50% improvement from baseline in F-VASI50  at Week 24 . 
Figure  3: INCB [ZIP_CODE] -211 Study Schema  
 
All ruxolitinib treatment arms demonstrated clinically meaningful efficacy and superiority over vehicle.  The proportion of participants who achieved an F- VASI50 at Week 24 was statistically 
significantly greater for ruxolitinib cream versus vehicle with response rates of 32.3%, 25.8%, 
50.0%, and 45.5% for ruxolitinib cream 0.15% QD, 0.5% QD, 1.5% QD, and 1.5% BID, 
respectively, and 3.1% for vehicle.  The proportion of participants who achieved an F- VASI75 at 
Week 24 was also statistically significantly greater for ruxolitinib cream versus vehicle with 
response rates of 9.7%, 16.1%, 16.7%, and 30.3% for ruxolitinib cream 0.15% QD, 0.5% QD, 
1.5% QD, and 1.5% BID, respectively,  and 0% for vehicle.  Participants who were initial ly 
randomized to ruxolitinib cream 0.5% QD, 1.5% QD, and 1.5% BID continued on these 
treatments until Week 52.  Continued improvement in F- VASI response in these treatment was 
observed with the proportion of participants who achieved an F-VASI75 at Week 52 
demonstrating response rates of 29.0%, 30.0%, and 51.5% for ruxolitinib cream 0.5% QD, 
1.5% QD, and 1.5% BID.   Large effect size (Cohen’s D  = 1.14) is observed based on percentage 
change from baseline between ruxolitinib cream 1.5%BID and vehicle.   
Impro vements in T-VASI were observed for both Week 24 and Week 52.  The proportion of 
participants who achieved a T -VASI50 at Week 24 was also statistically significantly greater for 
ruxolitinib cream 0.15% QD, 0.5% QD, 1.5% QD, and 1.5% BID compared with  vehic le with 
response rates of 16.1%, 6.5%%, 23.3%, and 12.1%, respectively, compared with 0% in vehicle- treated participants .  Continued improvement in participants treated with 0.5% QD, 
1.5% QD, and 1.5% BID through Week 52 was observed with response rates in T- VASI50 
Incyte Corporation  Page 28 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 20 20 
CONFIDENTIAL  of 25.8%, 30.0%, and 36.4%, respectively.   Similar to F -VASI, large effect sizes 
(Cohen’s D = 1.24) is observed based on percentage change from baseline between ruxolitinib 
cream 1.5%BID and vehicle.   
Compared with F-VASI, improvement in T- VASI was  slower.   This observation is not 
unexpected given that  repi[INVESTIGATOR_352846] a slower rate 
than facial repi[INVESTIGATOR_371].  Despi[INVESTIGATOR_129840], response rates fo r the F -VASI50, F-VASI75, and 
T-VASI50 favor ed the higher strength  treatment regimens (both 1.5% QD and 1.5% BID) versus 
vehicle at Week  24 and 1.5% BID regimen at Week 52  across the endpoints.  Given that many 
participants  may not achieve peak response by [CONTACT_10585] 24 and that there are constraints to the 
length of the vehicle period, the 1.5% BID regimen appears to have given a higher response over 
time.  Key secondary endpoints including percentage change in F- BSA, F- PhGVA, and PaGIC 
also follow ed a similar pattern , with separation from vehicle at Week 24 and continued 
impr ovement through Week 52.  
All ruxolitinib treatment arms were generally safe and well -tolerated with no significant TEAEs 
or application site events and no clinically relevant hematological changes.  TEAE rate overall is low and similar between active treatment and vehicle treatment.  There were 4 SAEs through 
52 weeks and all of them were not treatment -related.  Discontinuations from treatment through 
52 weeks was low.  Safety and tolerability were  similar between the Week 24 and Week 52 
period.   

Incyte Corporation  Page 29 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  

Incyte Corporation  Page 30 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  

Incyte Corporation  Page 31 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  

Incyte Corporation  Page 32 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  

Incyte Corporation  Page 33 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  3. OBJECTIVES AND ENDPO INTS  
Table  8 presents the objectives and endpoints. 
Table  8: Objectives and Endpoints  
Objectives  Endpoints  
Primary  
To evaluate the  efficacy of ruxolitinib cream in 
participants with vitiligo.  • Proportion of participants achieving F -VASI 75 at 
Week 24.  
Key Secondary  
To further assess the efficacy of ruxolitinib cream.  • Proportion of participants achieving F -VASI50 at 
Week 24.  
• Proportio n of participants achieving F -VASI 90 at 
Week 24.  
• Proportion of participants achieving T -VASI50 at 
Week 24 . 
• Proportion of par ticipants achieving a VNS of 
“4 – A lot less noticeable” or “5 – No longer 
noticeable” at Week 24.  
• Percentage change from baseline in F -BSA at 
Week 24 . 
Secondary  
To evaluate the safety and tolerability of ruxolitinib 
cream.  • The frequency, duration, and severity of AEs; 
physical examinations; vital signs; and laboratory 
data for hematology and serum chemistry.  
To further assess the e fficacy of ruxolitinib cream.  • Proportion of participants achieving 
F-VASI25/50/75/90 during  the treatment period 
(double -blind and treatment extension  periods) .  
• Percentage change from baseline in F-VASI during  the treatment period (double -blind and 
treatm ent extension  period s). 
• Percentage change from baseline in F -BSA 
during  the treatment period (double -blind and 
treatment extension  period s). 
• Percentag e change from baseline in T -VASI 
during  the treatment period (double -blind and 
treatment extension  period s). 
• Percentage change from baseline in T -BSA 
during  the treatment period (double -blind and 
treatment extension  period s). 
• Proportion of participants  achieving  
T-VASI25/50/75/90 during  the treatment period 
(double -blind and treatment extension  periods) .  
• Prop ortion of participants in each category of 
VNS during the treatment period (double -blind 
and treatment extension  period s). 
Incyte Corporation  Page 34 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  Table  8: Objectives and Endpoints  (Continued)  
Objectives  Endpoints  
Secondary  (continued) 
To evaluate the ruxolitinib PK  in plasma after 
treatment of ruxolitinib cream.  • Population -based (trough) plasma concentrations 
of ruxolitinib at Weeks 4,  24 and 40 . 
Exploratory  
To further assess the efficacy of ruxolitinib cream.  • Proportion  of participants achieving an 
F-PhGVA of clear (0) or almost clear (1) during  
the treatment period (double -blind and treatment 
extension  periods). 
• Proportion  of participants achieving an 
T-PhGVA of clear (0) or almost clear (1) during  
the treatment period (double -blind and treatment 
extension  periods). 
• Proportion of participants in each F -PhGVA 
category during the treatment period 
(double -blind and treatment extension  periods) . 
• Proportion of participants in each T -PhGVA 
category duri ng the treatment period 
(double -blind and treatment ex tension periods).  
• Proportion of participants who report F -PaGIC-V 
of very much improved or much improved during the treatment period (double -blind and treatment 
extension  periods). 
• Proportion of participants in each F -PaGIC-V 
category during the treatment period (double -blind and treatment extension  periods).  
• Proporti on of participants who report T -PaGIC-V 
of very much improved or much improved duri ng 
the treatment period (double -blind and treatment 
extension periods).  
• Prop ortion of participants in each T -PaGIC-V 
category during the treatment period (double -blind and treatment extension  periods).  
• Proportion of participant in each category for the color -matching question during the treatment 
period (double -blind and treatment extension 
periods).  
Incyte Corporation  Page 35 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  Table  8: Objectives and Endpoints  (Continued)  
Objectives  Endpoints  
Exploratory (continued) 
To determine the participants’ quality of life. • Change from baseline in DLQI  (or CDLQI) 
during  the treatment period (double -blind and 
treatment ext ension  period s). 
• Change from baseline in WHO-5 during the 
treatment period (double -blind and treatment 
extension  periods). 
• Change from baseline in  TSQM  during the 
treatment period (double -blind and treatment 
extension  periods). 
• Change from baseline in Viti QoL during the 
treatment period (double -blind and treatment 
extension  periods). 
• Change from baseline in HADS  during the 
treatment period (double -blind and treatment 
extension  periods). 
To evaluate translational biomarkers in the blood of 
participants treated with ruxolitinib cream.  • Change from baseline in the expression of select 
biomarkers in peripheral blood at Weeks 12, 24, 
40, and 52. 
Incyte Corporation  Page 36 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  4. STUDY DESIGN  
4.1. Overall Design 
This is a randomized, vehicle -controlled study in adolescent and adult participants ( age 
≥ 12 years) with non-segmental  vitiligo who have depi[INVESTIGATOR_352829] ≥ 0.5% BSA on 
the face, ≥  0.5 F- VASI, ≥ 3% BSA on nonfacial areas , ≥ 3 T- VASI,  and for whom total body 
involved vitiligo area  (facial and nonfacial)  does  not exceed 10% BSA.  Approximately 
300 participants will be randomized 2:1 to receive initial study treatment (ruxolitinib cream 1.5% 
BID:vehicle) for 24  weeks (see Figure  1).  Participants will be stratified by [CONTACT_11338] ( North 
America or Europe ) and skin type (Fitzpatrick scale Type I and II vs Type III, IV, V, and VI).  
Adolescents (≥ 12 to < 18  years) will make up at least 10% of the study population, and no more 
than 50% of participants will be  > 40 years old. 
During the double- blind, vehicle -control led period, participants will receive ruxolitinib cream 
1.5% BID or vehicle for 24 weeks to be applied to depi[INVESTIGATOR_352847] 10% total BSA.  Participants should continue to treat depi[INVESTIGATOR_352899]. 
After completion of the Week 24 assessments, participants will be off ered the opportunity to 
continue in the treatment extension period.  P articipants initially randomized to vehicle will be 
crossed over to active drug, and participants treated with ruxolitinib cream will re ceive an 
additional 28 weeks of treatment with ruxolitinib cream 1.5% BID.  To be eligible  for the 
treatment extension , participants must have completed the baseline and Week [ADDRESS_439420] any safety issues.  During the 
treatment extension, p articipants should continue to treat depi[INVESTIGATOR_352899].  Total treated areas 
(facial and nonfacial areas)  should not excee d to 10% BSA.   
Safety endpoints, such as nature of AEs (type, frequency, and severity), vital signs, targeted 
physical examination, and routine laboratory investigations, will be monitored and recorded 
throughout the course of this study. 
Following the last application of ruxolitinib cream at Week 52, there will be a 30- day safety 
follow-up period to evaluate safety and duration of response.   
Participants  who successfully complete the [ADDRESS_439421] and maintenance 
regimens.   
See Section  6.5 for detail ed information of study drug modification and application guidance. 
4.2. Overall Study Duration  
Screening is up to 32 days (~ 4 weeks) ; the double-blind, vehicle- controlled  treatment period is 
24 weeks; the treatment extension period is 28 weeks; and safety follow-up is 30 days.  Total 
duration is up to approximately 60 weeks (see Figure 1). 
Incyte Corporation  Page [ADDRESS_439422] participant (or parent or guardian) signs the ICF.  The end of 
the study is defined as the date of the last visit of the last participant in the study or the date that 
the last participant discontinued study drug and completed applicable safety follow- up 
assessments or is lost to follow -up.  A participant is considered to have completed the study if 
he/she has completed all study visits, including the safety follow -up visit. 
4.3. Study Termination  
The invest igator retains the right to terminate study participation at any time, according to the 
terms specified in the study contract.  The investigator is to notify the IRB/IEC in writing of the study's completion or early termination, send a copy of the notification to the sponsor or 
sponsor's designee, and retain 1 copy for the site study regulatory file. 
The sponsor may terminate the study electively or if  required by [CONTACT_352931].  In the event 
of significant safety findings, the study will be terminated.  If the study is terminated 
prematurely, the sponsor or designee will notify the investigators, the IRBs/IECs, and regulatory bodies of the decision and reason for termination of the study.   
5. STUDY POPULATION  
Deviations from eligibility criteria are prohibited because they can potentially jeopardize the scientific integrity of the study, regulatory acceptability, and/or participant safety.  Therefore, 
adherence to the criteria as specified in the Protocol is essential.  Prospective approval of 
Protocol deviations to recruitment and enrollment criteria, also known as Protocol waivers or exemptions, are not permitted. 
5.1. Inclusion Criteria  
Participants are eligible to be included in the study only if all of the following criteria apply:  
1. Adolescents and adults ag ed ≥ 12 years . 
2. Participants with a clinical diagnosis of non-segmental  vitiligo  with depi[INVESTIGATOR_352850] ≥ 0.5% BSA on the face, ≥ 0.5 F -VASI , ≥ 3% BSA on nonfacial areas , 
≥ 3 T- VASI,  and total body vitiligo area (facial and nonfacial) not exceeding 10% BSA.  
3. Participants who agree to discontinue all agents used to treat vitiligo from screening through the final safety follow-up visit.  Over-the-counter preparations deemed 
acceptable by [CONTACT_352932].  
4. Male and female participants must be willing to take appropriate contraceptive measures to avoid pregnancy or fathering a child for the duration of study participation with the exception of the following : 
a. Female s of non-childbearing potential (ie, or surgically sterile with a hysterectomy 
and/or bilateral oophorectomy OR postmenopausal, ≥ 12 months of amenorrhea  
without an alternative medical cause).  
b. Prepubescent adolescents.  
Note:  Information about specific types of acceptable contraceptive measures and 
duration of contraceptive use are provided in Appendix A . 
Incyte Corporation  Page 38 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  5. For adult participant, a bility to comprehend and willingness to sign an ICF ; for 
adolescent  participant,  written informed consent of the parent(s) or legal guardian and 
written assent from the adolescent participant . 
Note:  Adolescents, who during the course of the study become legal adults, will be asked 
for their consent to continue the study, and in the event of lack thereof, will be 
discontinued from further participation. 
5.2. Exclusion Criteria  
Participants are excluded from the study if any of the following criteria apply:  
1. Participants who have no pi[INVESTIGATOR_352900]. 
2. Other forms of vitiligo (e g, segmental)  or other differentia l diagnosis of vitiligo or other 
skin depi[INVESTIGATOR_262807] ( eg, pi[INVESTIGATOR_312303], p ityriasis alba, leprosy, postinflammatory 
hypopi[INVESTIGATOR_371], progressive macule hypomelanosis, nevus anemicus, chemical 
leukoderma, and tinea versicolor).  
3. Participants who have used  depi[INVESTIGATOR_352901] ( eg, monobenzone ) for past 
treatment of vitiligo or other pi[INVESTIGATOR_312294]. 
Note:  Prior use of hydroquinone is not prohibited ( as it is a bleaching agent, not a 
depi[INVESTIGATOR_352852]). 
4. Participants with concurrent conditions and history of other diseases: 
a. Any other skin disease that, in the opi[INVESTIGATOR_871], would interfere with 
the study medication application or study assessments.  
b. Active acute bacterial, fungal, or viral skin infection (eg, herpes simplex, her pes 
zoster, chicken pox) within 1 week before baseline. 
c. Conditions at baseline that would interfere with evaluation of vitiligo.  
d. Any serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opi[INVESTIGATOR_1649], would interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.  
Examples include but are not limited to the following: 
− Clinically significant or uncontrolled cardiac disease, including unstable angina, 
acute myocardial infarction within 6 months from Day 1 of study drug administration, [LOCATION_001] Heart Association Class III or IV congestive heart 
failure, and arrhythmia requiring therapy or uncontrolled hypertension (blood 
pressure > 150/90 mmHg) unless approved by [CONTACT_352933]/sponsor.  
− History of thrombosis, including deep venous thrombosis and pulmonary 
embolism.  
− Participants with concurrent malignant disease or a history of that in the 5 years 
preceding the baseline visit except for adequately treated nonmetastatic 
malignancies.  
− Current and/or history of liver disease , including known hepatitis B or C, with 
hepatic or biliary abnormalities.  
Incyte Corporation  Page 39 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  − Current and/or history  of tuberculosis.  
− History of alcoholism or drug addiction within 1 year before screening or current 
alcohol or drug use that, in the opi[INVESTIGATOR_871], will interfere with the 
participant's ability to comply with the administration schedule and study assessments.  
− Participants who are committed to a n institution by [CONTACT_352934].  
5. Participants using any of the following treatments within the indicated washout period 
before baseline:  
a. 1 week:   Topi[INVESTIGATOR_352853], for example, corticosteroids, 
calcineurin , and phosphodiesterase type 4 inhibitors or retinoids . 
b. 4 weeks:  
− Melanocyte-stimulating agents (eg, afamelanotide ). 
− Immunomodulating systemic medications (eg, corticosteroi ds, methotrexate, 
cyclosporine). 
− Any other systemic therapi[INVESTIGATOR_352854] y to UV/ visible 
light or impact skin pi[INVESTIGATOR_371], for example, tetracyclines, metoxypsoralens . 
− Received live vaccine.  
Note:   Live vaccine is prohibit ed during the course of the study and within 
4 weeks after the EOT  visit . 
c. 8 weeks:   Laser or any kind of phototherapy, including tanning bed or intentional UV 
exposure. 
d. 5 half- lives  or 12 weeks , whichever is longer:  Biologic agents, investigational or 
experimental therapy or procedures for vitiligo.  Investigational biologics should be 
discussed with the sponsor to determine whether a longer period of discontinuation is required. 
6. Participants who have previously received JAK inhibitors, systemic or topi[INVESTIGATOR_2855].  
7. Participants with clinically significant abnormal laboratory values at screening:  
a. Hemoglobin (< 10 g/dL).  
b. Liver function tests:  
− AST or ALT ≥ 2 × ULN . 
− Alkaline phosphatase and/or bilirubin > 1.5 × ULN (isolated bilirubin 
> 1.5 ×  ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%).  
c. Severe renal disease ( with creatinine clearance < 30 ml/min) or renal disease 
requiring dialysis. 
d. Clinically significant abnormal TSH or free T4 at screening as determined by [CONTACT_093].  
e. Positive serology test results at screening for HIV antibody . 
Incyte Corporation  Page 40 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  8. Body mass index < 17 or > 40 kg/m2 for adult participants (age ≥ 18 years).  BMI -for-age 
in the < 5th percentile or ≥ 85th percentile range for adolescent participants ( age ≥ 12 to 
< 18 years) according to according to the CDC BMI Percentile Calculator for Child and 
Teen ( 2019). 
9. Pregnant or lactating participants, or those considering pregnancy during the period of 
their study participation . 
10. Participants who, in the opi[INVESTIGATOR_871], are unable or unlikely to comply with 
the administration schedule and study evaluations.  
11. Employees of the sponsor or investigator or are otherwise dependents of them. 
12. Participants with known allergy or reaction to any component of the study formulation. 
13. Participants who live with anyone participating in any current Incyte-sponsored 
ruxolitinib cream study .  
5.3. Lifestyle  Considerations  
Participants should be cautioned to avoid excessive exposure to artificial sunlight (including tanning booths, sun lamps, etc). 
If sunscreen , makeup, or other cosmetics have been applied to the areas to be treated, participants 
should follo w the application guidance (see Section  6.6.1). 
It is recommended that swimming should not take place within 2 hours before and after the 
planned study drug application. 
5.4. Screen Failures  
Screen failures are defi ned as participants who consent to participate in the clinical study but are 
not subsequently assigned to study treatment.  Tests with results that fail eligibility requirements may be repeated once during screening if the investigator believes that the participant would be 
eligible if retested.  Additionally, a participant who fails screening may repeat the screening process 1 time if the investigator believes that there has been  a change in eligibility status or any 
laboratory abnormality is inconsistent with the participant’s medical history.  Participants who 
rescreen must be assigned a new screening number.   
5.5. Replacement of Participants  
Participants will not be replaced during the study.  
Incyte Corporation  Page 41 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  6. STUDY TREATMENT  
6.1. Study Treatment A pplication  
Table  9 presents the study treatment information.  
Table  9: Study Treatment Information  
Study treatment name:  [CONTACT_352991]:  Cream 
Unit dose strength(s)/dosage 
level(s):  1.5% Not applicable 
Route of administration: Topi[INVESTIGATOR_352902]: Double -blind and treatment 
extension periods :  BID.  A thin 
film is  applied to depi[INVESTIGATOR_352856].  Double -blind  period:   BID.   A thin 
film is applied to the depi[INVESTIGATOR_352856].  
Treatment  extension period:  Not 
applicable. 
Packaging and labeling:  Ruxolitinib cream and vehicle cream will be provided in 60 g tube.  Each tube will be labeled as required per country requirement.  
Storage:  Ambient (15°C -30°C/59°F -86°F) 
Status of treatment in participating countries:  Investigational  Not applicable 
On visit days, s tudy drug will be applied in the clinic during the visit.  Participants should 
remove study drug from the tube in fingertip units until all of the areas to be treated are covered 
by a thin film ; the tube will be weighed before and after application to determine the 
participant’s dosage.  On the day of a visit, the participant should not apply the study drug at 
home and will apply study drug from the new kit in the clinic.  Participants will be instructed to 
document treated areas and advised to limit use to no more than one [ADDRESS_439423] the study site to discuss with the investigator whether additional 
evaluation at the clinic is required.  If any other skin products that are permitted under the study Protocol are used, participants should continue these unchanged during the study.  
Incyte Corporation  Page 42 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  6.1.1. Application D uring  the Double -Blind Vehicle -Controlled Treatment Period  
During the double- blind vehicle -controlled period (up to Week 24), participants should follow 
the below study drug application guidance: 
• Participant s should apply study drug only to depi[INVESTIGATOR_352903] a T- BSA (facial and nonfacial) of ≤  10% BSA. 
• Participants should continue to treat all depi[INVESTIGATOR_352904] i f the area begins to improve or fully repi[INVESTIGATOR_2517]. 
6.1.2. Application D uring the Treatment Extension Period  
During treatment extension period (Week 24 to Week 52), participants should follow the below 
study drug application guidance: 
• Participants should apply study drug to depi[INVESTIGATOR_352905] a T- BSA  (facial and nonfacial) of ≤  10% BSA. 
• Participants should continue to treat all depi[INVESTIGATOR_352906]. 
• Participants who have an expansion of existing areas of vitiligo during the course of 
the treatment  extension period may treat these areas identified by [CONTACT_352965] a visit to document the VASI score and other measures of vitiligo (may be unscheduled visit), as long as the new treated T- BSA (facial and nonfacial) does not 
exceed 10% BSA. 
6.2. Preparation, Handling, and Accountability  
The investigator or designee must confirm and document that appropriate temperature conditions 
(both ruxolitinib cream and vehicle cream are to be stored between 15°C and 30°C [59°F-86°F]) 
have been maintained during transit for all study treatments received and any discrepancies are reported and resolved before use of the study treatment. 
Only participants enrolled in the study may receive study treatment, and only authorized site 
staff may supply study treatment.  Immediately after application of ruxolitinib cream, participants are to wash their hands thoroughly with soap and warm water  (unless the area to be 
treated includes the hands) .  Refer to the Study Pharmacy Manual for parti cipant instructions for 
handling of study drug. 
All study treatment must be stored in a secure, environmentally controlled, and monitored 
(manual or automated) area in accordance with the labeled storage conditions with access limited 
to the investigator a nd authorized site staff.  Participants should store study treatment at ambient 
temperature conditions.  
Incyte Corporation  Page 43 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  The investigator (or designee) is responsible for study treatment accountability, reconciliation, 
and record maintenance (ie, receipt, reconciliation, and final disposition records).  Inventory and 
accountability records must be maintained and readily available for inspection by [CONTACT_147117].  The investigator or designee  must maintain records that document: 
• Delivery of study drug(s) to the study site. 
• Inventory of study drug(s) at the site. 
• Participant use of the study drug(s) including tube counts from each supply 
dispensed. 
• Return of study drug(s) to the investigator or designee by [CONTACT_4317]. 
The investigational product must be used only in accordance with the Protocol.  The investigator will also maintain records adequately documenting that the participants were provided the 
specified study drug.  These records should include dates, quantities, and any available batch or serial numbers or unique code numbers assigned to the investigational product and study 
participants.  
Completed accountability records will be archived by [CONTACT_779].  The investigator or designee will 
be expected to collect and retain all used, unused, and partially used containers of study drug 
until verified by [CONTACT_11200] (unless otherwise agreed to by [CONTACT_456]).  At the 
conclusion of the study, the investigator or designee will oversee shipment of any remaining study drug back to the sponsor or its designee for destruction according to institutional SOP s.  If 
local procedures mandate on -site destruction of investigational supply, the site should (where 
local procedures allow) maintain the in vestigational supply until the study monitor inspects the 
accountability records in order to evaluate compliance and accuracy of accountability by [CONTACT_198373].  At sites where the study drug is destroyed before monitor inspection, the 
monitors rely on documentation of destruction per the site SOP. 
Further guidance and information for the final disposition of unused study treatments are 
provided in the study materials provided to sites. 
6.3. Measures to Minimize Bias:   Randomization and Blinding 
All participants will be centrally assigned to study treatment using an IRT system.  The system will assign in a 2 :1 ratio (ruxolitinib cream 1.5% BID:vehicle), stratified by [CONTACT_11338] (North 
America or Europe ) and skin type (Fitzpatrick scale Type I and II vs Type III, IV, V, and VI).  
Adolescents will make up at least 10% or participants, and no more than 50% of participants will be aged greater than 40 years.  The IRT will assign  participant ID  numbers , track participant 
visits, randomize participants according to the defined parameters, maintain the blinding, and 
manage study drug inventory.  Full details will be provided in the IRT Manual.  Study treatment 
will be dispensed at the study visits summarized in the Schedule of Activities (see Table  3 and 
Table  4). 
After the database lock for the primary analysis, the sponsor will be unblinded, but investigators and participants will still be blinded to individual treatment assignment s.  This is implemented to 
minimize bias for the Week [ADDRESS_439424] be emphasized to the participant by [CONTACT_89184], and appropriate steps should be taken to optimize compliance during the study.  
Compliance with ruxolitinib cream will be evaluated by [CONTACT_4317]' adherence to the application regimen and drug accountability documented by [CONTACT_352966]/designee (tube counts).  
In general, the application compliance will be determined by [CONTACT_352937], which should be within 70% to 130% of the prescribed 
number of applications.  Participants will be instructed to bring all study drugs with them to the 
study visits in order for site personnel to conduct tube counts to assess study drug accountability.  The drug accountability documentation will be used by [CONTACT_352967].  
6.5. Dose Modifications  
6.5.1. Criteria and Procedures for Application Interruptions of Study Drug  
Safety concerns should be discussed with the sponsor immediately upon occurrence or awareness to determine whether the participant should continue or discontinue study treatment.  
In some circumstances, it may be necessary to temporarily interrupt treatment with ruxolitinib 
cream.  Except in cases of emergency, it is recommended that any findings of concern (eg, AE) 
be confirmed and that the investigator consult with the sponsor medical monitor (or other 
representative of the sponsor) before interrupting study drug.  Additionally, the investigator must obtain approval from the sponsor before restarting study drug.  Participants who experience a 
recurrence of th e initial AEs upon restarting the study drug may need the study drug to be 
permanently discontinued.  
Instructions for application interruptions for ruxolitinib cream are outlined in Table  10.  
Individual decisions regarding interruptions should be made using clinical judgment in 
consultation with the medical monitor (whenever possible), taking into account relatedness of the AE to the study treatment and the participant's underlying condition. 
Incyte Corporation  Page 45 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  Table  10: Guidelines for Interruption and Restarting of Study Drug  
Adverse Event Action Taken  
Chemistry  
ALT (> 3 × ULN) or AST (> 3 × ULN)  • Laboratory abnormalities should be confirmed with 
repeat testing within 48 hours whenever possible  and 
immediate delivery of the laboratory results requested . 
• Study drug applications must be interrupted.  At the discretion of the investigator, after consultation with the sponsor, study drug application may be res tored 
once these have resolved. 
Other l aboratory abnormalities  
Any other Grade 3 or higher laboratory 
abnormality, with the exception of 
asymptomatic elevations in triglyceride, cholesterol, or amylase  • Laboratory abnormalities should be confirmed with repeat testing within 48 hours whenever possible and immediate delivery of the laboratory results requested . 
• Study drug applications must be interrupted.  At the discretion of the investigator, after consultation with the sponsor, study drug application may be restored once these have resolved.  
Any Grade [ADDRESS_439425] or 
ALT (> 5 × ULN)  • Laboratory abnormalities should be confirmed with repeat testing within 48 hours whenever possible and 
immediate delivery of the laboratory results 
requested.  
• Discontinue study drug if lab abnormalities are confirmed.  
6.5.2. Criteria for Permanent Discontinuation of Study Drug Due to an Adverse Event  
The occurrence of unacceptable severity of an AE not caused by [CONTACT_352968].  Unacceptable severity is defined as follows: 
• Occurrence of an AE that is related to treatment with the study drug that, in the 
judgment of the investigator or the sponsor's medical monitor, compromises the 
participant's ability to continue study -specific procedures or continuing treatment is 
considered to not be in the participant's best interest. 
• Worsening of vitiligo that requires treatment with a prohibited concomitant 
medication. 
See Section  7 for discontinuation procedures. 
6.6. Concomitant Medications and Procedures  
All concomitant medications and treatments (including over- the-counter or prescription 
medicines, vitamins, vaccines, and/or herbal supplements) must be recorded in the eCRF.  Any 
prior medication received up to [ADDRESS_439426] dose of study treatment will be recorded in the eCRF.  Any addition, deletion, or 
change in the dose of these me dications will also be recorded.  Concomitant 
treatments/procedures that are required to manage a participant's medical condition during the study will also be recorded in the eCRF.  The medical monitor should be contact[CONTACT_31182]. 

Incyte Corporation  Page [ADDRESS_439427] and maintenance 
regimens.   

Incyte Corporation  Page 48 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  7. DISCONTINUATION OF S TUDY TREATMENT AND 
PARTICIPANT DISCONTI NUATION/WITHDRAWAL  
7.1. Discontinuation of Study Treatment 
7.1.1. Reasons for Discontinuation 
Participants must be discontinued from study treatment for the following reasons: 
• A participant is found not to have met eligibility criteria  (any exclusion criterion or 
any inclusion criteria related to participant safety) or if legal requirements have been 
violated . 
• The participant becomes pregnant.  
• Consent is withdrawn.  
Note:   Consent withdrawn means that the participant has explicitly indicated that they 
do not want to be followed any longer; in this case no further data, except data in 
public domain, may be solicited from or collected on the participant.  Participants 
may choose to discontinue study treatment and remain in the study for safety monitoring. 
• Further participation would be injurious to the participant's health or well -being, in 
the investigator's medical judgment. 
• Any AE of unacceptable severity as noted in Section 6.5.2. 
• The study is terminated by [CONTACT_456]. 
• The study is terminated by [CONTACT_19407], IRB, or IEC. 
A participant may be discontinued fr om study treatment as follows:  
• If, at 2 consecutive study visits, a participant's drug usage exceeds one 60 g tube per 
week .   
• If a participant is noncompliant with study procedures or study drug administration in 
the investigator's opi[INVESTIGATOR_1649], the medical monitor should be consulted for instruction on 
handling the participant.  
7.1.2. Discontinuation Procedures 
In the event that the decision is made to permanently discontinue the study treatment, the EOT 
visit should be conducted ( EOT 1 or EOT2 depending on the period during with the participant 
discontinues treatment).  Reasonable efforts should be made to have the participant return for a safety follow -up visit.  The last date of the last dose of study drug(s)/treatment and the reason for 
discontinuation of study tre atment will be recorded in the eCRF.  
If a participant is discontinued from study treatment:  
• The study monitor or sponsor must be notified. 
• The reason(s) for withdrawal must be documented in the participant's medical record 
and the primary reason for withdr awal must be included in the eCRF. 
Incyte Corporation  Page 49 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  • The EOT visit should be performed. 
• The date of the EOT visit should be recorded in the eCRF. 
• Participants must be followed for safety until the time of the safety follow-up visit or 
until study drug/treatment–related AEs resolve, return to baseline, or are deemed irreversible, whichever is longest.  
If the participant discontinues study treatment and actively withdraws consent for collection of follow-up data (safety follow-up or disease assessment), then no additional data collection should occur; however, participants will have the option of withdrawing consent for study 
treatment but continuing in the safety follow-up period of the study for safety/efficacy 
assessments.  
7.2. Participant Withdrawal From the Study  
A participant may withdraw from the study at any time at his/her own request, or may be withdrawn at any time at the discretion of the investigator for safety, behavioral, compliance, or administrative reasons.  
If the participant withdraws consent for disclosure of future information, the sponsor may retain and continue to use any data collected before such a withdrawal of consent. 
If a participant withdraws from the study, he/she may request destruction of any samples taken 
and not tested, and the investigator must document this in the site study records.  
See Table  [ADDRESS_439428] be taken if a participant fa ils to return to the clinic for a required 
study visit: 
• The site must attempt to contact [CONTACT_14315].  The participant will be counseled regarding the importance of 
maintaining the assigned visit sche dule and ascertain whether or not the participant 
wishes to and/or should continue in the study. 
• Before a participant is deemed lost to follow -up, the investigator or designee must 
make every effort to regain contact [CONTACT_6635] (where possible, 3  telephone 
calls and, if necessary, a certified letter to the participant's last known mailing address 
or local equivalent methods).  These contact [CONTACT_21457]'s medical record.  
• Should the participant continue to be unr eachable, he/she will be considered to have 
withdrawn from the study with a primary reason of lost to follow-up. 
Incyte Corporation  Page 50 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  8. STUDY ASSESSMENTS AN D PROCEDURES  
8.1. Administrative and General Procedures 
8.1.1. Informed Consent Process  
• The investigator or his/her representative will explain the nature of the study to the 
participant or his/her legally authorized representative and answer all questions regarding the study. 
− Informed consent /assent  must be obtained before any study- related procedures are 
conducted, unl ess otherwise specified by [CONTACT_760].  
Note:   Adolescent participants who become legal adults during the study will be 
asked for their signed consent to continue the study, and in the event of lack 
thereof, will be discontinued from further participation.  
− Informed consent /assent  must be obtained using the IRB/IEC-approved version in 
a language that is native and understandable to the participant.  A template will be provided by [CONTACT_3552].  The sponsor or its designee must review and acknowledge the site- specific changes to the ICF/assent  template.  The 
ICF/assent  must include a statement that the sponsor or its designee and 
regulatory authorities have direct access to participant records.  
− The ICF /assent  must contain all required elements and describe the nature, scope, 
and possible consequences of the study in a form understandable to the study participant.  
• Participants must be informed that their participation is voluntary.  Participants or 
their legally authorized representative will be required to sign a statement of informed 
consent that meets the applicable requirements and regulations for the country in which the study is being conducted as well as the IRB/IEC or study center. 
• The participant must be informed that his/her personal study -related data w ill be used 
by [CONTACT_89192].  The level of disclosure must also be explained to the participant. 
• The participant must be informed that his/her medical records may be examined by [CONTACT_352969], by [CONTACT_6667]/IEC members, and by [CONTACT_9326]. 
• The medical record must include a statement that written informed consent was 
obtained before the participant was enro lled in the study and the date the written 
consent was obtained.  The authorized person obtaining the informed consent must also sign the ICF. 
• Participants must provide consent to the most current version of the ICF(s) during 
their participation in the stu dy. 
Incyte Corporation  Page 51 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  • A copy of the ICF(s) must be provided to the participant or the participant's legally 
authorized representative.  
• Participants who are rescreened are required to sign a new ICF.  
8.1.2. Screening Procedures  
Screening is the interval between signing the ICF and the day that the participant is assigned to the study drug (Day 1).  Screening assessments for determination of eligibility may be performed 
over a period lasting up to 32 days. 
Procedures conducted as part of the participant's routine clinical management (eg, clinical 
laboratory tests) and collected before informed consent is obtained may be used for screening or 
baseline purposes, provided the procedure meets the Protocol- defined criteria and has been 
performed within [ADDRESS_439429] recent  available result before administration of study drug will be used to determine eligibility.  
See Section  5.4 regarding screen failures.  
Participants aged ≥  12 to < [ADDRESS_439430] hemoglobin 
between 10 g/dL and 12 g/dL should be assessed for the cause of the abnormality per local 
practice guidelines/institutional standard of care before randomization.  This is a German y-
specific requirement.  Specific cases may be revi ewed with the medical monitor.  Participants 
with hemoglobin < 10 g/dL are not enrol led per the exclusion criteria. 
8.1.3. Interactive Response Technology Procedure  
Each participant will be identified in the study by a participant ID number, which is a 
combination of the site ID and participant number.  Site personnel should contact [CONTACT_352970].  Upon determining that the participant is 
eligible for study entry, the IRT system will be contact[CONTACT_352940].  Additionally, the IRT system will be contact[CONTACT_352971].  Additional details are provided in the IRT Manual. 
8.1.4. Distribution o f Study Reminder Cards and Diaries  
Starting at the Day 1 visit and each visit thereafter, a study drug–specific diary will be given to 
each participant in order to record use of the study drug.  The completed diary will be collected during each of the part icipant's visits.  
Qualified clinical site staff will review the participants' entries for compliance.  Participants who are noncompliant with their study drug schedule (defined as < 70% or > 130% of the expected number of applications between study visits) will have their administration instructions 
reinforced by [CONTACT_1720] a qualified designee.  Participants will be considered compliant 
Incyte Corporation  Page [ADDRESS_439431] 70% but no more than 130% of the expected 
applications during participation in the treatment period of the study.  
Participants will be provided with a reminder card starting on Day 1 and at all visits (through Week 52).  The reminder card will indicate the date/time of the next visit and will also remind the participant that they should have their application at the clinic during the visit under site 
supervision after their blood draws for PK and safety evaluations have been completed. 
8.1.5. Demography and Medical History 
[IP_ADDRESS]. Demographics and General Medical History  
Demographi c data and general medical history will be collected at screening by [CONTACT_312356]/age, race, ethnicity, medical and surgical 
history, and current illnesses.  Medical history will include relevant medical or surgical treatment 
within the last 2 years that are considered to be clinically significant by [CONTACT_093].  
[IP_ADDRESS]. Disease Characteristics and Treatment History  
A vitiligo medical and treatment history, including date of diagnosis, relevant disease 
characteristics, and prior treatments, including systemic treatments, phototherapy, and surgical 
procedures, will be recorded.  A medical history of other conditions related to vitiligo will also be collected at screening.  

Incyte Corporation  Page 53 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  8.2. Efficacy Assessm ents 
8.2.1. Body Surface Area  
Total % BSA (includes facial and nonfacial areas) depi[INVESTIGATOR_352907].  Body surface area assessment will be performed by [CONTACT_352942].  BSA should 
be estimated to the nearest 0.1%.  T he approximate size of the participant’s entire palmar surface 
(ie, the palm plus 5 digits) should be considered as 1% BSA, and the approximate size of the 
participant’s thumb should be considered as 0.1% BSA. 
8.2.2. Vitiligo Area Scoring Index  
Areas affected by [CONTACT_61911][INVESTIGATOR_352908].  It is based on 
a composite estimate of the overall area of vitiligo patches at baseline and the degree of macular 
repi[INVESTIGATOR_312316].  
Facial VASI  is measured by [CONTACT_352943] ( % of BSA) and the degree of 
depi[INVESTIGATOR_371].  The percentage of BSA (hand unit) vitiligo involvement is estimated by [CONTACT_352972] (see Section  8.2.1).  Hand unit is based on participant ’s 
hand size.  Investigator uses his/her hand to mimic the participant ’s hand size to evaluate 
percentage of BSA vitiligo involvement.  The degree of depi[INVESTIGATOR_352909] i s determined and estimated to the nearest of the following percentages:  0, 
10%, 25%, 50%, 75%, 90%, or 100%.  At 100% depi[INVESTIGATOR_371], no pi[INVESTIGATOR_352865]; at 90%, 
specks of pi[INVESTIGATOR_352866]; at 75%, the depi[INVESTIGATOR_352867]; at 
50%, the depi[INVESTIGATOR_352910]; at 25%, the pi[INVESTIGATOR_352911]; at 10%, only specks of depi[INVESTIGATOR_352871].  The F -VASI is then 
derived by [CONTACT_352973] (possible 
range 0- 3). 

Incyte Corporation  Page 54 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL   
 
 
Total body VASI  is calculated using a formula that includes contributions from all body regions 
(possible range, 0-100). 
VASI = Σ [hand units] × [Residual Depi[INVESTIGATOR_371]] all body sites  
The body is divided into the following 6 separate and mutually exclusive sites:   (1) head/neck, 
(2) hands, (3) upper extremities (excluding hands), (4) trunk, (5) lower extremities (excluding 
feet), and (6) feet.  The percentage of vitiligo involvement is estimated in hand units ( % of BSA) 
by [CONTACT_312357].  Hand unit is based on participant ’s hand size.  The i nvestigator uses his/her hand to mimic the participant ’s hand size to 
evaluate % BSA vitiligo involvement.  The degree of depi[INVESTIGATOR_352872] i s 
determined and estimated to the nearest of the following percentages:  0, 10%, 25%, 50%, 75%, 90%, or 100%.  The T-VASI is then derived by [CONTACT_352974] ( Hamzavi et al 2004).  Full details will b e provided i n the Study Manual. 
8.2.3. Physician’s Global Vitiligo Assessment  (Facial)  
The severity of vitiligo will be assessed by [CONTACT_352947], which has a 5-point scale ( Table  11).  Response will be reported for fa ce (F -PhGVA).  
Table  11: Facial Physician's Global Vitiligo Assessment Scale  
Score  Severity  Description  
0 Clear  No signs of vitiligo or complete/near complete repi[INVESTIGATOR_371]  
[ADDRESS_439432] Clear  Mostly pi[INVESTIGATOR_352912] ( eg, philtrum, nares, corners of eyes, perioral skin)  
[ADDRESS_439433] areas of depi[INVESTIGATOR_371] (not more than half of facial skin) with 
approximately 50% pi[INVESTIGATOR_352874] s or signifi cant 
perifollicular pattern present 
3 Moderate Disease  Large areas of depi[INVESTIGATOR_352875] s (more than half of facial skin); 
significan t depi[INVESTIGATOR_352874] s 
4 Severe Disease  Extensive areas of vitiligo to complete  depi[INVESTIGATOR_352876] 
8.2.4. Physician’s Global Vitiligo Assessment (Total Body) 
The severity of total body vitiligo will be assessed by [CONTACT_352947], which has 
a 5-point scale ( Table  12).  Response will be reported for total body (T- PhGVA).  

Incyte Corporation  Page 55 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  Table  12: Total Body Physician's Global Vitiligo Assessment Scale  
Score  Severity  Description  
0 Clear  No signs of vitiligo or complete/near complete repi[INVESTIGATOR_371] 
[ADDRESS_439434] Clear  Mostly pi[INVESTIGATOR_352913] ( eg, hands , feet, philtrum, nares, corners of eyes, perioral skin ) 
[ADDRESS_439435] areas of depi[INVESTIGATOR_352878] 50% pi[INVESTIGATOR_352914] n present  
3 Moderate Disease  Large areas of depi[INVESTIGATOR_352875] s; significant depi[INVESTIGATOR_352880] s 
4 Severe Disease  Extensive areas of vitiligo with complete depi[INVESTIGATOR_371]  
8.2.5. Photography 
Photography of the face and/or body areas affe cted with vitiligo will be obtained at visits listed 
in Table  3 and Table  4. 
All sites will use 2D photography, and selected sites will also use 3D photography, to 
photograph areas of the participant’s face affected with vitiligo .  2D photography will be used at 
all sites for the target nonfacial depi[INVESTIGATOR_312320].  
Target nonfacial vitiligo depi[INVESTIGATOR_352881] :  At the baseline visit, depi[INVESTIGATOR_352915] s that ar e representative of the participant's overall disease and that are  to be 
treated with study drug will be selected as target ed nonfacial vitiligo depi[INVESTIGATOR_312294].  Th ese 
areas will be assessed, measured, and documented in the participant's medical record at each subsequent visit during the study (see Table  3 and Table  4).  A note should be made in their 
medical record, and the baseline photographs can be marked with the location of the target 
depi[INVESTIGATOR_352916].  The genitalia area should not be photographed. 
Ad hoc photography of skin -related AEs is recommended.  
Photographic procedures will be standardized, and a full description of the methodology will be 
provided in a photogr aphy manual to be provided to the sites. 
8.2.6. Patient -Reported Outcomes  
Patient -reported outcomes and quality of life will be assessed (see Table  3 and Table  4) using the 
followin g tools: 
• VNS  (Section  [IP_ADDRESS]) 
• Color-matching question (Section [IP_ADDRESS]) 
• F-PaGIC-V (Section  [IP_ADDRESS]) 
• T-PaGIC-V (Section  [IP_ADDRESS]) 
• DLQI  or CDLQI  (Section  [IP_ADDRESS]) 
• WHO -5 (Section  [IP_ADDRESS] ) 
Incyte Corporation  Page 56 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  • TSQM (Section  [IP_ADDRESS]) 
• VitiQoL (Section  [IP_ADDRESS] ) 
• HADS (Section  [IP_ADDRESS]) 
In order to avoid bias in the participants' responses to the questionnaires, all these assessments 
should be completed before any other evaluations or study procedures on the day of the study 
visit and prior to discussions with the investigator or study si te staff.  
At the baseline visit, all patient -reported outcomes must be completed before the participant's 
first study drug application. 
[IP_ADDRESS]. Vitiligo Noticeability Scale  
The VNS is a patient ‐reported measure of vitiligo treatment success, which has a 5 -point scale 
(Batchelor et al 2016 ).  The baseline facial photograph will be shown to the participants for 
reference and a mirror will be provided for th e participants to assess the vitiligo on their face. 
The participant will be asked to respond to the following query: 
Compared with before treatment, how noticeable is the vitiligo now?  Responses:  (1) More 
noticeable, (2) As noticeable, (3) Slightly less noticeable, (4) A lot less noticeable, and 
(5) No longer noticeable.  
VNS scores of 4 or 5 can be interpreted as representing treatment success.  
[IP_ADDRESS]. Color- Matching Question 
The baseline photograph and current participants’ facial image (participants will be p rovided a 
mirror) will be shown to the participant for reference , and the participant will be asked to 
respond to the following query: 
At this point of your treatment, how well does your skin color match between your face treated vitiligo skin and face nor mal skin?  Responses:  (1) Excellent, (2) Very good, 
(3) Good, (4) Poor, and (5) Very poor. 
[IP_ADDRESS]. Patient Global Impression of Change -Vitiligo  (Facial) 
The F- PaGIC- V is an assessment of improvement by [CONTACT_2299].  It is a 7 -point scale 
comparing the vitilig o areas at baseline with the participant's treated areas of facial vitiligo at the 
study visit.  Response will be reported for face (F- PaGIC-V).  The baseline photograph and 
current participants’ facial image (participants will be provided a mirror) will b e shown to the 
participant for reference.  The participant will be asked to respond to the following query: 
Since the start of the treatment you've received in this study, your vitiligo on your face 
treated with the study drug is:  (1) Very much improved, (2) Much improved, (3) M inimally 
improved, (4) No change, (5) M inimally worse, (6) Much worse, and (7) Very much worse. 
F-PaGIC-V scores of 1 or 2  can be interpreted as representing treatment success.  
Incyte Corporation  Page 57 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  [IP_ADDRESS]. Patient Global Impression of Change -Vitiligo (Total Bod y) 
The T- PaGIC- V is an assessment of improvement by [CONTACT_2299].  It is a 7 -point scale 
comparing the vitiligo areas at baseline with the participant's treated areas of total body vitiligo 
at the study visit.  Response will be reported for total body (T- PaGIC- V).  The participant will be 
asked to respond to the following query: 
Since the start of the treatment you've received in this study, your vitiligo on your total body treated with the study drug is:  (1) Very much improved, (2) Much improved, (3) M inimally 
improved, (4) No change, (5) M inimally worse, (6) Much worse, and (7) Very much worse. 
T-PaGIC-V scores of 1 or 2  can be interpreted as representing treatment success.  
[IP_ADDRESS]. Dermatology Life Quality Index  
The DLQI is a simple, 10 -question validated questionnaire to measure how much the skin 
problem has affected the participant over the previous 7 days ( Finlay and Khan 1994).  
Participant s age ≥ 16 years will answer the questionnaire with (1) very much, (2) a lot, (3) a 
little, or (4) not at all.  
The questionnaire is analyzed under 6 headings as follows: 
• Symptoms and feelings (Questions 1 and 2)  
• Daily activities (Questions 3 and 4)  
• Leisure (Questions 5 and 6)  
• Work and school (Question 7)  
• Personal relations (Ques tions 8 and 9)  
• Treatment (Question 10)  
CDLQI is the youth/children’s version of the DLQI.  For participants who are age ≥ 12 years to < 16 years at baseline, the CDLQI will be completed instead  of the CDLQI throughout their 
participation in the study .  This  questionnaire is self -explanatory and can be simply given to the 
participant who is asked  to fill it in and who may ask the help of the parent or guardian.  The 
questionnaire is analyzed under 6 headings as follows:  
• Symptoms and feelings (Questions 1 and 2)  
• Leisure (Questions 4, 5, and 6)  
• School or holidays (Question 7)  
• Personal relationsh ips (Questions 3 and 8)  
• Sleep (Question 9)  
• Treatment (Question 10)  
Full details will be provided in the Study Manual. 
Incyte Corporation  Page 58 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  [IP_ADDRESS]. WHO-[ADDRESS_439436] 2 weeks, whi ch can be used as an outcome measure for  the wanted and 
unwanted effects of treatments ( WHO Collaborating Center for Mental Health , Topp et al 2015 ).  
The questionnaire consists of 5 statements, w hich respondents rate according to the following 
scale:  0  = At no time; 1  = Some of the time; 2  = Less than half of the time ; 3 = More than half of 
the time; 4  = Most of the time; 5  = All of the time . 
The raw score is calculated by [CONTACT_352975] [ADDRESS_439437] possible quality of life.   A score 
below 13 indicates poor well-being. 
Full details will be provided in the Study Manual. 
[IP_ADDRESS]. Treatment Satisfaction Ques tionnaire for Medication  
TSQM is a  validated  9-item questionnaire that measures a participant’s  satisfaction with 
medication  taken in a clinical study using a recall period of the past [ADDRESS_439438] used.  The questionnaire uses a 7 -point scale for each question ( Bharmal 
et al 2009 ).  Full details will be provided in the Study Manual. 
[IP_ADDRESS]. VitiQoL  
VitiQoL is a [ADDRESS_439439] month using a 7- point scale ( “Not at all ” to “ All of the time”) 
(Lilly et al 2013 ).  Full details will be provided in the Study Manual. 
[IP_ADDRESS]. Hospi[INVESTIGATOR_352917] 14- item questionnaire that assesses the levels of anxiety  and depression  that a person is 
currently experiencing  (Zigmond and Snaith 1983).  There  are 7 questions each for measuring 
anxiety and for measuring depression, with 4 possible responses to each question (responses are 
scored as 0, 1, 2, or 3).  Separate scores are calculated for anxiety and depression.   Full details 
will be provided in the Study Manual. 
8.3. Safety Assessments  
Planned timepoints for all safety assessm ents are provided in the Table  [ADDRESS_439440] dose of study treatment.  Adverse events that begin or worsen after informed consent should be recorded on the Adverse Event Form in the eCRF regardless of the 
assumption of a causal relationship with the study drug.  Conditions that were already present at 
the time of informed consent should be recorded on the Medical History Form in the eCRF.  Adverse events (including laboratory abnormalities that constitute AEs) should be described 
using a diagnosis whenever possible rather than by [CONTACT_147108]. 
Incyte Corporation  Page 59 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  Adverse events will be reported by [CONTACT_2299] (or, when appropr iate, by a caregiver, 
surrogate, or the participant's legally authorized representative).  The investigator and any 
qualified designees are responsible for detecting, documenting, and recording events that meet 
the definition of an AE or SAE and remain responsible for following-up on AEs that are serious, considered related to the study treatment, or that caused the participant to discontinue the study 
treatment.  Care will be taken not to introduce bias when detecting AEs and/or SAEs.  
Open -ended and nonleading verbal questioning of the participant, such as "How are you 
feeling?" is the preferred method to inquire about AE occurrences.  Adverse events may also be 
detected when they are volunteered by [CONTACT_352949], or through physical examinations, laboratory tests, or other assessments.  The definition, reporting, and recording requirements for AEs are described in Section  9. 
The investigator will submit any updated SAE data to the sponsor immediately, without undue delay, under no circumstances later than 24 hours following knowledge of the event. 
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/c ontacts.  All SAEs will be followed until resolution, stabilization, the event 
is otherwise explained, or the participant is lost to follow -up (as defined in Section 7.3 ). 
8.3.2. Physical Examinations  
Physical examinati ons will be conducted at the timepoints listed in Table  3 and Table  4. 
A comprehensive physical examination will include height and body weight and assessment of 
the followin g organ or body systems:  skin; head, eyes, ears, nose, and throat; thyroid; lungs; 
cardiovascular system; abdomen (liver, spleen); extremities; and lymph nodes.  A brief 
neurological examination will also be performed. 
A targeted physical examination should be conducted as indicated by [CONTACT_312361], AEs, or other findings.  Abnormalities that are considered clinically significant in the 
judgment of the investigator are to be reported as AEs. 
Physical examinations must be performed by a medically qualified individual such as a licensed 
physician, physician's assistant, or an advanced registered nurse practitioner, as local law 
permits.  
8.3.3. Vital Signs 
Vital sign measurements include blood pressure, pulse, respi[INVESTIGATOR_697], and body temper ature.  
Blood pressure and pulse will be taken with the participant in the recumbent, semi-recumbent, or sitting position after [ADDRESS_439441].  Electrocardiograms should be performed as indicated in Ta ble 3.  
Additional 12- lead ECGs may be performed at other visits as deemed clinically necessary.  
Twelve -lead ECG performed within 2 months before baseline is acceptable for using as a 
screening value.  
Incyte Corporation  Page 60 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  Electrocardiograms will be interpreted by [CONTACT_312362], and the results 
will be used for immediate management of the participant's care.  There is no central reader of 
ECGs for this study. The decision to include or exclude a participant or withdraw a participant 
from the study based on an ECG flagged as "Abnormal, Clinically Significant" is the responsibility of the investigator, in consultation with the sponsor's medical monitor, as 
appropriate.  Any abnormalities that are considered clinically significant in the judgment of the 
investigator are to be reported as AEs.  
8.3.5. Laboratory Assessments  
Required laboratory tests are listed in  Table  13, which include hematology, chemistry, urinalysis, 
serology, f ree T4, TSH, FSH , and pregnancy test (see Table  3 and Table  4).  Clinical laboratory 
tests will be performed at a central laboratory (refer to the Laboratory Manual for sample handling and shippi[INVESTIGATOR_3931]). 
Clinically significant abnormal laboratory findings are those that are not associated with the 
underlying disease, unless judged by [CONTACT_19448]'s condition.  All laboratory tests with values considered clinically significantly 
abnormal during participation in the study, or within [ADDRESS_439442] dose of study 
treatment, should be repeated until the values return to normal or baseline or are no longer considered clinically significant by [CONTACT_10982].  
See Section  9.1 for information regarding laboratory abnormalities that should be recorded as an 
AE in the eCRF.  
Incyte Corporation  Page 61 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  Table  13: Required Laboratory Analytes  
Serum Chemistriesa Hematology  Urinalysis With  
Microscopic 
Examination  Serology  Other  
Albumin  
Alkaline phosphatase  
ALT 
AST  
Bicarbonate or CO [ADDRESS_439443] bilirubin (if total bilirubin is elevated above ULN)  
Total protein  Complete blood count, including:  
• Hemoglobin  
• Hematocrit  
• Mean corpuscular volume (MCV)  
• Platelet count  
• Mean platelet volume  
• Red blood cell 
count  
• Reticulocyte count  
• White blood cell count  
 
Differential count, 
including:  
• Basophils  
• Eosinophils  
• Lymphocytes  
• Monocytes  
• Neutrophils  Color and appearance  
pH and specific gravity  
Bilirubin  
Glucose  
Ketones  
Leukocytes  
Nitrite  
Occult blood  
Protein HIV antibody  FSH 
Free T4  
TSH 
Pregnancy Testing  
Female participants of childbearing potential have a serum test at screening and safety follow -up visits.  A urine test will be 
conducted at all other visits.  A positive urine test will be 
confirme d by a serum test.  
a All serum chemistries will be performed on samples collected without respect to food intake (ie, non-fasting). 
Note:  Additional tests may be required, as agreed by [CONTACT_147100], based on emerging safety data.  
[IP_ADDRESS]. Pregnancy Testing  
A serum pregnancy test will be required for all women of childbearing potential during screening 
and at the safety follow-up visit (30 [+ 7] days after EOT ; EOT1 or EOT2 as applicable) .  Urine 
pregnancy tests will be conducted as outlined in Table  [ADDRESS_439444] was positive, the investigator will assess 
the potent ial benefit/risk to the participant and determine whether it is in the participant's best 
interest to resume study drug and continue participation in the study. 
If a pregnancy is confirmed by a serum pregnancy test, see Section  9.6 for reporting 
requirements.  
Incyte Corporation  Page 62 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  [IP_ADDRESS]. Serology 
An HIV antibody assessment will be performed at the screening visit to rule out infection (see 
Table  3).  Serology tests should be performed early in the screening process due to the length of 
time needed to obtain the results.  Additional tests may be performed if clinically indicated.  
8.4. Pharmacokinetic  Assessments  
Venous blood samples will be collected to assess the PK of ruxolitinib cream in this study 
population at each study visit indicated in Table  3. 
The exact date and time of the PK blood draws and the date and time of the last application of 
study drug preceding the blood draw (if applicable) will be recorded in th e eCRF.  
Instructions for sample preparation and shippi[INVESTIGATOR_352884].  Participants will receive reminder cards in advance of the study visit providing instruction to hold the application of study drug on the day of the visit and a place to record the time of the 
prior dose of study drug.  
Pharmacokinetic blood samples can be collected at any time during study visits noted in the 
Table  3.  Blood samples must not be drawn from the area that has been treated with study drug.  
If it is not possible to access an area that is not treated with study drug, the site must adequately document this in the eCRF and not take the PK blood sample for that visit.  After the PK sample is drawn, participa nts will apply ruxolitinib cream 1.5% or vehicle cream at the site.  
All analyses will be conducted by [CONTACT_109912] (Wilmington, DE) or Incyte's designee.
 
8.5. Pharmacodynamic and Translational Assessments  
Serum will be collected from  all participants at all sites for proteomic analysis at timepoints 
outlined in Table  3 and Table  4.  The purpose of this  analys is will be to retrospectively evaluate 
correlative and pharmacodyna mic biomarkers  of response. 
All analyses will be conducted by [CONTACT_109912] (Wilmington, DE) or Incyte's designee.  
Refer to the Study Manual for detailed instructions.  
8.6. Unscheduled Visits  
Unscheduled visits may occur at any time at the investigator's discretion, and appropriate clinical and laboratory tests may be performed, as clinically indicated. 
8.7. End of Treatment and/or Early Termination  
If a decision is made that the participant will permanently discontinue study drug, then the EOT visit should be conducted (EOT1 or EOT2 depending on the study period when the participant 
discontinues).  If the EOT visit coincides with a regular study visit, then the EOT evaluations 
will supersede those of that scheduled visit, and the data should be entered in the EOT page in 
the eCRF.  If this decision does not coincide with a regular visit, reasonable efforts should be 
made to have the participant return to the site to have the EOT procedures completed. 
Incyte Corporation  Page 63 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  8.8. Safety Follow -Up 
For participants who do not participate in a separate extension study , the safety follow -up period 
is the interval between the EOT  visit (EOT 1 or EOT2  depending on the study period when the 
participant discontinues ) and the scheduled safety follow-up visit, which should occur 
30 (+  7) days after the EOT visit (or after the last dose of study drug/treatment if an  EOT visit 
was not performed).  
Adverse events and SAEs must be reported up until at least [ADDRESS_439445] dose of study 
drug/treatment, the date of the safety follow-up visit, or until toxicities resolve, return to 
baseline, or are deemed irreversible, whichever is longer.  Reasonable efforts should be made to 
have the participant return for the safety follow-up visit and report any AEs that may occur during this period. 
9. ADVERSE EVENTS:  DEFINITIONS AND PROC EDURES FOR 
RECORDING, EVALUATING, FOLLOW -UP, AND RE PORTING 
9.1. Definition of Adverse Event 
Adverse Event Definition  
• An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not 
considered drug-related.  
• An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment.  
Events Meeting  the Adverse Event Definition  
• Any safety assessments (eg, ECG, vital signs measurements), including those that worsen from baseline, considered clinically significant in the medical and scientific judgment of the investigator (ie, not related to progression of underlying disease).  
• Abnormal la boratory test results constitute an AE if they are considered clinically meaningful, induce 
clinical signs or symptoms, require concomitant therapy, or require changes in study drug.  Whenever 
possible, a diagnosis (eg, anemia, thrombocytopenia) should be recorded in the eCRF rather than the 
abnormal lab result (eg, low hemoglobin, platelet count decreased). 
• Exacerbation of a chronic or intermittent pre -existing condition including either an increase in 
frequency and/or intensity of the condition.  
• New condi tions detected or diagnosed after study treatment administration even though it may have 
been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
• Signs, symptoms, or the clinical sequelae o f a suspected overdose of either study treatment or a 
concomitant medication.  Overdose per se will not be reported as an AE/SAE unless it is an intentional overdose taken with possible suicidal/self-harming intent.  Such overdoses should be reported regar dless of sequelae.  
• "Lack of efficacy" or "failure of expected pharmacological action" per se will not be reported as an AE or SAE.  Such instances will be captured in the efficacy assessments.  However, the signs, symptoms, and/or clinical sequelae resulti ng from lack of efficacy will be reported as AE or SAE if they fulfill the 
definition of an AE or SAE.   
Incyte Corporation  Page 64 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  Events NOT  Meeting the Adverse Event Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety assessments that are 
associated with the underlying disease, unless judged by [CONTACT_19448]'s condition.  
• The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder being studied, unless more severe than expected for the participant's condition or considered to be treatment-related by [CONTACT_093].  
• Medical or surgical procedure (eg, endoscopy, appendectomy):  the condition that leads to the procedure is the AE if it occurred after signing the ICF.  If present before entering the study, the condition should be captured as medical history.  
• Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospi[INVESTIGATOR_307]).  
• Anticipated day -to-day f luctuations of pre -existing disease(s) or condition(s) present or detected at the 
start of the study that do not worsen.  
9.2. Definition of Serious Adverse Event  
If an event is not an AE per the definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study, death due 
to progression of disease). 
A Serious Adverse Event is defined as any untoward medical occurrence that, at any dose:  
a. Results in death 
b. Is life-threatening  
The term "life -threatening" in the definition of "serious" refers to an adverse drug experience that places 
the participant, in the opi[INVESTIGATOR_89155], at immediate risk of death from the adverse 
experience as it occurred.  This does not include an adverse drug experience that, had it occurred in a 
more severe form, might have caused death. 
c. Requires inpatient hospi[INVESTIGATOR_9234], hospi[INVESTIGATOR_19949] (usually  involving at least an 
overnight stay) at the hospi[INVESTIGATOR_9235]/or treatment that would not have 
been appropriate in the physician's office or outpatient setting.  Complications that occur during hospi[INVESTIGATOR_1084].  If a complication prolongs hospi[INVESTIGATOR_9236], the event is serious.  When in doubt as to whether "hospi[INVESTIGATOR_059]" occurred or was necessary, the AE should be considered serious.  
Hospi[INVESTIGATOR_5187] a p re-existing condition that did not worsen from baseline is not 
considered an AE.  
d. Results in persistent or significant disability/incapacity  
• The term disability means a substantial disruption of a person's ability to conduct normal life functions.  
• This definition is not intended to include experiences of relatively minor medical significance, such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg,  sprained 
ankle), that may interfere with or prevent everyday life functions but do not constitute a substantial disruption.  
Incyte Corporation  Page 65 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  e. Is a congenital anomaly/birth defect  
f. Other situations (Important Medical Event)  
An event that may not result in death, be immediately life-threatening, or require hospi[INVESTIGATOR_059], but may 
be considered serious when, based on appropriate medical judgment, the event may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in the above definition.
  Examples of such events include invasive or malignant cancers (excluding the 
disease[s] under study in oncology protocols), intensive treatment in an emergency department or at home for allergic bronchospasm, blood dyscrasias, or convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency or drug abuse.  
9.3. Recording and Follow -Up of Adverse Event s and/or Serious Adverse 
Event s 
Adverse Event and Serious Adverse Event Recording  
• An AE/SAE that begins or worsens after informed consent is signed should be recorded on the Adverse Even t Form in the eCRF.  Conditions that were present at the time informed consent was given should 
be recorded on the Medical History Form in the eCRF.  
• When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation (eg, hospit al progress notes, laboratory reports, and diagnostics reports) related to the event.  
• The investigator (or delegate) will then record all relevant AE/SAE information in the eCRF. 
• It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]'s medical records to 
sponsor or designee in lieu of completing the AE eCRF page.  
• There may be instances when copi[INVESTIGATOR_63475].  In this case, all participant identifiers, with the exception of the participant nu mber, will be redacted on the copi[INVESTIGATOR_346590].  
• The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information.  Whenever possible, the diagnosis (not the individual signs/symptoms) will be documented as the AE/SAE.  When a clear diagnosis cannot be identified, each sign or symptom should be reported as a separate AE/SAE.  
To the extent possible, each AE/SAE should be evaluated to determine: 
• The severity grade (CTCAE Grade 1 to 5).  See below for further instructions on the assessment of 
intensity.  
• Whether there is at least a reasonable possibility that the AE is related to the study drug:  suspected (yes) or not suspected (no).  See below for further instructions on the assessment of causality.  
• The start and end dates, unless unresolved at final safety follow -up. 
• The action taken with regard to study drug as a result of the AE/SAE(s).  
• The event outcome (eg, not recovered/not resolved, recovered/resolved, recovering/resolving, recovered/resolved with sequelae, fatal, unknown).  
• The seriousness, as per the SAE definition provided in Section  9.2. 
• The action taken with regard to the event.  Note:  If an AE is treated with a con comitant medication or 
nondrug therapy, this action should be recorded on the Adverse Event Form, and the treatment should be specified on the appropriate eCRF (eg, Prior/Concomitant Medications, Procedures and Non-Drug Therapy).  
Incyte Corporation  Page 66 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  Assessment of Intensity  
The severity of AEs will be assessed using CTCAE v5.0 Grades 1 through 5.  If an event is not classified 
by [CONTACT_3989], the severity of the AE will be graded according to the scale below to estimate the grade of 
severity.  
The investigator will make an assessmen t of intensity for each AE and SAE reported during the study and 
assign it to 1 of the following categories:  
• Grade 1:   Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention 
not indicated. 
• Grade 2:   Moderate; minimal, local, or noninvasive intervention indicated; limiting age appropriate 
activities of daily living.  
• Grade 3:   Severe or medical ly significant but not immediately life -threatening; hospi[INVESTIGATOR_8942]; disabling; limiting self -care activities of daily living.  
• Grade 4:   Life -threatening consequences; urgent intervention indicated.  
• Grade 5:   Fatal . 
Assessment of Causality  
• The investigator is obligated to assess the relationship between study treatment and each occurrence of 
each AE/SAE.  
• A "reasonable possibility" of a relationship conveys a relationship cannot be ruled out.  
• The investigator will use clinical judgment to determine the relationship.  
• The investigator will also consult the RSI in the IB and/or Product Information, for marketed products, in his/her assessment.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well as the temporal relationship of the event to study treatm ent administration, will be considered and 
investigated.  
• For each AE/SAE, the investigator must  document in the medical notes that he/she has reviewed the 
AE/SAE and has provided an assessment of causality.  
• With regard to assessing causality of SAEs:  
− There may be situations in which an SAE has occurred and the investigator has minimal information 
to include in the initial report to the sponsor or designee.  However, it is very important that the 
investigator always make an assessment of causality for every event before the initial 
transmission of the SAE data to the sponsor or designee.  
− The investigator may change his/her opi[INVESTIGATOR_9242] -up information and send a 
SAE follow -up report with the updated causality assessment.  
Follow -Up of Adverse Events and Serious Adverse Events  
• The investigator is obligated to perform or arrange for the conduct of supplemental measurements 
and/or evaluations as medically indicated or as requested by [CONTACT_352950]/or causality of the AE/SAE as fully as possible.  This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other healthcare professionals.  
• If a participant dies during participation in the study or  during a recognized safety follow -up period, the 
investigator will provide the sponsor or designee with a copy of any postmortem findings, including histopathology.  
• New or updated information will be recorded in the originally completed eCRF.  
• Any updated SAE data will be submitted to the sponsor or designee immediately, without undue delay, 
under no circumstances later than 24 hours f ollowing knowledge of the event . 
Incyte Corporation  Page 67 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  • Once an AE is detected, it should be followed until it has resolved or until it is judged t o be permanent; 
assessment should be made at each visit (or more frequently if necessary) of any changes in severity, 
the suspected relationship to the study drug, the interventions required to treat the event, and the outcome.  
• When the severity of an AE changes over time for a reporting period (eg, between visits), each change in severity will be reported as a separate AE until the event resolves.  
9.4. Reporting of Serious Adverse Events  
Regar dless of suspected causality (eg , relationship to study drug or study procedure[s]), all SAEs 
occurring after the participant has signed the ICF through the last study visit (or [ADDRESS_439446] dose of study treatment, whichever occurs later) must be reported to the sponsor (or designee) immediately, without undue delay, under no circumstances later than 24 hours 
following knowledge of the event. 
Investigators are not obligated to actively seek AE or SAE information after conclusion of the 
study participation.  However, if the investigator learns of any SAE, including a death, at any 
time after a participant has been discharged from the study, and he/she considers it is at least 
reasonably possible that the event is related to the study treatment or study participation, then the 
investigator must notify the sponsor (or designee) immediately, without undue delay, under no circumstances later than 24 hours following knowledge of the event. 
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts.  All SAEs will be followed until resolution, stabilization, the event 
is otherwise explained, or the participant is lost to follow -up (as defined in Section  7.3). 
Prompt notification by [CONTACT_352976] a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of a study treatment under clinical investigation are met.  
If the SAE is not documented in the IB for the study drug (new occurrence) and is thought to be 
related to the sponsor's study drug, the sponsor or its designee may urgently require further information from the investigator for reporting to health authorities.  The sponsor or its designee 
may need to issue an Investigator Notification to inform all investigators involved in any study with the same drug that this SAE has been reported.  Suspected Unexpected Serious Adverse 
Reactions will be collected and reported to the competent authorities and relevant ethics 
committees in accordance with Directive 2001/20/EC, or as per national regulatory requirements in participating countries. 
The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study treatment under clinical investigation.  The sponsor will comply with country- specific regulatory requirements relating to safety reporting to 
the regulatory authority, IRB/IEC, and investigators. 
Investigator safet y reports must be prepared for S[LOCATION_003]Rs according to local regulatory 
requirements and sponsor policy and forwarded to investigators as necessary. 
An investigator who receives an investigator safety report describing a SAE or other specific 
safety informatio n (eg, summary or listing of SAEs) from the sponsor will review and then file it 
along with the IB and will notify the IRB/IEC, if appropriate according to local requirements.  
Incyte Corporation  Page 68 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  Serious Adverse Event Reporting  
• Information about all SAEs is collected and rec orded on the Adverse Event Form in the eCRF.  
• The investigator must also complete the Incyte Serious Adverse Event Report Form, in English.  Refer 
to the Incyte Reference Guide for Completing the Serious Adverse Event Report Form.  
• Facsimile or email transmi ssion of the Serious Adverse Event Report Form is the preferred method to 
transmit this information to the PhV/designee.  The contact [CONTACT_89208]'s study -specific 
representatives is listed in the Study Manual provided to each site.  The orig inal copy of the Serious 
Adverse Event Report Form and the confirmation sheet must be kept at the study site.  
• Follow -up information is recorded on an amended or new Serious Adverse Event Report Form, with an 
indication that it is follow -up to the previously reported SAE and the date of the original report.  The 
follow -up report should include information that was not provided on the previous Serious Adverse 
Event Report Form, such as the outcome of the event (eg, resolved or ongoing), treatment provided, action taken with study drug because of the SAE (eg, dose reduced, interrupted, or discontinued), or participant disposition (eg,  continued or withdrew from study participation).  Each recurrence, 
complication, or progression of the original event should be reported as follow -up to that event, 
regardless of when it occurs.  
• In rare circumstances and in the absence of facsimile or computer equipment, notification by [CONTACT_13186] a copy of the Incyte Serious Adverse Event Report Form sent by [CONTACT_352977].  Initial notification via telephone does not replace the need for the investigator to 
complete and sign the Serious Adverse Event Report Form within the designated reporting time frames. 
• Contacts for SAE reporting can be found in the Study Manual.  
9.5. Emergency Unblinding of Treatment Assignment  
In a medical emergency during the double- blind, vehicle -control led period, if the investigator 
deems it necessary to determine optimal medical management of the participant, emergency 
unblinding will be performed exclusively by [CONTACT_079] [INVESTIGATOR_352885].  The IRT system has an option to select for "Emergency 
Code Break" action for a given participant.  After entering the 6- digit stu dy drug tube number 
and verification of the unmasking information, the investigator/subinvestigator will proceed to 
either final confirmation or cancellation of the code break procedure. 
If a participant's treatment assignment is unblinded, the sponsor or its designee must be notified 
immediately by [CONTACT_352953]-up with an email.  
If an investigator, site personnel performing assessments, or participant is unblinded, the 
participant must be withdrawn from the study treatment, unless there are ethical reasons to have the participant remain on the study treatment.  In these cases, the investigator must obtain 
specific approval from the sponsor's (or its designee's) medical monitor for the participant to 
continue in the study
 
Incyte Corporation  Page [ADDRESS_439447] interfered with the effectiveness of a contraceptive medication or method.  When a 
pregnancy has been confirmed in a participant during maternal or paternal exposure to study drug, the following procedures should be followed in order to ensure safety: 
• The study drug must be discontinued immediately. 
• The investigator must complete and submit the Incyte Clinical Trial Pregnancy Form to the sponsor or its designee within 24 hours of learning of the pregnancy. 
Data on fetal outcome are collected for regulatory reporting and drug safety evaluation.  Follow-up should be conducted for each pregnancy to determine outcome, including spontaneous or voluntary termination, details of t he birth, and the presence or absence of any birth defects, 
congenital abnormalities, or maternal and/or newborn complications, by [CONTACT_352978]-baby [CONTACT_765].  Pregnancy should be recorded on a Clinical Trial Pregnancy Form and reported 
by [CONTACT_89211].  Pregnancy follow-up information should be 
recorded on the same form and should include an assessment of the possible causal relationship 
to the sponsor's study drug to any pregnancy outcome, as well as follow- up to the first well -baby 
[CONTACT_89212], whichever is later.   Refer to the Incyte 
Reference Guide for Completing the Clinical Trial Pregnancy Form.  
Any SAE occurring during pregnancy of a study participant must be r ecorded on the 
Serious Adverse Event Report Form and submitted to the sponsor or designee.  
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital anomalies, or ectopic pregnancy) are considered SAEs (if occurring in the study participant) and must be reported as described in Section  9.4.  If an abnormal pregnancy outcome is reported in a 
study participant's partner, the event should be reported to the sponsor on the Clinical Tri al 
Pregnancy Form. 
9.7. Warnings and Precautions  
Special warnings or precautions for the study drug, derived from safety information collected by [CONTACT_3552], are presented in the IB .  Additional safety information collected 
between IB updates will be communicated in the form of Investigator Notifications.  Any 
important new safety information should be discussed with the participant during the study, as 
necessary.  If new significant risks are identified,  they will be added to the ICF. 
9.8. Product Complaints  
The sponsor collects product complaints on study drugs and drug delivery systems used in clinical studies in order to ensure the safety of study participants, monitor quality, and facilitate process and product improvements. 
All product complaints associated with material packaged, labeled, and released by [CONTACT_319862].  All product complaints associated with other study material will be reported directly to th e respective manufacturer.  
Incyte Corporation  Page 70 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  The investigator or his/her designee is responsible for reporting a complete description of the 
product complaint via email or other written communication to the sponsor contact [CONTACT_352979] g information.  Any AE associated with a product 
complaint should be recorded as described in Section 9.3. 
If the investigator is asked to return the product for investigation, he/she will return a copy of the 
product complaint communication with the product. 
9.9. Treatment of Overdose  
There has been no clinical experience with overdose of ruxolitinib cream.  Treatment of overdose should consist of general supportive measures. 
10. STATISTICS  
10.1. Sample Size Determination  
Approximately 300 participants will be randomized 2:1 to ruxolitinib cream 1.5% BID  or vehicle 
and stratified by [CONTACT_352955] (Fitzpatrick scale Type I and II vs Type III, IV, V , and VI) 
and region ( North America  or Europe ). The sample size is calculated to provide sufficient power 
(> 85%) to detect a difference between the 1.5% BID with the vehicle in primary and key 
secondary endpoints.  The powers for different endpoints are provided in Table 14.  The Fisher’s 
exact test with a 2 -sided alpha of 0.05 is used to provide a conservative evaluation of statistical 
power, and it is accurate when there is a small expected number of responders in the vehicle 
group. 
Table 14: Powering for Primary an d Key Secondary Endpoints  
Endpoints  Response Rates in  
Ruxolitinib 1.5% BIDa Response Rates  
in Vehiclea Powerb 
F-VASI75 at Week 24  20% 5% 95% 
F-VASI50 at Week 24  30% 10%   95% 
F-VASI90 at Week 24  10% 1% 88% 
T-VASI50 at Week 24  10% 1% 88% 
Vitiligo - VNS Response 
at Week 24  10% 1% 88% 
a Based on the res ults from a Phase 2, randomized, dose -ranging study (INCB18424- 211).  
b Based on the Fisher’s exact test with a 2 -sided alpha of 0.05.  
Incyte Corporation  Page 71 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  10.2. Populations for Analysis  
The populations for analysis are presented in Table  15. 
Table  15: Populations for Analysis 
Population  Description  
ITT The ITT population includes all randomized participants.  Treatment groups for this 
population will be defined according to the treatment assignment at randomization.  
PP The PP population includes randomized participants who are considered to be sufficiently compliant with the Protocol. 
Safety  The safety population includes all participants who applied at least 1  dose of study 
drug.  Treatment groups for this population will be determined according to the actual treatment the participant received on Day 1.  
PK/ 
pharmacodynamic evaluable The PK/pharmacodynamic evaluable population includes participants who appl ied 
at least [ADDRESS_439448] will review data listings of participant 
administration and sample records to identify participants to be excluded from the analysis.  
10.3. Statistical Analyses  
The Statistical Analysis Plan will be developed and finalized before database lock and will 
describe the details of the statistical analyses and procedures for accounting for missing data.  
This section is a summary of the planned statistical analyses of the primary and secondary 
endpoints. 
The gatekeepi[INVESTIGATOR_352886] I error rate, 2- sided α = 0.05.  These endpoints will be 
tested in a fixed sequence at 2 -sided α = 0.05 level in the following order:  
• Proportion of participants achieving F-VASI75 at Week 24 
• Proportion of participants achieving F-VASI50 at Week 24 
• Proportion of participants achieving F-VASI90 at Week 24 
• Proportion of particip ants achieving T-VASI50 at Week 24 
• Vitiligo - VNS Response at Week 24  
• Percentage change from baseline in F -BSA at Week 24  
10.3.1. Efficacy Analyses 
[IP_ADDRESS]. Primary Analysis 
The primary analysis will be based on the intent- to-treat population.  The primary alternative 
hypothesis (superiority of ruxolitinib cream 1.5% BID compared with vehicle) will be tested 
using exact logistic regression  (Mehta and Patel 1995) .  This model will include the treatment 
group (1.5% BID and vehicle) and stratification factors.  The p -value for  between -treatment 
Incyte Corporation  Page 72 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  group testing will be compared with 0.05.  Odds ratio and corresponding 95% confidence 
interval will be provided for comparing ruxolitinib cream and vehicle group at Week 24. 
All nonresponders in the double- blind treatment period, as well as all participants who 
discontinue study treatment at any time before the timepoint of interest, or discontinue from the 
study for any reason, will be defined as nonresponders for the nonresponder imputation anal ysis. 
Analysis will also be performed in the PP population for the primary endpoint.  The following 
deviations are considered major:  
• Missing primary endpoints on F- VASI;  
• Compliance less than 60% based on the application numbers. 
Participants  with 1 or more such deviations will be excluded from the PP population.  In 
addition, P rotocol deviations related to inclusion/e xclusion criteria, discontinuation criteria, and 
use of excluded concomitant medications will be evaluated and decided whether they should be 
excluded.  Any exclusion from the PP population will be decided prior to breaking the blind. 
In addition, sensitivity analyses, including MI and LOCF , may be performed.  For MI, a fully 
conditional specification method ( van Buuren et al 2007) that assumes the existence of a joint 
distribution for all variables will be used to impute F -VASI scores.  A regression model 
including treatment group, stratification factors, and baseline and postbaseline F -VASI scores up 
to Week  [ADDRESS_439449]. 
Subgroup analysis by [CONTACT_352956], for example, skin type, age, and region, will be performed.  Details will be provided in the Statistical Analysis Plan.  
[IP_ADDRESS]. Key Secondary Analys is 
If the primary objective is achieved, the statistical hypotheses for key secondary endpoints will 
be tested in the frequency specified in Section  10.3. 
Key secondary efficacy analyses at Week 24 will be conduc ted in the ITT population.  The 
statistical comparisons for binary outcomes (VASI50/90 and VNS response) will be analyzed using the similar method as specified in the primary analysis.   For F- BSA, the missing values at 
Week  [ADDRESS_439450] for superiority between INCB018424 1.5% BID and vehicle cream 
will be performed using the least squares mean estimate of the percentage change from baseline 
in F-BSA at Week 24 from the ANCOVA model  specified above.  Superiority will be 
established  if the p -value of the difference (INCB018424 1.5% BID minus vehicle) is less than 
0.05. 
[IP_ADDRESS]. Secondary Analysis 
All other secondary and exploratory efficacy variables will be summarized using descriptive 
statistics.  For categorical measurements, summary statistics will include sample size, frequency, 
and percentages.  Similar exact logistic regression models as specified in the primary and key secondary analysis will be used if applicable.  For continuous measurements, summary statistics 
will include sample si ze, mean, median, SD, standard error of the mean, minimum, and 
maximum.  Continuous efficacy endpoints, including the actual measurement, change from 
baseline, and percentage change from baseline may also be analyzed by [CONTACT_352980].  
Secondary endpoint analyses at Week 52 on VASI (eg, F-VASI25/50/75/90 and 
T-VASI25/50/75/90) will be performed in the ITT population with the following methods: 
• Participants  who discontinue the study drug before Week 24 due to any reason will be 
defined as nonresponders for subsequent visits until Week 52. 
• For pa rticipants  who completed Week 24 in the vehicle and 1.5% BID group, missing 
values of VASI in treatment extension period (including Week 52) will be imputed using linear extrapolation method.  The binary outcomes on responses, 
VASI50/75/90, will be derived based on the imputed values.  The statistical 
comparisons for these endpoints will be analyzed using the similar method as 
specified in the primary analysis.  
10.3.2. Safety Analyses 
A TEAE i s any AE either reported for the first time or worsening of a pre -existing event after 
first dose of study drug.  Analysis of AEs will be limited to TEAEs, but data listings will include all AEs regardless of their timing to study drug administration.  Adv erse events will be tabulated 
by [CONTACT_169108].  Severity of AEs will be based on the 
National Cancer Institute CTCAE v5 .[ADDRESS_439451] a relationship to study drug will be 
considered to be treatment-related AEs.  If the investigator does not specify the relationship of 
the AE to study drug, then the AE will be considered treatment- related.  The incidence of AEs 
and treatment- related AEs will be tabulate d. 
The clinical laboratory data will be analyzed using summary statistics; no formal treatment group comparisons are planned.  Laboratory test values outside the normal range will be assessed for 
severity based on the normal ranges for the clinical referen ce laboratory.  The incidence of 
abnormal laboratory values and shift tables relative to baseline will be tabulated.  
Incyte Corporation  Page 74 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  Descriptive statistics and mean change from baseline will be determined for vital signs (blood 
pressure, pulse, respi[INVESTIGATOR_697], and body temperature) at each assessment time.  
10.4. Analysis  Plan  
No formal interim analysis is planned in this study.  The primary analysis will occur after the primary database lock, when all participants have completed the vehicle-controlled, double-blind 
treatment p eriod.  Sponsors will all be unblinded, while investigators and participants will still be 
blinded, to the study treatment after the primary database lock.  After Week 52, investigators and 
participants will be unblinded.   
11. SUPPORTING DOCUMENTA TION AND OPE RATIONAL 
CONSIDERATIONS  
11.1. Investigator Responsibilities  
• The Protocol, Protocol amendments, ICF, IB, and other relevant documents (eg, advertisements) must be submitted to an IRB/IEC by [CONTACT_22843]/IEC before the study is initiated.  
• The investigator is responsible for ensuring that the safety reports provided by [CONTACT_352981], the policies and procedures established by [CONTACT_1201]/IEC, and institutional re quirements.  
• Any amendments to the Protocol will require IRB/IEC approval before implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study participants.  
• The investigator will be responsible fo r the following: 
− Providing written summaries of the status of the study to the IRB/IEC annually or more frequently in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/IEC.  
− Notifying the IRB/IEC of SAEs or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures.  
− Providing oversight of the conduct of the study at the site and adherence to GCP, IRB/IEC requirements, institutional requirements, and applicable laws and country- specific regulations.  
• Adhering to the Protocol as described in this document and agreeing that changes to the Protocol procedures, with the exception of medical emergencies, must be discussed and approved, first, by [CONTACT_89223], second, by [CONTACT_5040]/IEC.  Each investigator is re sponsible for enrolling participants who have met 
the specified eligibility criteria.  
Incyte Corporation  Page 75 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  • Retaining records in accordance with all local, national, and regulatory laws, but for a 
minimum period of at least [ADDRESS_439452] article for 
investigation to ensure the availability of study documentation should it bec ome 
necessary for the sponsor or a regulatory authority to review. 
− The investigator must not destroy any records associated with the study without 
receiving approval from the sponsor.  The investigator must notify the sponsor or 
its designee in the event o f accidental loss or destruction of any study records.  If 
the investigator leaves the institution where the study was conducted, the sponsor 
or its designee must be contact[CONTACT_89224].  
− All eCRF data entered by [CONTACT_779] (including audit trail), as well as computer hardware and software (for accessing the data), will be maintained or made available at the site in compliance with applicable record retention regulations.  
The sponsor will retain the original eCRF data and a udit trail.  
11.2. Data Management 
Data management will be performed in a validated EDC system.  The investigator will be provided with access to an EDC system so that an eCRF can be completed for each participant.  
The site will be provided with eCRF completion guidelines for instructions on data entry in the 
eCRF.  The study monitor will reference the Monitoring Plan in order to ensure that each issue 
identified is appropriately documented, reported, and resolved in a timely manner in accordance 
with the plan's requirements.   Other data outside the EDC system required in the study conduct 
of the protocol such as documents or results transmitted to the sponsor via a central laboratory or 
specialized technical vendors, and as designated by [CONTACT_456], will have their own data flow 
management plans, or study charters, or biomarker plans, as applicable. 
The sponsor (or designee) will be responsible for: 
• Managing the integrity of the data and the quality of the conduct of the study, such as 
ensuring that study monitors perform ongoing source data verification to confirm that data entered into the eCRF by [CONTACT_1191], complete, and 
verifiable from source documents; that the safety and rights of participants are being 
protected; and that the stu dy is being conducted in accordance with the currently 
approved protocol and any other study agreements, ICH GCP, and all applicable 
regulatory requirements. 
• Managing and reconciling the data generated, and/or collected including documents 
and results such  as laboratory or imaging data analyzed centrally by a designated 
vendor of the sponsor. 
Incyte Corporation  Page 76 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  The investigator will be responsible for: 
• Recording, or ensuring the recording of, all relevant data relating to the study in the 
eCRF.  
• Delivering, or ensuring the delivery of, all other results, documents, data, know-how, 
or formulas relating to the study to the sponsor or designee electronically and/or centrally (eg, laboratory data, imaging data, biomarker data, photographs, diary data), 
or as otherwise specified in  the Protocol.   
• Verifying that data entries are accurate and correct by [CONTACT_108125]. 
• Maintaining accurate documentation (source data) that supports the information 
entered in the eCRF , or sent to a central vendor designated by [CONTACT_456], or as 
described in other study and data flow manuals. 
− Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected.  Source documents are filed at the investigator's site.  
− Data entered in the eCRF that are transcribed from source documents must be 
consistent with the source documents or the discrepancies must be explained.  The investigator may need to request previous medical records or transfer records, depending on the study.  Also, current applicable medical records must be 
available.  
• May have responsibility for sending participants’ data, either as unique samples, or 
copi[INVESTIGATOR_014], or photographs, to be evaluated centrally or analyzed centrally, or both, by a 
qualified vendor designated by [CONTACT_456]. 
• Permitting study -related monitoring, sponsor audits, IRB/IEC review, and regulatory 
inspections by [CONTACT_190083]. 
− Monitoring:  Qualified representatives of the sponsor or its designee, study 
monitors, will monitor the study according to a predetermined plan.  The 
investigator must allow the study monitors to review any study materials and 
participant records at each monitoring visit.  
− Auditing:  Qualified representatives of the sponsor or its designee may audit the clinical study site and study data to evaluate compliance with the Protocol, 
applicable local clinical study regulations, and overall study conduct.  The 
investigator must allow the auditors to review origi nal source records and study 
documentation for all participants.  
− Regulatory inspection:  Regulatory authorities may conduct an inspection of the 
study and the site at any time during the development of an investigational 
product.  The investigator and staf f are expected to cooperate with the inspectors 
and allow access to all source documents supporting the eCRFs and other 
study-related documents.  The investigator must immediately notify the sponsor 
when contact[CONTACT_169109]. 
Incyte Corporation  Page [ADDRESS_439453] adhere to applicable data privacy laws and 
regulations.  The investigator and the sponsor or its designee are responsible for ensuring that 
sensitive information is handled in accordance with local requirements (eg, HIPAA).  Appropriate consent and authorizations for use and disclosure and/or transfer (if applicable) of 
protected information must be obtained. 
Participant na mes will not be supplied to the sponsor or its designee.  Only the participant 
number and the participant's initials (participant's initials will only be recorded if allowable by 
[CONTACT_427]) will be recorded in the eCRF, where permitted; if the participant's name 
[CONTACT_75502] (eg, laboratory report), it must be obliterated on the copy of the document to be supplied to the sponsor or its designee.  Study findings stored on a computer will 
be stored in accordance with local data protec tion laws.  
11.4. Financial Disclosure  
Before study initiation, all clinical investigators participating in clinical studies subject to 21 CFR Part 54 – Financial Disclosure by [CONTACT_6230] (ie, "covered studies") are 
required to submit a completed Clinical Investigator Financial Disclosure Form that sufficiently details any financial interests and arrangements that apply.  For the purpose of this regulation, 
"clinical investigator" is defined as any investigator or subinvestigator who is directly involv ed 
in the treatment or evaluation of research participants, including the spouse and each dependent 
child of the clinical investigator or subinvestigator.  These requirements apply to both US and 
foreign clinical investigators conducting covered clinical s tudies.  
Any new clinical investigators added to the covered clinical study during its conduct must also 
submit a completed Investigator Financial Disclosure Form.  During a covered clinical study, 
any changes to the financial information previously reported by a clinical investigator must be 
reported to the sponsor or its designee.  At the conclusion of the covered clinical study, the clinical investigators will be reminded of their obligations.  In the event that the clinical 
investigator is not reminded, they nevertheless will remain obligated to report to the sponsor or 
its designee any changes to the financial information previously reported, as well as any changes in their financial information for a period of 1 year after completion of the covered clinical study.  
11.5. Publication Policy 
By [CONTACT_352982], the investigator and his or her institution agree that the results of 
the study may be used by [CONTACT_456], Incyte Corporation (Incyte), for the purposes of national 
and international registration, publication, and information for medical and pharmaceutical 
professionals.  Study results will be published in accordance with applicable local and national regulations.  Sponsor commits to also adhere to supranational/international rules regarding 
publishing research results, as set by [CONTACT_352983].   If necessary, the authorities will 
be notified of the investigator's name, address, qualifications, and extent of involvement.  The terms regarding the publication of study results are contained in the agreement signed with the 
sponsor or its designee.  A signed agreement will be retained by [CONTACT_3552]. 
Incyte Corporation  Page [ADDRESS_439454] been collected and a study- site closure visit has been performed.  
The investigator m ay initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination. 
Reasons for the early closure of a study site by [CONTACT_11004]: 
• Failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines. 
• Inadequate recruitment of participants by [CONTACT_093]. 
• Discontinuation of further study treatment development. 
Incyte Corporation  Page 79 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  12. REFERENCES  
American Academy of Dermatology. Vitiligo: Diagnosis and Treatment.  2020. 
Bae JM, Jung HM, Hong BY, Lee JH, Choi WJ, Lee JH, Kim GM. Phototherapy for vitiligo : a 
systematic review and m eta-analysis. JAMA Dermatol 20 17;153:666-674. 
Bharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E. Validation of an 
abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on 
antihypertensive medications. Health Qual Life Outcomes 2009;7:36. 
Batchelor JM, Tan W, Tour S, Yong A, Montgomery AA, Thomas KS. Validation of the Vitiligo 
Noticeability Scale: a patient -reported outcome measure of vitiligo treatment success. Br J 
Dermatol 2016;174:386-394. 
Boniface K, Seneschal J, Pi[INVESTIGATOR_94593] M, Taïeb A. Vitiligo: f ocus on clinical aspects, 
immunopathogenesis, and therapy. Clin Rev Allergy Immunol 2018;54:52-67. Castanet J, Ortonne JP. Pathophysiology of vitiligo. Clin Dermatol 1997:15:845-851. Centers for Disease Control and Prevention. BMI Percentile Calculator for Child and Teen. 
2019. Clinical Trials Facilitation and Coordination Group. Recommendations related to contraception 
and pregnancy testing in clinical trials. 2014. 
Coondoo A, Phiske M, Verma S, Lahiri K. Side- effects of topi[INVESTIGATOR_8826]: a l ong overdue 
revisit. Indian Dermatol Online J 2014;5:416-425. 
Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis -directed 
Therapy. JAMA Dermatol 2015;151:1110-1112. Eleftheriadou V, Thomas KS, Whitton ME, Batchelor JM, Ravenscroft JC. Which outcomes 
should we measure in vitiligo? Results of a systematic review and a survey among patients and 
clinicians on outcomes in vitiligo trials. Br J Dermatol 2012;167:804 -814. 
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) --a simple practical measure for 
routine clinical use. Clin Exp Dermatol 1994;19:210-216. 
Frisoli ML, Harris JE. Vitiligo: mechanistic insights lead to novel treatments. J Allergy Clin 
Immunol 2017;140:654-662. 
Gawkrodger DJ, Ormerod AD, Shaw L, et al. Guideline for the diagnosis and management of 
vitiligo. Br J Dermatol 2008;159:1051-1076. 
González U, Whitton M, Eleftheriadou V, Pi[INVESTIGATOR_352888] M, Batchelor J, Leonardi -Bee J. Guidelines for 
designing and reporting clinical trials in vitiligo. ArchDermatol 2011;147:1428-1436. 
Hamzavi I, Jain H, McLean D, Shapi[INVESTIGATOR_2152] J, Zeng H, Lui H. Parametric modeling of narrowband 
UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol 2004;140:677-683. 
Harris JE, Rashighi M, Nguyen N, et al. Rapid skin repi[INVESTIGATOR_352889] a 
patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol 2016;74:370-371. 
Incyte Corporation  Page 80 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  Joshipura D, Alomran A, Zancanaro P, Rosmarin D. Treatment of vitiligo with the topi[INVESTIGATOR_352890]: a 32 -week open-label extension study with optional narrow-band 
ultraviolet B. J Am Acad Dermatol 2018;78:1205-1207. 
Krüger C, Panske A, Schallreuter KU. Disease- related behavioral patterns and experiences affect 
quality of life in children and adolescents with vitiligo. Int J Dermatol 2014;53:43-50. 
Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in 
children/adolescents and adults. Int J Dermatol 2012;51:1206-1212. 
Lai YC, Yew YW, Kennedy C, Schwartz RA. Vitiligo and depression: a systematic review and 
meta -analysis of observational studies. Br J Dermatol 2017;177:708-718. 
Lilly E, Lu PD, Borovicka JH, et al. Development and validation of a vitiligo -specific 
quality-of- life instrument (VitiQoL). J Am Ac ad Dermatol 2013;69:e11- 18. 
Linthorst Homan MW, de Korte J, Grootenhuis MA, Bos JD, Sprangers MA, van der Veen JP. Impact of childhood vitiligo on adult life. Br J Dermatol 2008;159:915-920.  
Linthorst Homan MW, Spuls PI, de Korte J, Bos JD, Sprangers MA, van der Veen JP. The 
burden of vitiligo: patient characteristics associated with quality of life. J Am Acad Dermatol 
2009;61:411-420. 
Mehta CR, Patel NR. Exact logistic regression: theory and examples. Stat Med 
1995;14:2143-2160. 
Osinubi O, Grainge MJ, Hong L, et al. The prevalence of psychological comorbidity in people 
with vitiligo: a systematic review and meta-analysis. Br J Dermatol 2018;178:863-878. 
Porter J R, Beuf A H, Lerner A B, Nordlund JJ, et al. The effect of vitiligo on sexual relationships. 
J Am A cad Dermatol 1990;22:221-222. 
Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE, Vitiligo Working Group. New 
discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol 2017;77:1-13. 
Rothstein B, Joshipura D, Saraiya A, et al. Treatment of vitiligo with the topi[INVESTIGATOR_352891]. J Am Acad Dermatol 2017;76:1054-1060. 
Ruxolitinib Cream Investigator's Brochure. Wilmington, DE: Incyte Corporation. 
Salzer BA, Schallreuter KU. Investigation of the personality st ructure in patients with vitiligo 
and a possible association with impaired catecholamine metabolism. Dermatology 
1995;190:109-115. 
Silverberg JI, Silverberg NB. Association between vitiligo extent and distribution and 
quality-of- life impairment. JAMA Dermatol 2013;149:159-164. 
Speeckaert R, van Geel N. Vitiligo: an update on pathophysiology and treatment options. Am J Clin Dermatol 2017;18:733-744. 
Taieb A, Alomar A, Böhm M, et al. Guidelines for the management of vitiligo: the European 
Dermatology Forum consensus. Br J Dermatol 2013;168:5- 19. 
Taieb A, Pi[INVESTIGATOR_94593] M. Clinical practice. Vitiligo. N Engl J Med 2009;360:160-169. 
Topp CW, Østergaard SD, Søndergaard S, Bech P. The WHO -5 Well -Being Index: a s ystematic 
review of the l iterature.  Psychother Psychosom 2015;84:167-176. 
Incyte Corporation  Page 81 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  van Buuren S. Multiple imputation of discrete and continuous data by [CONTACT_352958]. Stat Methods Med Res 2007;16:219-242. 
Vitiligo Research Foundation. Treatment Guidelines. 2020. 
Wang G, Qiu D, Yang H, Liu W. The prevalence and odds of depression in patients with vitiligo: 
a meta-analysis [published online ahead of print December 9, 2017]. J Eur Acad Dermatol 
Venereol. doi: 10.1111/jdv.[ZIP_CODE]. 
Whitton M, Pi[INVESTIGATOR_352888] M, Batchelor JM, et al. Evidence -based management of vitiligo: su mmary of a 
Cochrane systematic review. Br J Dermatol 2016;174:962-969. World Health Organization. WHO Model Prescribing Information: Drugs Used in Skin Diseases. 
1997. 
WHO Collaborating Center for Mental Health , Psychiatric Research Unit. The WHO -5 website. 
Yazdani Aby[CONTACT_312376], Griffith R, Falto-Aizpurua L, Nouri K. The dark history of white spots. 
JAMA Dermatol 2014;150:936. 
Zigmond AS, Snaith RP. The hospi[INVESTIGATOR_56105].  Acta Psychiatr Scand  
1983;67:361-370. 
Incyte Corporation  Page 82 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  APPENDIX A. INFORMATION REGARDING EFFECTIVENESS OF 
CONTRACEPTIVE METHOD S 
For male participants in the study:  
Male participants should use a condom during treatment through [ADDRESS_439455] had a vasectomy qualify as having met the requirement 
for a highly effective birth control method.  
For female participants in the study:  
The following methods that can achieve a failure rate of less than 1% per year when used consistently 
and correctly are considered as highly effective birth control methods:  
• Combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibition of ovulation  
− oral 
− intravaginal  
− transdermal  
• Progestogen- only hormonal contraception associated with inhibition of ovulation  
− oral 
− injectable  
− implantablea 
• Intrauterine devicea 
• Intrau terine hormone -releasing systema 
• Bilateral tubal occlusiona 
• Vasectomized partnerab 
• Sexual abstinencec 
Acceptable birth control methods that result in a failure rate of more than 1% per year include:d 
• Progestogen- only oral hormonal contraception, where inhibition of ovulation is not the primary 
mode of action  
• Male or female condom with or without spermicidee 
• Cap, diaphragm, or sponge with spermicidee 
• Tubal ligation 
a Contraception methods that in the context of this guidance are considered to have low user dependency.  
b Vasectomized partner is a highly effective method of avoiding pregnancy provided that partner is the sole sexual 
partner of the woman of childbearing potential study participant and that the vasectomized partner has received 
medical assessment of the surgical success.  
c In the context of this guidance, sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated with the study treatments.  The  
reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the 
preferred and usual lifestyle of the participant.  
d Choices are for US and Canada  participants only and include above less than 1% failure rate methods.  
e A combination of male condom with either cap, diaphragm, or sponge with spermicide (double barrier methods) 
are also cons idered acceptable, but not highly effective, birth control methods.  
Source:  Clinical Trial s Facilitation and Coordination Group [ADDRESS_439456] with the Class I ultra -high–potency 
preparations, which should only be used for limited time periods (2-3 weeks).  Representative preparations by [CONTACT_352984].  These groups may vary depending on the 
formulation and concentration and should be considered approximate.  In general, ointments are 
more potent than creams or lotions.  Potency is also increased when topi[INVESTIGATOR_352918].  
Potency  Class  Topi[INVESTIGATOR_352919]  I Clobetasol propi[INVESTIGATOR_225332], 0.05%  
Diflorasone diacetate  Ointment, 0.05%  
High  II Amcinonide  Ointment, 0.1%  
Betamethasone dipropi[INVESTIGATOR_352920], 0.05%  
Desoximetasone  Cream or ointment, 0.025%  
Fluocinonide  Cream, ointment or gel, 0.05%  
Halcinonide  Cream, 0.1%  
III Betamethasone dipropi[INVESTIGATOR_225332], 0.05%  
Betamethasone valerate  Ointment, 0.1%  
Diflorasone diacetate  Cream, 0.05%  
Triamcinolone acetonide  Ointmen t, 0.1%  
Moderate  IV Desoximetasone  Cream, 0.05%  
Fluocinolone acetonide  Ointment, 0.025%  
Fludroxycortide  Ointment, 0.05%  
Hydrocortisone valerate  Ointment, 0.2%  
Triamcinolone acetonide  Cream, 0.1%  
V Betamethasone dipropi[INVESTIGATOR_225334], 0.02%  
Betamethasone valerate  Cream, 0.1%  
Fluocinolone acetonide  Cream, 0.025%  
Fludroxycortide  Cream, 0.05%  
Hydrocortisone butyrate  Cream, 0.1%  
Hydrocortisone valerate  Cream, 0.2%  
Triamcinolone acetonide  Lotion, 0.1%  
Low VI Betamethasone valerate  Lotion, 0.05%  
Desonide  Cream, 0.05%  
Fluocinolone acetonide  Solution, 0.01%  
VII Dexamethasone sodium phosphate  Cream, 0.1%  
Hydrocortisone acetate  Cream, 1%  
Methylprednisolone acetate  Cream, 0.25%  
Source :  WHO 1997 . 
Incyte Corporation  Page 84 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  APPENDIX C. PROTOCOL AMENDMENT SUMMARY OF CHANGES  
Document  Date 
Amendment 1:  [ADDRESS_439457]  2019  
Amendment 2:  12 DEC 2019  
Amendment 3:  21 FEB 20 20 
Amen dment 3 -US-CA:  13 MAR 2020 
Amendment 3 -US-CA (13 MAR 2020) 
Overall Rationale for the Amendment:  To clarify BMI criteria for adult and adolescent 
participants . 
1. Section 5.2, Exclusion Criteria  
Description of changes:   Added BMI- for-age criterion for adole scent participants 
(≥ 12 to < 18 years ) to exclusion criterion 8.  
Rationale for change:   Body mass index is interpreted differently for children and teens, 
even though it is calculated using the same formula as adult BMI.  For children and teens, BMI need s to be age- and sex -specific.  The normal or healthy weight category for BM I 
in children and teens per CDC is ≥ 5th to < 85th percentile range.  Therefore, for 
adolescent participants the BMI -for-age ≥ 5th to < 85th percentile ranking is consi dered 
eligible for this study.  
2. Incorporation of administrative changes.  Other minor, administrative changes have 
been incorporated throughout the Protocol and are noted in the redline version of the 
amendment.  
 
Incyte Corporation  Page 85 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  Amendment 3 ( 21 FEB 20 20) 
Overall Rationale for the Amendment:  The primary purpose of this amendment is to 
incorporate revisions requested by [CONTACT_352985] C ommittees (ECs) and FDA.  
1. Section 1, Protocol Summary (Table 1:  Primary and Secondary Objectives and Endpoints); Section 3, Objectives and Endpoints (Table 8: :Objectives and Endpoints); Section 10.1, Sample Size Determination (Table 14:  Powering for 
Primary and Key Secondary Endpoints); Section 10.3, Statistical Analyses, 
Section  [IP_ADDRESS], Primary Analysis; Section [IP_ADDRESS], Key Secondary Analysis; 
Section [IP_ADDRESS], Secondary Analysis  
Description of changes:   Reordered and revised the key secondary endpoints and 
updated the analysis plan. 
Rationale for change:   To address FDA response.  
2. Section 1, Protocol Summary (Table 2: Key Study Design Elements)  
Description of changes:   Added 1 key exclusion criteria (exclude other forms of vitiligo) 
to the Population section, added information about the exit interview in the Study Design 
section, and added a DSMB section to indicate that a DSMB is not required in this study. 
Rationale for change:   To address Fr ench  EC response.  
3. Section 1, Protocol Summary (Table 3:  Schedule of Activities:  Double -Blind, 
Vehicle- Controlled Treatment Period [Day 1 -Week 24]; Table 4:  Schedule of 
Activities:  Treatment Extension Period [Week 28 -Week 52])  
Description of changes:   Added language that per protocol Section 8.3.2, targeted 
physical examination should be conducted as indicated by [CONTACT_312361], AEs, or other findings.  Abnormalities that are considered clinically significant in the judgment of the investigator are to be reported as AEs. 
Rationale for change: To clarify that targeted physical examination is not required 
unless there are symptoms reported by [CONTACT_2299], AEs, or other findings. 
4. Section 8.1.2, Screening Procedures 
Description of changes:   Added language to instruct that adolescent participants 
screened in [LOCATION_013] whose hemoglobin is between 10 g/dL and 12 g/dL during the 
screening visit should be further evaluated per local guidelines before being enrolled into 
the study. 
Rationale for change:   To address German EC response.  
5. Incorporation of administrative changes.   Other minor, administrative changes have 
been incorporated throughout the Protocol and are noted in the redline version of the 
amendment.  
 
Incyte Corporation  Page 86 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  Amendment 2 ( 12 DEC 2019) 
Overall Rationale for the Amendment:  
The primary purpose of this amendment is to incorporate revisions requested by [CONTACT_352986] (VHP). 
1. Section 5.2, Exclusion Criteria  
Description of change:   Added language to exclude participant who has current and/or 
history of tuberculosis. 
Rationale for change:   To address VHP response.  
2. Section 5.2, Exclusion Crite ria 
Description of changes:   Added language to exclude participants who live with anyone 
participating in any current Incyte -sponsored ruxolitinib cream study. 
Rationale for change:   To avoid study drug sharing and reinforce treatment compliance. 
3. Section 8. 1.2, Screening Procedures 
Description of changes:   Added language to instruct that German participants whose 
hemoglobin is  between 10 g/dL and 10.5 g/dL during the screening visit should be further 
evaluated per local guidelines before enrolling into the study.  Rationale for change:   To address VHP response.  
Incyte Corporation  Page 87 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  Amendment 1 ( [ADDRESS_439458] 2019) 
Overall Rationale for the Amendment:  
This amendment is considered to be nonsubstantial based on the criteria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council of the European Union, 
because it does not have a signif icant impact on the safety or physical/mental integrity of the 
participants nor on the scientific value of the study. 
The primary purpose of this amendment is to incorporate revisions requested by [CONTACT_352986] (VHP) and to add the option for a subgroup of study participants to be included in a substudy involving exit interviews at Week 24 and Week 52.  
1. Section 1, Protocol Summary (Table 3:  Schedule of Activities:  Double -Blind, 
Vehicle- Controlled Treatment Period [Day 1 -Week 24]; T able 4:  Schedule of 
Activities:  Treatment Extension Period [Week 28 -Week 52]); Section 8.1.6, Exit 
Interviews 
Description of change:   Exit interviews and informed consent to participate in them 
were added to the Schedule of Activities, and a description of the exit interview was 
added.    
Rationale for change:   To provide details on the exit interviews and their timing, 
duration, and numbers of participants involved in the substudy. 
2. Section 2.5.1, Scientific Rationale for Study Design 
Description of changes:   Added the meaning and medical/clinical relevance of endpoints 
and their outcomes.  
Rationale for change:   To address VHP response.  
3. Section 2.4, Ruxolitinib Cream  
Description of changes:   Added language “no precautions are anticipated for [ruxolitinib 
cream’s] concomitant use with systemic drugs or for  participants with hepatic 
impairment .” 
Rationale for change:   To address VHP response and add a statement regarding 
participants  with hepatic function impairment. 
4. Appendix A , Information Regarding Effectiveness of Contraceptive Methods  
Description of change:   The following footnote was removed:  Hormonal contraception 
may be susceptible to interaction with the investigational medicinal product, which may 
reduce the efficacy of the contraception method. 
Rationale for change:   The statement is specific for oral ruxolitinib , as most of 
hormonal contraception is metabolized by [CONTACT_352987] (CYP3A4) for ruxolitinib.  
The systemic exposure for  topi[INVESTIGATOR_352921].  Thus, this precaution is not warranted. 
Incyte Corporation  Page 88 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  5. Appendix A , Information Regarding Effectiveness of Contraceptive Methods  
Description of change:   Added footnote and clarified that the a cceptable birth control 
methods that result in a failure rate of more tha n 1% per year are for US and Canada 
participants only.  
Rationale:   To address VHP response. 
6. Section 1, Protocol Summary (Table 3:  Schedule of Activities :  Double -Blind, 
Vehicle- Controlled Treatment Period [Day1 -Week 24] ); Section 5.1, Inclusion 
Criteria  
Description of change:   Updated the definition of postmenopausal state to having 
amenorrhea for at least 12 months without an alternative medical cause.  
Rationale for change:   To address VHP request and provide completed definition of 
postmenopausal. 
7. Secti on 5.2, Exclusion Criteria (Exclusion Criterion 12)  
Description of change:   Added language in exclusion criteria to exclude participants 
with known allergy or reaction to any component of the study formulation. 
Rationale for change:   To address VHP request .  
8. Section 5.3, Lifestyle Considerations; Section 6.6.1, Permitted Medications and 
Procedures  
Description of changes:   Updated the study drug application guidance with respect to  
emollients, camouflage makeups, sunscreens, and after shaving.  
Rationale for change:   To remove unnecessary limitation of concomitant application of 
study drug and other cosmetic products. 
9. Section 6.2, Preparation, Handling, and Accountability 
Description of changes:   Added language of application guidance for participants with 
hand vitiligo.  
Rationale for change:   If patients have vitiligo on their hands, they do not need to wash 
the hand after study drug application. 
10. Section 6.6.2, Restricted Medications and Measures; Appendix B, WHO 
Classification of Topi[INVESTIGATOR_352922]:   Added WHO classification of topi[INVESTIGATOR_11930].  
Rationale for change:   To address VHP response and provide topi[INVESTIGATOR_352923] s. 
Incyte Corporation  Page 89 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  11. Section [IP_ADDRESS], Patient Global Impression of Change- Vitiligo (Facial)  
Description of changes:   Added that the baseline photograph and a mirror will be 
provided to the participant for reference.  
Rationale for change:   To allow participant s to self -evaluate the before and after 
treatment facial repi[INVESTIGATOR_352924] F -PaGIC.  
12. Section 1, Protocol Summary (Table 4:  Schedule of Activities:  Treatment 
Extension Period (Week 28- Week 52)])  
Description of changes:   Added “Assess compliance” up to  Week 52 visits. 
Rationale for change:  To further evaluate the compliance in the treatment extension 
period. 
13. Section 7.1.1, Reasons for Discontinuation  
Description of changes:    Language for participants found not to have met eligibility 
criteria was updat ed from “may be discontinued from study treatment” to “must be 
discontinued from study treatment.”  Also added definition of “not met eligibility 
criteria.”  
Rationale for change:   To address VHP response.  
14. Section 8.3.1, Adverse Events; Section 9.3, Record ing and Follow -Up of Adverse 
Events and/or Serious Adverse Events; Section 9.4, Reporting of Serious Adverse 
Events  
Description of changes:   Updated SAE repor ting timeframe from “within 24 hours” to 
“immediately, without undue delay, under no circumstances later than 24 hours following knowledge of the event .” 
Rationale for change:   To address VHP response.  
15. Section 9.3, Recording and Follow- Up of Adverse Events and/or Serious Adverse 
Events  
Description of changes:   Revised the language on “Assessment of Cau sality.”  
Rationale for change:  To address VHP response.  
16. Section 11.5, Publication Policy  
Description of changes:   Added language of “Sponsor commits to also adhere to 
supranational/international rules regarding publishing research results, as se t by [CONTACT_352988].”  
Rationale for change:   To address VHP response.  
Incyte Corporation  Page 90 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  17. Section 1, Protocol Summary; Section 4.1, Overall Design; Section 6.3, Measures to 
Minimize Bias:  Randomization and Blinding; Section 10.1, Sample Size 
Determination  
Description of changes:   Removed the stratification criterion by [CONTACT_352989] (North America or Europe ).  
Rationale for change:   To address VHP response and include region as one of 
stratification factors.  
18. Section [IP_ADDRESS], Primary Analysis 
Description of changes:   Revised the definition of per protocol (PP) population and 
clarified  the language of primary analysis.  
Rationale for change:   To address VHP response.  
19. Section [IP_ADDRESS].3, Vitiligo 
Description of changes:   Added language to address the observed effect size/efficacy 
rate of ruxolitinib cream (Cohen’s D ), and the expected effect size/efficacy rate of 1.5% 
BID.  
Rationale for change:   To address VHP request . 
20. Section 5.1, Inclusion Criteria (Inclusion Criterion 5)  
Description of change:   Revi sed language in the inclusion criterion  to clarify that for 
adolescent participant s, the written informed consent of the parents or legal guardian and 
written assent from the adolescent participant are required.  Adult participant s must  
possess the ability  to comprehend and willingness to sign an ICF. 
Rationale for change:   To address VHP request.  
21. Section [IP_ADDRESS], Primary Analysis; Section [IP_ADDRESS], Secondary Analysis 
Description of changes:   The exact logistic regression will be used for primary and key 
secondary analysis.  
Rationale of change:  To address VHP response.  
22. Section 3, Objectives and Endpoints (Table 8:  Objectives and Endpoints) ; 
Section  8.2.6, Patient- Reported Outcomes  
Description of changes:   Moved F- PhGVA, T -PhGVA, F -PaGIC- V, T-PaGIC-V, and 
color-matching endpoints from quality-of- life objective to efficacy objective.  
Rationale for change:   These are efficacy assessments not intended to evaluate patient 
quality of life. 
Incyte Corporation  Page 91 of 91 
Protocol INCB [ZIP_CODE]- 307 Am 3-US-CA Version 4-US-CA 13 MAR 2020 
CONFIDENTIAL  23. Section 1, Protocol Summary (Table 3:  Schedule of Activities:  Double -Blind, 
Vehicle- Controlled Treatment Period [Day1 -Week 24]; Table 4:  Schedule of 
Activities:  Treatment Extension Period [Week 28 -Week 52])  
Description of changes:   Removed re -dispended study drug language. 
Rationale for changes:   Unused study drugs and tubes will not be re -dispensed in this 
study. 
24. Incorporation of administrative changes.   Other minor, administrative changes have 
been incorporated throughout the Protocol and are noted in the redline version of the 
amendment.  